

Index

Italicized page numbers indicate a table, figure, or box on the designated page

- abacavir, 348
 abciximab, 161, 161
 abdominal aneurysm, 31, 189, 199
 ABDs. *See* autoimmune blistering disorders
 acamprosate, 292
 ACC. *See* American College of Cardiology
 ACC/AHA Task Force on Practice Guidelines, 436, 437–438, 440
 Acceptable Macronutrient Distribution Range (AMDR), 90
 ACCORD-BP study, 429
 acetaminophen
 in benign breast disease, 405
 in cancer-related pain, 553, 554
 in headaches, 221, 221, 223
 in osteoarthritis, 454
 in pain management, in delirium, 154
 acetazolamide
 for cerebellar ataxia, 261
 for glaucoma, 572
 for secondary headaches, 226
 acetylcholinesterase inhibitors (ACEIs), 150. *See also* donepezil; galantamine; rivastigmine
 for AD/dementia, 134–135
 for aortic insufficiency, 173
 memantine with, 135
 for myasthenia gravis, 207
 side effects, 135
 Achilles tendinitis, 602
 acitretin, for psoriasis, 491
 acral lentiginous melanoma, 487
 acroangiokeratosis, 495
 acrochordons, 481–482
 actinic keratosis (AK), 485–487, 577
 actinic purpura (solar purpura), 483
 Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial, 424
 Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, 424
 active years of living, 1
 activities of daily living. *See also* instrumental activities of daily living
 assessment tools, 35
 disabilities and, 99
 domains, 35
 exercise recommendations, 48, 79
 falls/gait impairments and, 107
 functional independence and, 79
 occupational therapy and, 11
 pain and, 39
 preexisting conditions and, 17
 activity theory, of retirement, 731
 acupressure, 705, 707
 acupuncture, 705, 707
 acute angle closure glaucoma, 228
 Acute Care for the Elderly units
 CGA in, 40
 acute coronary syndrome, 160
 acute kidney injury (AKI), 358–360
 acute tubular necrosis and, 359
 complicating factors, 359
 diagnosis, 359–360
 etiology of, 358–359
 HIV infection and, 349
 prevalence of, 360
 acute motor axonal neuropathy, 206
 acute myelogenous leukemia (AML), 531–532
 acute otitis externa (AOE), 577
 acute ST-segment elevation myocardial infarction (STEMI)
 atherosclerotic plaque rupture in, 160
 primary PCI in, 163
 reperfusion with fibrinolytic therapy, 163, 163
 acute tubular necrosis (ATN), 359
 acute vestibular syndrome (AVS), 120–122
 causes, 121
 differential diagnosis, 118, 121
 stroke evaluation, 118
 treatment, 121–122
 acyclovir
 exacerbation of tremors, 247
 for herpes zoster, 338, 500
 for postherpetic neuralgia, 212
 for recurrent keratitis, 568
 adalimumab
 for psoriasis, 491–492
 for rheumatoid arthritis, 456
 adamantane derivatives, 335–336. *See also* amantadine; rimantadine
 adherence
 to CGA recommendations, 30
 to goals and interventions, 32
 to medications, 58, 64
 improvement strategy, 64
 adrenal gland disorders
 adrenal insufficiency, 417
 Cushing's syndrome, 188, 415, 416–417
 muscle weakness and, 207
 nodules, 415
 pheochromocytoma, 117, 188, 415, 416
 primary aldosteronism, 415–416
 adrenergic alpha2-agonists (Brimonidine), 571
 adrenocortical carcinoma, 415
 ADRs. *See* adverse drug reactions
 adult children
 physician partnerships with, 7
 role of/dealing with, 5
 adult day care programs, 4, 655, 752
 Adult Protective Services (APS), 52, 689
 adult T-cell leukemia, 410
 advance care planning, 781–792
 challenge of not having, 306
 for dementia patients, 139
 from documents to orders, 791
 durable power of attorney for health care, 781, 782, 785, 786, 788, 798
 family covenant in, 786–787, 792–795
 greater acceptance of, 661
 for idiopathic pulmonary fibrosis, 304
 living will, 172, 781–782, 798
 palliative care specialists role, 671

- Patient Self-Determination Act, 782–783
- primary care provider's role, 672
- advance directives
- as CGA domain, 32
 - for COPD patients, 300, 301
 - discussing contents, 139
 - ethical challenges with, 783–786
 - example, 792
 - greater acceptance of, 661
 - for heart failure patients, 172
 - historical background, 781
 - increased use in hospitalized patients, 233
- MOLST/POLST, 783, 786, 787, 788, 790, 798
- preventive ethics strategy for, 787–790
- special considerations, 790–792
- advanced dementia scale (PAIN-AD), 674
- advanced glycation end products (AGEs), 21
- advanced phase sleep disorder, 271
- adverse drug reactions (ADRs)
- alcohol and, 53
 - CGA medication review, 33
 - cognitive impairment, risk factors, 63
 - falls, risk factors, 62–63
 - possible problems, 9
 - prescribing diligence and, 58, 61
 - prevalence/consequences, 61, 62
 - susceptibility to, 60–61
- aerobic exercise
- benefits, 70–75, 78, 81
 - description, 78–79
 - gait impairment and, 75
 - guidelines, 48, 69
 - high impact activities, 79
 - intensity, 79–80, 80
 - modes, 79
 - pre-exercise assessment, 75
 - prescribing, 78
 - risks, 81–83
 - volume, 79, 81
 - weight-bearing, 79
- affect assessment, 34–35. *See also* depression
- Affordable Care Act (ACA), 668, 764, 776
- African American Heart Failure Trial (A-HeFT), 168
- African Americans
- acral lentiginous melanoma in, 487
 - cardiovascular disease rates, 436
 - dementia, prevalence, 125–126
 - glaucoma, incidence, 570
 - lifespan estimates, 22
 - osteoporosis, fracture risks, 446
 - prostate cancer risk factors, 543
 - stroke incidence, 235
 - women's prevalence of frailty, 99
- Agency for Health Care Policy and Research (AHCPR), 674
- Agency for Healthcare Research and Quality (AHRQ), 745, 757–758, 764
- AGEs. *See* advanced glycation end products
- aging. *See also* lifespan
- appetite and, 88
 - biology of, 17–23 (*See also* biology of aging)
 - declining liver mass, hepatic blood flow, 59
 - defined, 8, 17
 - early theories of, 18
 - exercise goals, 69–70
 - genetic basis for, 18–19
 - global population growth of, 12
 - respect for individuals, 1
 - species variability, 17
 - theories
 - antagonistic pleiotropy theory, 18
 - disposable soma theory, 18
 - DNA damage theory, 19
 - evolutionary senescence, 18
 - mutation accumulation theory, 18
 - programmed aging, 18–19
 - somatic inevitability, 19
 - US Census Bureau data, 1
- aging, premature
- of childhood cancer survivors, 22
 - of HIV patients, 22
 - mice research, 20
- agranulocytosis, 218
- AGS. *See* American Geriatrics Society
- AHA. *See* American Heart Association
- AHRQ. *See* Agency for Healthcare Research and Quality
- AIDS (acquired immunodeficiency syndrome)
- age-associated infections, 349
 - age-related diagnosis data, 632
 - HIV infection and, 345
 - lifestyle changes with, 351
 - Men's AIDS Cohort Study (MACS), 348
 - pneumocystis pneumonia and, 345
 - proximal subungual infections and, 501
 - transmission risk factors, 630, 632
 - tuberculosis complication, 347
- albuterol bronchodilator, 246, 247, 299
- alcohol misuse/abuse
- ADRs and, 53
 - assessment for, 33, 274, 289
 - existential vacuum and, 6
 - history evaluation, 275
 - ischemic stroke and, 235
 - medication interventions, 292
 - prevalence rates, 285–286
 - prevention and screening, 53–54
 - psychosocial/behavioral treatments, 292
 - risk factors, 53, 286
 - screening and assessment
 - ASSIST, 291
 - AUDIT, 290–291
 - CAGE/CAGE-AID questionnaires, 290
 - CARET, 291
 - MAST-G, 290
 - Short Alcohol Related Problems Survey, 291
 - SMAST-G, 53, 290
- Alcoholics Anonymous, 292
- alcohol-related neuropathy, 212–213
- aldosteronomas, 415
- alendronate, for osteoporosis, 448, 449
- Alexander Technique, 705
- alfuzosin (Uroxatral), 373
- Allen, Woody, 7
- allergic conjunctivitis, 567
- allopurinol, for gout, 457
- alogliptin, 428
- alpha-2 adrenergic receptor agonists, 489. *See also* brimonidine
- alpha (α)-adrenergic antagonists, for BPH, 373–374, 393
- alpha (α 1)-blockers, 60, 62
- alpha receptor antagonists, 191
- alpha-hydroxy acids, 481
- alprazolam, for anxiety disorders, 276
- ALS. *See* amyotrophic lateral sclerosis
- alternate healing systems
- chiropractic, 704, 705, 706, 708
 - homeopathy, 706, 707–708
 - naturopathic medicine, 706, 708
 - spiritual healing practices, 708
 - Traditional Chinese Medicine, 706, 707
 - Traditional Oriental Medicine, 707
- Alzheimer's Association, 134
- Alzheimer's Disease (AD), 126–127
- aggregation of proteins in, 21
 - brain pathology, 51, 127
 - caregiving for someone with, 4
 - characteristics/symptoms, 19, 127, 641
 - decision-making capacity in, 688
 - diagnosis, 133
 - Down syndrome and, 641
 - driving and, 139
 - elder abuse and, 687–688
 - epileptic seizures and, 216
 - genetic testing for, 133
 - heart disease comorbidity, 127
 - hypertension and, 189

Index

- Alzheimer's Disease (AD) (cont.)
 immunization clinical trials, 136
 incidence rates, 125, 126
 marginalization of patients with, 7
 Medicare Part A coverage for, 775
 musculoskeletal injuries and, 462
 neuroimaging in, 133–134
 pharmacological treatment, 134–135
 risk factors, 126
 stages of, 126
 trazodone for insomnia in, 271–272
 urinary incontinence in, 386
- amantadine
 for cerebellar ataxia, 261
 for influenza, 335–336
 for PD, symptomatic treatment, 251, 253
- AMDA. *See* Society for Post-Acute and Long-Term Care Medicine
- AMDR. *See* Acceptable Macronutrient Distribution Range
- American Academy of Clinical Endocrinologists, 448
- American Academy of Family Physicians, 11, 50–51
- American Academy of Hospice and Palliative Medicine, 11
- American Academy of Nursing, 11
- American Association of Clinical Endocrinologists, 415
- American Association of Endocrine Surgeons, 415
- American Association of Endocrinologists, 412
- American Association on Intellectual and Developmental Disabilities (AAIDD), 640
- American Board of Internal Medicine Foundation, 10–11
- American Cancer Society, 10, 11, 46
- American College of Cardiology (ACC), 47–48
- American Dental Association, 587
- American Geriatrics Society (AGS), 11, 409, 739
- American Heart Association (AHA), 47–48
- American Medical Association, 52
- American Medical Association Consortium for Performance Improvement (AMA-PCPI), 759–760
- American Medical Directors Association, 11, 61
- American Physical Therapy Association, 11
- American Recovery and Reinvestment Act, 764
- American Society of Consultant Pharmacists, 61
- American Society of Emergency Physicians, 11
- American Society of Nephrology, 11
- American Thyroid Association, 412
- Americans with Disabilities Act (ADA), 667
- aminoglycosides, 59
- amiodarone, 163, 246, 412
- amitriptyline, 63
 for migraines/tension type headaches, 222
 for neuropathic pain, 215
 for postherpetic neuralgia, 338
- amnesic mild cognitive impairment (aMCI), 131, 135–136
- amoxicillin
 for acute bacterial sinusitis, 581
 for erysipelas, 497
 for otitis media, 578
 for urinary tract infection, 368
- amphetamines, 63, 247, 324
- ampicillin, for UTI, 368
- amyloidosis, 211, 214, 529–531
- amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease), 205, 206
- amyotrophy, 212
- anabolic steroids, exogenous, 84
- anal fissure, 322
- anastrozole, 542
- Andres, R., 8
- anemia
 aplastic anemia, 218, 219
 approach to
 classification, 523–524
 initial evaluation, 524
 autoimmune hemolytic anemias, 528
 clinical consequences, 523
 common etiologies, 523
 Crohn's disease and, 320
 definition/prevalence, 523
 delirium and, 153
 dizziness and, 118
 fall risks and, 53
 fecal incontinence and, 388
 gastric cancer and, 316
 gastrointestinal bleeding and, 319
 GERD and, 311
 heart failure and, 166, 167
 HIV infection and, 347, 349
 hyponatremia and, 360
 hypoproliferative anemia, 531
 hypothyroidism and, 410
 immune thrombocytopenic purpura, 529
 of inflammation, 523
 kidney disease and, 358
 macrocytic anemias, 523
 myelodysplastic syndrome, 523, 527–528
 vitamin B12 deficiency, 526–527
 malnutrition and, 328
 as medication side effect, 219
 microcytic anemias, 523
 iron deficiency anemia, 524–525
 thalassemia, 525
 normocytic anemias, 328, 523
 anemia of chronic kidney disease, 523, 526
 anemia of inflammation, 523, 525–526
 odynophagia and, 314
 peptic ulcer disease and, 315
 pneumonia and, 335
 renal disease and, 358
 thrombocytopenia, 347, 528–529
- angina
 beta blockers for, 191
 exertional, 159
 peripheral arterial disease and, 199
- angiodyplasia, 320
- angiotensin receptor blockers (ARBs)
 acute tubular necrosis and, 359
 in albuminuria, 431
 in heart failure, 168
 for hypertension, 191
 in MI, 161, 162
- angiotensin-converting enzyme (ACE) inhibitors
 acute tubular necrosis and, 359
 in albuminuria, 431
 in heart failure, 168
 for hypertension, 190
 in MI, 161, 162
 side effects, 190
- angle-closure glaucoma, 571
- Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA) program, 439
- animal models of aging research, 18–19, 23
- Animal Naming test, 133
- ankle fractures, 470
- Annual Wellness Visit, 32
- anorectal disorders
 colonic ischemia, 323–325, 324
 constipation/fecal incontinence, 321–323
- anorexia nervosa, 88–89
 bupropion contraindication, 292
 depression and, 50
 frailty and, 100, 101
- antagonistic pleiotropy theory, 18
- anthracyclines, 542
- antiarrhythmics. *See also* amiodarone; lidocaine; mexiletine; procainamide
 empiric, 163

- exacerbation of tremors, 247
in supraventricular tachycardias, 176
type Ia, 63 (*See also* digoxin)
- antibiotics
antistaphylococcal antibiotics, 339
for bacterial conjunctivitis, 567
causative for headaches, 227
for colonic ischemia, 325
for corneal infections, 568
for diverticulitis, 320
for MRSA, 340
for nontuberculous mycobacterium, 305
for paronychia, 600
for pneumonia, 301–302, 335
for urinary tract infection, 368
- anticholinergics. *See also* benztropine; trihexyphenidyl
adverse drug reactions, 62, 63
for parkinsonian tremor, 245
for PD, symptomatic treatment, 251
for rhinitis, 581
for urinary incontinence, 390, 391
- anticoagulants. *See also* apixaban; dabigatran; direct thrombin inhibitors; oral factor Xa agents; rivaroxaban; warfarin
in atrial fibrillation, 161, 169, 174
in heart failure, 169
hematuria and, 367
hemorrhagic stroke and, 235
oral, in MI, 161
in pulmonary embolism, 303–304
side effects of, 178–179
in strokes
dabigatran, 237
oral factor Xa agents, 237
selection, 237
timing of, 236
warfarin, 237
- anticonvulsants. *See also* gabapentin; topiramate
for acute vestibular syndrome, 118
for diabetic neuropathy, 211
fall risks, 62
for neuropathic pain, 215, 676
for postherpetic neuralgia, 338
for uncommon TACs, 224
- antidepressants. *See also* bupropion; selective noradrenergic/serotonergic uptake inhibitors; selective serotonin reuptake inhibitors; tricyclic antidepressants
adverse reactions to, 62, 63
for anxiety disorders, 276
causative for adrenal insufficiency, 417
for depression in dyspepsia, 316
dosage/tolerability issues, 282
- with lithium, for bipolar disorder, 278
for major depression, 277–278
for neuropathic pain, 215
- antiemetics. *See also* chlorpromazine; metoclopramide
causative for parkinsonism, 250
for migraines with nausea, vomiting, 221, 223
for rebound (withdrawal) headaches, 227
- antiepileptics, 218, 219–220. *See also* carbamazepine; lamotrigine; valproic acid
exacerbation of tremors, 247
for neuralgia-induced headaches, 226
- antifungals, topical. *See also* clotrimazole; miconazole nitrate; terbinafine hydrochloride
for onychomycosis, 599
for tinea pedis, 599
- antihistamines
adverse reactions to, 63
for allergic conjunctivitis, 567
anticholinergic actions of, 63
contraindicated in BPPV, 120
driving crash risk caution, 692
for nocturnal itching, 493
for pruritus, 494, 501, 598
for rhinitis, 581
- antihyperlipidemics, 64
- antihypertensives. *See also* angiotensin receptor blockers; angiotensin-converting enzyme (ACE) inhibitors; beta blockers; calcium channel blockers; thiazide type diuretics
classes of, 190–191
dosage consideration, 190
erectile dysfunction and, 636
falling risks, 62, 63, 235, 238
risk/benefit considerations, 191
side-effect profile consideration, 429
underuse of, 64
- antiinflammatory drugs
in heart failure, 169
in Peyronie's disease, 377
in prostatitis, 376
in urethral caruncles, 379
- antimicrobials
exacerbation of tremors, 247
in HAP, 302
for pneumonia, 302
resistance to, 332, 338
- antiplatelet therapy. *See also* aspirin; clopidogrel; vorapaxar
AHA guidelines, 197
for myocardial infarction, 160, 161
- in PAD, 196, 199
in stroke reduction, 237
as stroke risk factor, 235, 237
- antipneumococals, 335. *See also* cephalosporin, third generation; fluoroquinolone; macrolide
- antipsychotics. *See also* droperidol; haloperidol; thiothixene
adverse reactions to, 62
causative for adrenal insufficiency, 417
in delirium management, 155
in dementia management, 137–138
dosage/tolerability issues, 282
hallucinations and, 138
- antipsychotics, atypical, 150, 645. *See also* aripiprazole; olanzapine; quetiapine; risperidone
- antiretroviral therapy (ART), 22, 344
adherence issues, 351, 352
associated adverse events, polypharmacy, 352
bone less from, 350
cholesterol/triglyceride levels on, 348
mortality risks, 633
side effects, 351
- antisocial personality disorder, 279
- antispasmodics, 62, 571
- antistaphylococcal antibiotics, 339
- antithrombotic therapy, 161, 161–162, 197. *See also* apixaban; dabigatran; edoxaban; rivaroxaban
- antiviral medications. *See also* acyclovir; famciclovir; valacyclovir
for herpes zoster, 338, 500
for influenza, 335–336
for neuralgia-induced headaches, 226
for post-herpetic neuralgia, 212
- anus
Crohn's disease and, 320
fecal incontinence and, 322–323, 384–385, 389
HPV and, 347
nervous system control, 383
urinary incontinence and, 392
- anxiety disorders, 276
depression with, 276–277
generalized anxiety disorder, 276
HIV infection and, 351
pharmacologic/nonpharmacologic treatment, 276
psychotherapy for, 282
- aortic aneurysm, 75
- aortic arch atheroma, 239
- aortic disease, contributing factors, 157
- aortic insufficiency, 173
- aortic stenosis (AS), 172–173
exercise risk factors, 75

Index

- aortic stenosis (AS) (cont.)
 prognosis, 172
 symptoms, 172
 treatment, 172–173
- aphasia
 cognitive impairment and, 34
 in stroke patients, 241
- APIC. *See* Association for Professionals in Infection Control and Epidemiology
- apixaban
 for ischemic stroke, 237
 prescribing cautions, 61, 174
 warfarin comparison, 179
- aplastic anemia, 218, 219
- apnea hypopnea index (AHI), 269
- apomorphine, subcutaneous, for PD, 251
- appearance assessment, 275
- appetite, 88. *See also* nutrition
- applied kinesiology, 705
- aripiprazole, 137, 645
- aromatase inhibitors, 542. *See also* anastrozole; exemestane; letrozole
- aromatherapy/use of essential oils, 707
- ARPS (Alcohol-Related Problems Survey), 53
- arrhythmias and conduction disturbances
 atrial fibrillation, 176–178 (*See also* atrial fibrillation)
 bradycardia, 176 (*See also* bradycardia)
 hypertension and, 189
 muscle weakness and, 207
 as side effect, 218
 supraventricular tachycardias, 176–179
 ventricular arrhythmias, 179
- art therapy, 676
- arterial (ischemic) ulcers, feet, 598
- arteriovenous fistula, 166
- arteriovenous malformation (AVM), 525
- arthritis. *See also* osteoarthritis; rheumatoid arthritis
 balance/mobility problems and, 108
 biomechanical inefficiency and, 79
 crystal-induced arthritis, 456–457
 early post-traumatic, 470
 exercise assessment and, 75
 exercise benefits for, 79, 81
 falling and, 108, 109
 hip and knee, 75
 lower extremity, 75
 muscle weakness and, 207
 NSAIDs for, 169
 polypharmacy and, 361
 prevalence, 109
 psoriatic, 491
 resistance training benefits, 84
 sarcopenia and, 69
- Ascertain Dementia (AD-8), screening tool, 52
- ASDs. *See* autism spectrum disorders
- aspirin
 for antiplatelet therapy patients, 169
 for CVD and diabetes, 430
 for myocardial infarction, 160
 for tension type headaches, 221
- ASSIST (Alcohol, Smoking, and Substance Involvement), 53
- ASSIST, alcohol screening assessment, 291
- assisted suicide, 7
- assisted-living facilities (ALFs), 660
- assistive devices, in rehabilitation, 618–621
- Association for Professionals in Infection Control and Epidemiology (APIC), 669
- asthma
 benefits of exercise for, 74
 beta-blockers caution, 222
 chronic, muscle weakness and, 207
 driving caution and, 693
 GERD and, 311
 reversibility of, 298
- ataxic gait, 109
- atenolol, 245–246
- atherosclerotic cardiovascular disease (ASCVD). *See also* coronary heart disease; peripheral arterial disease; strokes
 abdominal aortic aneurysm and, 199
 ACC/AHA treatment guidelines, 437–438
 age-related onset of, 436
 centenarians and, 21
 cerebrovascular, 386
 chronic inflammation in, 19
 exercise benefits for, 71
 hypertension and, 187, 188
 large artery, 234
 peripheral artery disease and, 192, 193
 prevention, treatment guidelines, 47–48
 risk factors, 157
 statin therapy, 438, 439
 strokes/TIA and, 234
 therapeutic lifestyle changes, 440–441
 types of, 440
- atherosclerotic renal vascular disease, 358
- Athlete's foot (tinea pedis), 494, 497–498, 502, 599
- atopic dermatitis (AD), 492–493
 characteristics, 492
 diagnosis, 492
 etiology, 492
 treatment options, 492–493
- atrial fibrillation
 anticoagulation for, 161, 169, 174
 CABG and, 165
 CHADS₂/CHA₂DS₂-VASc assessments, 178
 complications of, 178
 diagnosis, 177
 heart failure and, 167
 hypertension and, 189
 impact of, 157
 ischemic stroke and, 235
 management of, 177–178
 mitral stenosis and, 173–174
 peripheral arterial disease and, 199
 precipitants of, 176–177
 sick sinus syndrome and, 176
 stroke risk factors, 236
 treatment/treatment risks, 178–179
 as vascular dementia risk factor, 127
- atrophic vaginitis, 399
- atropine, 63
- AUDIT tool (Alcohol Use Disorders Identification Test), 33, 53, 290–291
- auditory issues
 age-related hearing loss, 579
 hallucinations, 275
 sudden sensorineural hearing loss, 579
 tinnitus, 579–580
- autism spectrum disorders (ASDs), 642–643
- autoimmune blistering disorders (ABDs), 495–497
 characteristics, 495–496
 classification/presentation, 498
 diagnosis, 496–497
 treatment, 497
- autoimmune hemolytic anemias (AHA), 528
- autonomic neuropathy, 212
- autonomy principle (in ethical decision-making), 2, 7, 14, 661, 688, 785–786, 797
- AVS. *See* acute vestibular syndrome
- axillary lymph node dissection (ALND), 542
- Ayurvedic medicine, 706
- azathioprine
 for atopic dermatitis, 493
 for autoimmune blistering disorders, 497
 causative for drug-induced pancreatitis, 328
 for idiopathic pulmonary fibrosis, 304
 for myasthenia gravis, 207

- azelaic acid, for rosacea, 489
- baby boom generation
alcohol misuse data, 285–286
demographic data, 1
illicit drug use data, 53, 285, 286
- Bacillus-Calmette-Guérin vaccination, 337
- baclofen, 226, 622
- bacterial conjunctivitis, 567
- bacterial meningitis, 347
- bacterial pneumonia, 333–335, 334
causes of, 334
clinical manifestations, diagnosis, 333–334
in HIV infection, 345
management, 334–335
- bacterial vaginosis, 399
- bacteriuria, asymptomatic, 368
- bacteriuria, symptomatic, 368
- balance. *See also* gait disorders;
Ménière's disease; vertigo
age-related changes, 580
common pathologies, 580
exercise assessment and, 75
stressors of, 85–86
- balance training
benefits, 85, 87
frequency, 86–87
for gait impairment, 87
general technique, 86
intensity, 86
risks, 87
volume, 86–87
- balanitis xerotica obliterans (BXO), 376
- balanoposthitis, 376–377
- ball sports, 78
- Baltimore City Almshouse, 659
- Baltimore Longitudinal Study of Aging, 8
- bapineuzumab, 136
- barbiturates, 221, 227
- baroreceptor reflex, 60
- Barrett's esophagus, 312, 314
- Bartels, S. J., 645
- Barthel Index, 35
- basal cell carcinoma (BCC), 484–485, 565–566, 577
- basic calcium pyrophosphate hydroxyapatite deposition disease, 457
- Beck Depression Inventory, 50
- Beers Criteria for Potentially Inappropriate Medications in the Elderly, 9, 33, 60–61
- behavioral/psychological symptoms of dementia, 136–138
- behavioral-variant FTD, 128
- Bellevue Hospital, 659
- Bell's palsy (facial nerve palsy), 207, 583
- beneficence principle (in ethical decision-making), 38, 788, 790, 797
- benign paroxysmal positional vertigo (BPPV), 116, 118, 119
- benign prostatic hyperplasia (BPH), 373–375
assessment/treatment decisions, 393
bladder outlet obstruction in, 386–387
medical therapies, 373, 373–374, 393
minimally invasive therapies, 375
surgery, 374–375
surgical treatment, 374–375
- benzodiazepines. *See also* temazepam
adverse drugs reactions, 62, 63
for anxiety disorders, 276
contraindication in HIV infection, 351
dosage/tolerability issues, 281–282
for essential tremor, 245–246
for insomnia, 266
metabolism and, 59–60
nonmedical use of, 286
risk factors for delirium, 150
withdrawal-induced tremors, 246
- benzotropine, for PD, 251, 251
- Berwick, Donald, 1, 758
- beta adrenergic agonists, 247. *See also* albuterol; isoproterenol
- beta blockers. *See also* atenolol; carvedilol; metoprolol; propranolol; timolol
in atrial fibrillation, 177
causative for headaches, 227
contraindication in bradycardia, 176
for essential tremor, 245–246
for glaucoma management, 571
in Grave's disease, 412
in heart failure, 168–169
in myocardial infarction, 162
oral, for acute MI, 161
for secondary headaches, 226
for stroke recurrence reduction, 238
in supraventricular tachycardias, 176
- betrixaban, 237
- bicycling, 78
- biguanides, 425–427, 426. *See also* metformin
- biliary disease. *See* cholecystitis; cholelithiasis
- bimatoprost, for glaucoma, 571–572
- biofeedback
for fecal incontinence, 393–394
for headaches, 221
for prostatodynia, 376
for tinnitus, 580
for urinary incontinence, 390, 392
- biologically-based therapies
aromatherapy/essential oils, 707
dietary therapies, 706
herbal medicines, nutraceuticals, 706–707
- biology of aging, 17–23
animal models, 18–19
antagonistic pleiotropy theory, 18
centenarians, 21–22
clinical translation of research
caloric restriction, 23
healthspan interventions, 22–23
senolytic therapy, 23
DNA damage theory, 19
evolutionary senescence theory, 18
gender differences, 22
mutation accumulation theory, 18
premature aging
childhood cancer survivors, 22
HIV patients, 22
programmed aging theory, 18–19
somatic inevitability theory, 19
tissue-level changes
cellular senescence, 20
chronic “sterile” inflammation, 19–20
macromolecular dysfunction, 20–21
progenitor cell function decline, 21
U.S. disparities, 22
- biopsychosocial-spiritual model, 1
- BIPAP (bilevel positive airway pressure) therapy, for sleep apnea, 305–306
- bipolar disorder, 278, 643
- bismuth subsalicylate, for diarrhea, 318
- bisphosphonates
atypical femur fractures and, 464–465
for cancer-related pain, 554
for osteoporosis, 218, 449, 450, 463
for Paget's disease, 451
for primary hyperparathyroidism, 409
risk factors, 311, 448
- bivalirudin, 161
- bladder
cancers, 366, 367, 369
catheter issues, 154, 369
continence/micturition mechanisms, 383–385
diabetic neurogenic bladder, 212
emptying disorders, 331, 333, 368
incontinence, and MSA, 249
myelopathy/infectious etiology
warnings, 207
neurogenic, and UTI, 333, 386–387
outlet obstruction, 359, 386–387
overactive, medications for, 370

Index

- bladder (cont.)
parkinsonism and, 248, 254
- blepharitis, 566
- Blumenthal, J. A., 756. *See also* health-care performance improvement
- BMI (body mass index), 20
as CGA component, 33
nutrition and, 92
WHO guidelines, 92
- body work, 705
- body-weight supported treadmill training (BWSTT), 622
- bone disorders. *See* metabolic bone disorders
- bone mineral density (BMD)
ART impact on, 350
ectopic ACTH production and, 415
HIV infection and, 350
hyperparathyroidism and, 409, 450
in osteoporosis, 48
testing, 446, 447
testosterone replacement therapy and, 415
- Borg's Rating of Perceived Exertion (RPE) scale, 75
- Botox (onabotulinumtoxinA), 314, 481
- bowel sphincter function, 383–385. *See also* fecal incontinence
- BPPV. *See* benign paroxysmal positional vertigo
- Braden Scale, for pressure ulcer assessment, 514
- bradycardia, 176
acute symptom treatment, 176
beta blocker contraindication, 168
as drug side effect, 169, 176
symptoms, 176
- bradykinesia
extrapyramidal disorders and, 257
Parkinson's disease and, 129, 247, 258
PSP and, 129
- BRAF inhibitors, 488
- brain biopsy, in dementia diagnosis, 134
- brain infarct, 127
- branch retinal vein occlusion (BRVO), 574
- breast cancer
characteristics, 540
clinical presentation, diagnosis, 540
epidemiology, 539
exercise benefits for, 81
management
chemotherapy, targeted therapy, 542
early stage disease, 541
endocrine therapy, 542
locally advanced disease, 543
metastatic disease, 543
surgery and radiation, 542
survivorship, 543
systemic adjuvant therapy, 542
prognosis, 541, 541
risk factors, 539, 539–540
screening and prevention, 49, 540
staging, 541, 541
- Brief Abuse Screen Inventory for the Elderly, 38
- brimonidine, 489, 571
- brinzolamide, 572
- Brody, E. M., 36
- bronchodilators, 63, 299, 678
- Brown, M., 436
- Brown-Séquard syndrome, 209
- bulbar palsy, progressive, 206
- bulbar/spinal motor neuron disease (FTD-motor neuron disease), 128
- bulimia nervosa, 292
- bunion (hallux valgus), 109, 454, 597, 600
- buprenorphine, 293
- bupropion
for major depression, 138, 278
for tobacco dependence, 54, 292
- bupirone
for anxiety disorders, 276
for cerebellar ataxia, 261
- butyrophenones, 247
- C. difficile* diarrhea, 318
- cachexia, 84, 89, 101
- CAD. *See* coronary artery disease
- caffeine
atrial fibrillation and, 177
causative for headaches, 227
GERD and, 312
for headaches, 221, 224
hypertension and, 187
osteoporosis and, 449
prostatitis and, 376
sleep issues and, 266, 267
sundowning and, 271
urinary incontinence and, 389
- CAGE questionnaire (Cut down, Annoyed, Guilty, Eye opener), 33, 53
- CAGE/CAGE-AID questionnaires, for alcohol misuse, 290
- CAHPs survey. *See* Consumer Assessment of Healthcare Providers and Systems (CAHPs) survey
- calcitonin, for osteoporosis, 449, 451
- calcium channel blockers, 60, 163. *See also* diltiazem; verapamil
for acute MI, 161
for atrial fibrillation, 177
causative for headaches, 227
contraindication in bradycardia, 176
for hypertension, 190
mechanisms of action, 190
for migraines/cluster headaches, 222
side effects, 190
for supraventricular tachycardias, 176
- calcium metabolism diseases. *See* parathyroid/calcium metabolism diseases
- calcium pyrophosphate deposition disease (CPPD), 457
- calcium supplements
for frailty, 102
loop diuretics and, 447
for osteoporosis, 218
underuse of, 64
- Caldwell, J., 646
- California Health Care Foundation (CHCF), 422–423
- caloric intake recommendations, 90
- caloric restriction (CR), 23
- cancer, 537–556. *See also* breast cancer; colorectal cancer; lung cancer; prostate cancer
age-related changes in, 17
bladder cancer, 366, 367, 369, 371–372
cachexia and, 89
CAM mind-body therapies, 704, 707
cervical cancer, 49, 400–401
chemotherapy, 176–177
childhood cancer, 22
clinical trials, 539
colon cancer, 49, 321, 321
comprehensive geriatric assessment, 537–539
endometrial cancer, 399, 401, 542
exercise benefits for, 84
gastric cancer, 316–317, 317
geriatric oncology principles, 537–539, 538
head and neck, 583
hereditary nonpolyposis colorectal cancer, 401–402
hospice care, 553
kidney cancer, 372
melanoma skin cancer, 488
non-melanoma skin cancer, 485, 486
ovarian cancer, 2, 401–402
palliative care, 552, 553, 554, 556
pancreatic cancer, 328
polypharmacy and, 361
prevention and screening
breast cancer, 49
cervical cancer, 49
colon cancer, 49
prostate cancer, 49
risk factors, 17
squamous cell bladder cancer, 369

- squamous cell esophageal cancer, 314
- symptom management, 553–556
 bowel dysfunction, 555
 dyspnea, 555–556
 fatigue, 556
 nausea and vomiting, 554–555, 555
 neuropathy, 555
 pain, 553, 554
- testicular cancer, 347
- testis cancer, 372
- thyroid gland cancer, 413
- urethral cancer, 372
- USPSTF screening recommendations, 49
- uterine cancer, 401
- vaginal cancer, 400
- vulvar cancer, 400
- candesartan, 171
- candidiasis
 esophageal, 314, 345
 HIV infections and, 345, 346
 odynophagia and, 314, 314
 oral (thrush), 345, 346
 UTIs and, 333
 vulvovaginitis and, 398
- capecitabine, 542
- captopril, 168
- carbamazepine
 for bipolar disorder, 278
 exacerbation of tremors, 247
 for neuralgia-induced headaches, 226
 for seizure treatment, 219
 side effects, 218
- carbon dioxide retention headaches, 228
- carbonic anhydrase inhibitors, topical and oral
 for glaucoma, 572
- cardiac arrhythmia, 118, 135, 325
- cardiac resynchronization therapy (CRT), 170
- cardiologist, 2
- cardiomyopathy, 207, 238
- cardiopulmonary disease, 462
- cardiovascular disease (CVD). *See also* atherosclerotic cardiovascular disease; coronary artery disease
 age-related risk factors, 17, 436–437
 antihypertensive considerations, 429
 aspirin recommendation, 430
 diabetes risk factors, 429–430
 glycemic control in, 424
 HIV infection and, 347, 348–349
 inflammatory factors in, 20
 insomnia and, 270
 ischemic stroke and, 235
 markers of, 2
 statins for prevention, 429–430
 surgery, 12
- cardiovascular endurance training, 78–79
- Cardiovascular Health Study (CHS), 437, 438
- cardiovascular system, aging's effects on, 60, 157, 158
- caregiver burden
 assessing, 751, 751
 behavioral disturbances, 136
 as CGA domain, 32
 depression, 139–140
 description, 749–750
 economic, 241, 750
 increased mortality, 37, 750
 interventions for, 125, 140, 646, 751–752, 752
 Jane, case study, 749, 751, 752–754
 limiting factors, 1
 lost work days, 5
 social and emotional, 126, 241, 750
- caregiving/caregivers, 749–754
 challenges facing, 614
 for coronary disease patients, 165
 cross-cultural perspectives, 752
 definition, 749
 for delirium patients, 151, 281
 for dementia patients, 139–140, 281, 283, 750–751
 for diabetes patients, 422
 for Down syndrome patients, 646
 driving questions about patient, 694
 economic issues from caregiving, 4
 elder abuse and, 37, 52, 687
 epidemiology of, 749
 Family Caregiver Alliance report, 4
 for fecal incontinence patients, 389
 for gait disorder patients, 256
 GEM units assessment of, 40
 health impact of, 4, 37, 126, 750
 health literacy and, 38
 home-based, 4
 for ID/SPMI patients, 640, 646, 749
 informal, by family and friends, 654–655
 irreplaceability of, 621
 Medicaid funding data, 4
 medication counseling for, 65
 for pain management patients, 553
 for Parkinson's disease patients, 256
 patient drug adherence and, 64
 peer intervention support for, 646
 physician communication with, 33, 518, 709
 physician recommendations to, 4
 for pressure ulcer patients, 509, 517
 rating of patient's driving ability, 139, 694
 rehabilitation role of, 616, 623
 resources for, 753
 shortages, in the aging society, 726–727, 728
 for sleep disorder patients, 271
 for stroke patients, 240, 241
 support programs for, 140, 752
 training for, 137
 U.S. data on, 4
 for UTI patients, 241, 369, 389, 393
- CARET. *See* Comorbidity Alcohol Risk Evaluation Tool
- carotid disease, 237, 238–239
- Carotid Revascularization Stenting *versus* Endarterectomy Treatment of Carotid-Artery Stenosis (CREST) trial, 239
- carvedilol, 162
- cataracts/cataract surgery, 49, 568–570, 569, 692
- catechol-o-methyltransferase (COMT) inhibitor, 253
- cauda equina syndrome, 196
- Causative Classification of Stroke System (CSS), online database, 233–234
- cautious gait, 259, 261
- CBTI. *See* Cognitive Behavioral Treatment for Insomnia
- ceftaroline, for MRSA, 340
- cellular senescence, 20
- cellulitis, 479, 495, 497–499
- Center for Advance Palliative Care (CAPC), 671
- Center of Epidemiologic Studies Depression Scale (CES-D), 35
- Centers for Disease Control and Prevention (CDC)
 coverage for wellness visits, 51
 herpes vaccine (Zostavax) recommendation, 47
- Centers for Medicare and Medicaid Services (CMS), 51, 509, 510–511, 664, 758
- central nervous system lymphomas, 347
- central retinal vein occlusion (CRVO), 574
- central sleep apnea (CSA), 266–267, 305
- cephalosporin, third generation, 335
- cerebellar ataxia, 258, 260–261
- cerebral amyloid angiopathy, 127
- cerebral aneurysm, 75
- cerebral hemorrhage, 127
- cerebrovascular accident, 8
- cerebrovascular atherosclerosis, 386
- cerebrovascular disease (CVD), 127, 205. *See also* atherosclerotic cardiovascular disease; cerebral

Index

- amyloid angiopathy; vascular dementia/vascular cognitive impairment (VaD/VCI); white matter lesions
 epileptic seizures and, 216
 headaches as symptom, 227–228
 hypertension and, 189
 migraine similarity to, 223
 parkinsonism and, 250
 certolizumab, 456
 cervical cancer, 400–401
 prevention, 49
 screening guidelines, 49, 401
 treatment options, 401
 cervical polyps, 399–400
 cervical spondylosis, 386
 CES-D. *See* Center of Epidemiologic Studies Depression Scale
 CGA. *See* comprehensive geriatric assessment
 CHF. *See* California Health Care Foundation
 chemotherapy
 atrial fibrillation and, 176–177
 healthcare-associated pneumonia and, 301, 302
 neoadjuvant, to surgery, 317
 cherry angiomas, 480, 482
 chewing function, 88
 CHF. *See* congestive heart failure
 childhood cancer, premature aging in, 22
 chiropractic, 704, 705, 706, 708
 ChIs. *See* acetylcholinesterase inhibitors
 chlamydia, 347, 400, 567
 chlordiazepoxide, 59
 chlorpromazine, 221, 223, 417
 chlorpropamide, 427
 cholecystitis, 327
 cholelithiasis, 327
 Cholesterol and Recurrent Events (CARE) trial, 439
 Cholesterol Treatment Trialist Collaboration, 438
 Choosing Wisely Initiative, 10–11
 choreic gait, 259
 chronic bronchitis, 299
 chronic conjunctivitis, 567
 chronic disease management, 1, 652
 chronic inflammatory demyelinating polyneuropathy (CIDP), 212
 chronic kidney disease (CKD), 358
 anemia and, 523, 526
 cachexia and, 89
 complications, 358
 creatine levels, 357
 ESRD and, 357, 358
 HIV infection and, 349
 hyperparathyroidism and, 409–410
 prevalence of, 357, 358
 renal osteodystrophy and, 451
 chronic liver failure (CLF), 89
 chronic lymphocytic leukemia (CLL), 529, 531
 chronic myeloid leukemia (CML), 531
 chronic obstructive pulmonary disease (COPD), 298–301
 acute exacerbations of, 300
 anorexia and, 88
 cachexia and, 89
 carbon dioxide retention headaches in, 228
 classifications, 299, 299
 defined, 298
 diagnosis, 299, 299
 exercise benefits for, 84
 GERD diagnosis and, 311
 infections and, 331
 influenza vaccine for, 300
 management of, 299–300
 muscle weakness and, 207
 nontuberculous mycobacterium in, 305
 rehabilitation strategies, 300
 sepsis and, 306
 smoking cessation recommendation, 299–300
 special considerations, 300–301
 treatment, 299
 chronic vestibular syndrome (CVS), 122
 differential diagnosis, 122
 treatment, 122
 cirrhosis of the liver. *See also* primary biliary cirrhosis
 chronic viral hepatitis and, 325
 pericardial constriction and, 175
 sepsis and, 306
 citalopram, 137, 276, 277
 Civil Rights Act (1964), Title VI, 737
 CKD mineral-bone disorder, 358
 Clark, B., 8
 claudication. *See* intermittent claudication
 clindamycin
 for bacterial vaginosis, 399
 for MRSA, 340
Staphylococcus aureus, 583
 for vaginal discharge, 399
 Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE, 2006), 137
 Clock Drawing Test (CDT), 39, 52, 132, 693
 clonazepam
 for anxiety disorders, 276, 282
 dosage/tolerability issues, 281–282
 for REM sleep behavior disorder, 254
 clonidine, 54, 176
 clopidogrel, 160, 161, 162, 178, 197
 clotrimazole, 502, 599
 clozapine, 137
 cluster headaches, 222, 223
 Cochrane Database Review, 29, 92
 Cockcroft-Gault (CG) equations, 60
 Cognitive Behavior Social Skills Training, 645
 cognitive behavioral therapy (CBT), 292
 Cognitive Behavioral Treatment for Insomnia (CBTI), 266
 cognitive function
 CGA assessment, 32, 34
 diabetes-related changes, 431
 falling risk factors, 109
 HIV infection and, 350
 IADLs as indicators of, 36
 insulin self-administration and, 428
 interdisciplinary assessment of, 29
 maintaining, 1
 medications and, 63
 NPH and, 260
 physical activity benefits, 136
 Positive Attitude Towards Life correlation, 14
 religiosity/spirituality and, 38
 slower walking and, 110
 cognitive impairment. *See also* mild cognitive impairment
 caregiver report on, 33
 differential diagnosis, 130
 driving and, 692
 exercise benefits for, 81, 84
 falling and, 108, 109
 frailty and, 100
 in HIV infection, 351
 hypertension and, 189
 mild cognitive impairment, 51
 psychiatric evaluation, 276
 risk factors, 17, 53
 screening for, 34, 132, 134
 sleep apnea and, 269
 stroke and, 623–624
 underdiagnosis of, 51
 walking for exercise in, 79
 colchicine
 for acute pericarditis, 175
 for constipation, 323
 for CPPD, 457
 for gout, 456, 603
 colon disorders
 colon cancer, 49, 321, 321
 diarrhea, 317–319, 318
 diverticular disease, 319–320, 320
 inflammatory bowel disease, 320, 320–321
 colonic ischemia, 323–325, 324
 causes, 324

- diagnosis, 324–325
treatment, 325
- colonoscopy, indications for, 321
- colorectal cancer (CRC), 525, 546–550
clinical presentation, 548
epidemiology, 546
prognosis, 548, 548
risk factors, 546–547
screening and prevention, 547
stage 1–3 (early stage) disease
adjuvant chemotherapy, 549, 549–550
follow up, 550
surgery and radiation, 549
stage 4 (advanced stage) disease, 550
staging, 548, 548
- Commission on Law and Aging
(American Bar Association), 689
- communication skills, 1, 5–6
- community-acquired pneumonia
(CAP), 301, 302, 334
- community-based long-term care,
651–656
adult day care programs, 4, 655, 752
home care, 4, 652
home health care (HHC), 652
hospice care programs, 2, 3, 172,
553, 655–656
informal caregiving, 654–655
medical house calls, 652–653
nutrition programs, 655
PACE programs, 656
residential care facilities, 653–654
VHA programs, 656
- commuted fractures, 463–464
- Comorbidity Alcohol Risk Evaluation
Tool (CARET), 291
- compassionate care, 1, 12–13
- complementary and alternative medicine (CAM)
alternate healing systems
chiropractic, 704, 705, 706, 708
homeopathy, 706, 707–708
naturopathic medicine, 706, 708
spiritual healing practices, 708
Traditional Chinese Medicine,
706, 707
Traditional Oriental Medicine,
707
- biologically-based therapies
aromatherapy/essential oils, 707
dietary therapies, 706
herbal medicines, nutraceuticals,
706–707
definition, 702
growing use of, 702–703
manipulative/body-based therapies
massage, body work, 705
touch therapies, 705
mind-body therapies
biofeedback/neurofeedback, 704,
709 (*See also* biofeedback)
hypnosis, 703, 704, 709
meditation, 704–705
mindful exercises, 705, 709
- Natural Medicines Comprehensive
Database, 707
- patient-provider disconnect about,
704
- prevention/wellness/self-care
emphasis, 710
rationale for integrating, 708–710
reasons for using, 703–704
- comprehensive geriatric assessment
(CGA), 28–40
adherence to recommendations, 30
analyses/evaluations of, 28–29
Cochrane Review of, 29
components (assessments), 28–29,
30, 32
ADL, 35
affect, 34–35
cognitive, 34
driving, 38–39
environment, 37
falls, 36
functional assessment, 35
health literacy, 38
history, 32–33
IADL, 36
incontinence, 36–37
nutrition, 37
pain, 39
physical examination, 33–34
social, 37–38
spirituality, religiosity, 38
- content/construct/criterion validity,
30
- domains of, 32
for frailty, 28, 103
goals of, 28–29
group investigations findings, 29
instruments use in, 30–31
mobile applications for, 31
patient selection/targeting criteria,
29–30, 30, 32
in primary care settings, 29
settings for, 39–40
- Comprehensive Unit-based Safety
Program (CUSP, AHRQ), 757
- compression/entrapment neuropathy,
212
- compulsions, 275–276
- “The Computer-Based Patient Record:
An Essential Technology for
Health Care” (IOM), 763–764
- computerized tomography, 12
- condylomata acuminata, 347
- Conflict Tactics Scale, 38
- confusion
in Alzheimer’s disease, 127
in delirium, 151, 274, 332
as disorder symptom, 8, 63
in diverticulitis, 320
from medication
antihistamines, 496
benzodiazepines, 266
lomotil, 318
memantine, 135
opioid analgesics, 63
tricyclic antidepressants, 62, 222
MI and, 159
in pneumonia, 334
seizures and, 216
in subarachnoid hemorrhage, 225,
228
in sundowning, 137, 271
in transient ischemic attacks, 223
- Confusion Assessment Method
(CAM), 40, 150–151, 151, 306
- congenital heart disease, 10
- congestive heart failure (CHF), 10
ACE inhibitors for, 190
angiotensin receptor blockers for,
191
beta blockers for, 191
cachexia and, 89
colonic ischemia and, 325
muscle weakness and, 207
PRT benefits for, 84
- conjunctival malignancy, 567
- conjunctivitis, 566–567
- connective tissue diseases, 207
- constipation, 321–323. *See also* fecal
incontinence
common causes, 322
delirium and, 149, 154
diabetes and, 212
diagnosis, 322–323
diverticular disease and, 319
as drug side effect, 62, 215, 293
ischemic stroke and, 240
PD and, 254
treatment, 323, 323
- constraint-induced movement therapy
(CIMT), 622
- constrictive pericarditis, 166
- construct validity, in CGA, 30
- Constructional Praxis, 133
- Consumer Assessment of Healthcare
Providers and Systems (CAHPS)
survey, 759
- content validity, in CGA, 30
- continence assessment (of CGA), 32,
34
- continuity of care, 1, 3
- continuity theory, of retirement, 732
- COPD. *See* chronic obstructive pul-
monary disease
- Coppus, A. M., 641

Index

- cornea, 567–568
 acanthamoeba infection, 568
 Fuchs endothelial corneal dystrophy, 567
 fungal keratitis, 568
 infectious keratitis, 568
- Cornell Scale for Depression, 35
- corns (feet). *See* hyperkeratotic lesions, feet
- coronary artery disease (CAD). *See also* cardiovascular disease
 age-related incidence, 437
 aspirin for, 169
 beta blockers for, 191
 clinical presentation, 158–159
 contributing factors, 157
 epidemiology/primary prevention, 157
 heart failure and, 166
 HIV infection and, 347
 hypertension and, 189
 peripheral arterial disease and, 199
 PRT benefits for, 84
 sleep apnea and, 269
 statin therapy for, 162
- coronary bypass surgery, 161
- coronary care units, 3
- coronary heart disease (CHD), 439–440
- coronaviruses, 335. *See also* Middle East respiratory syndrome; severe acute respiratory syndrome
- corticobasal ganglionic degeneration
 classic symptoms, 250
 discovery, MRI findings, primary pathology, 249
- corticosteroids
 adverse drug reactions, 62
 in giant cell arteritis, 227
 in gout, 457
 in myasthenia gravis, 207
 in osteoarthritis, 455
 in pain management, 676
 in refractory pericarditis, 175
- cough headaches, 224
- Cousins, N., 6
- CPAP (continuous positive airway pressure) therapy, for sleep apnea, 269–270, 305–306. *See also* PAP (positive airway pressure) therapy
- CPPD. *See* calcium pyrophosphate deposition disease
- CPT code. *See* Current Procedural Terminology (CPT) code
- cranial neuropathy, 212
- C-reactive protein
 frailty and, 100
 HIV infection and, 348
 inflammation and, 20, 348
 lipid management and, 437, 439
- MI and, 159
 peripheral artery disease and, 192
- creatinine, 60
- Creutzfeldt-Jakob disease, 129–130
- criterion validity, in CGA, 30
- critical care (ICU) issues, 306
- critical limb ischemia (CLI), 194, 198–199
- Crohn's disease, 314, 320–321, 379, 588
- “Crossing the Quality Chasm” report (IOM), 1, 757
- crowded nest syndrome, 5
- cryptococcal meningitis, 345
- cryptogenic stroke, 236
- crystal-induced arthritis, 456–457
- cultural aspects of health care, 5
- cultural competence
 cohort experiences, 739–740
 cross-cultural geriatric assessments, 741
 cultural humility/unconscious bias, 738–739
 definition, 735
 eliciting explanatory models, 740, 740, 741
 epidemiology of disease risks, 740
 as ethnogeriatric imperative, 735–736
 health beliefs and values, 739
 LEARN model of cross-cultural communication, 741
 of organizations, 736–738, 737
 of providers, 738
 showing culturally appropriate respect, 740–741
 working with interpreters, 741
- cultural humility, 738–739
- Culturally and Linguistically Appropriate Standards (CLAS), in health and health care, 736–738
- curcumin, 23
- Current Procedural Terminology (CPT) code, 778
- Cushing's syndrome, 416–417
 adrenal nodules and, 415
 ectopic ACTH production and, 415, 416
 hypertension and, 188
 osteoporosis and, 416, 447, 463
 cutaneous T-cell lymphoma, 494
- CVS. *See* chronic vestibular syndrome
- cyclobenzaprine, 63
- cyclosporine
 exacerbation of tremors, 247
 for myasthenia gravis, 207
 for psoriasis, 491
- cyst of the follicular infundibulum, 483
- cystoid macular edema, 569
- cytokines, 20
- cytomegalovirus (CMV) enteritis, 345
- cytomegalovirus (CMV) retinitis, 345
- D2 antagonists. *See also* metoclopramide; prochlorperazine
 for cancer-related nausea, vomiting, 555
- dabigatran
 for ischemic stroke, 237
 prescribing cautions, 61, 174
 for pulmonary embolism, 304
 warfarin comparison, 179
- dalteparin, 161, 161
- dancing, 78
- daptomycin, 339, 340
- darifenacin, 370, 390
- DART program. *See* Diabetes Awareness and Rehabilitation Training (DART) program
- DASH (Dietary Approach to Stop Hypertension) diet, 440
- Davis, T. C., 745
- day care programs, for adults, 4, 655, 752
- decision-making. *See* ethical decision-making
- deep brain stimulation (DBS)
 for ET treatment, 246
 for Parkinson's disease, 245, 255, 624
- deep vein thrombosis (DVT)
 hospitalization risks, 467
 patent foramen ovale and, 238
 pulmonary embolism and, 303
 regional anesthesia and, 466
 strokes and, 240
- deficit model of frailty, 98
- delirium, 148–152
 caregiving suggestions, 154
 characteristics, 130
 cognitive impairment and, 34
 Confusion Assessment Method, 40, 150–151, 151
 diagnosis, 148, 150–151
 diagnostic studies, examples, 153
 drug nonadherence and, 64
 economic costs of, 148
 environmental modifications for, 40
 etiology, 149–150
 evaluation, 151, 152
 Hospital Elder Life Program, 150, 151
 management strategies, 152–154
 as medication side effect, 9, 62, 63, 150
 medication strategies, 150
 pain assessment, 154
 pathophysiology, 149
 pharmacological treatment, 154–155
 prediction of, 150

- predisposing/precipitating factors, 149, 154
- prevalence/incidence, in care settings, 149
- prevention, 150
- prognosis/mortality rate, 148
- with psychiatric disturbances, 8
- psychotic symptoms in, 280
- underdiagnosis of, 148
- delirium room (restraint free room), 154
- delusional disorder, 280, 667
- delusions
- antipsychotics for, 138
 - assessment for, 275
 - in bipolar disorder, 278
 - in cognitive disorders, 280, 281
 - in DLB, 129, 249
 - elopement and, 667
 - in Huntington's disease, 281
 - in major depression, 277
 - in Parkinson's disease, 248, 281
 - possible psychiatric causes, 280
- dementia. *See also* Alzheimer's disease
- advance care planning, 139
 - age-related changes in, 17
 - CAM mind-body therapies, 704, 707
 - caregiving issues, 4, 137, 139–140
 - CGA assessment, 34
 - cognitive impairment and, 34
 - community resources, 140
 - definition, 125
 - depression with, 138, 281
 - diagnostic approach, 131–134
 - brain biopsy, 134
 - cognitive assessment, 132–133
 - genetic testing, 133
 - history, 131–132
 - laboratory evaluation, 133
 - neuroimaging, 133–134
 - physical examination, 132
 - screening guidelines, 134
 - Down syndrome and, 641
 - driving and, 139
 - elder abuse and, 687–688
 - elopement issues, 667
 - epidemiology, 125
 - ethical decision-making, case study, 801–802
 - gait disorders and, 108, 109
 - HIV-associated (HAD), 350
 - home-based interventions, 4
 - intellectual disabilities and, 641
 - lifestyle management, 136
 - management issues, 136–139
 - behavioral disturbances, 136–138
 - depression, 138, 281
 - safety, 139
 - mild cognitive impairment and, 641
 - myxedema and, 10
 - nutrition, 136
 - pain assessment in, 39, 674
 - parkinsonism and, 248
 - potentially reversible, 131
 - prevention and screening, 51–52
 - psychotic symptoms in, 280, 281
 - risk factors, 125–126, 126, 136
 - sleep disorders and, 267, 271–272
 - subtypes, 126–131
 - Alzheimer's Disease, 126–127
 - Creutzfeldt-Jakob disease, 129–130
 - delirium, 130
 - dementia with Lewy bodies, 128–129
 - dementia with parkinsonism, 128
 - frontotemporal dementia, 128
 - mild cognitive impairment, 130–131
 - normal pressure hydrocephalus, 130
 - Parkinson's Disease Dementia, 129
 - progressive supranuclear palsy, 129
 - reversible dementia, 130
 - VaD/VCI, 127–128
 - treatment, 134–136
 - nonpharmacological, 136–137
 - pharmacological, 134–136, 137–138
- Dementia with Lewy Bodies (DLB)
- antipsychotics, cautions, 138
 - causes, 126
 - delusions in, 129, 249
 - dementia and, 249
 - description, 128–129
 - discovery, MRI findings, primary pathology, 249
 - presenting symptoms, 249
- dementia with parkinsonism, 128
- demographics of an aging society, 719–728
- active life expectancy projections, 721
 - caregiver shortages, 726–727
 - changing government policies, 723
 - consumer spending, 722
 - death rate impact, 721
 - family relationships, 727–728
 - federal/state entitlement programs
 - Medicaid, 725–726 (*See also* Medicaid)
 - Medicare, 724–725 (*See also* Medicare)
 - Social Security, 659, 724, 728
 - global consequences, 719
 - health care delivery, 727
 - housing needs, preferences, 722–723
 - labor shortages, 722
 - life expectancy projections, 720–721
 - slowing gait speed impact, 721–722
- demyelinating neuropathies, 212. *See also* chronic inflammatory demyelinating polyneuropathy; Guillain-Barré Syndrome; multiple sclerosis
- denosumab, 448
- dental care, 587–595. *See also* oral cavity
- aging-related caries, gum disease, 582
 - American Dental Association on, 587
 - endocarditis and, 173, 175
 - glandular tissue, 591–592
 - age-related changes, 591
 - examination techniques, 591–592
 - xerostomia, 313, 459, 591–592, 592
 - jaw necrosis, 448
 - joints and osteology (*See also* temporomandibular joint)
 - age-related changes, 589–590
 - anatomy/characteristics, 589
 - examination techniques, 590
 - muscles of mastication, facial expression
 - age-related changes, 590
 - anatomy/characteristics, 590
 - examination techniques, 590–591
 - nerves (*See also* trigeminal neuralgia)
 - age-related changes, 591
 - anatomy/characteristics, 591
 - examination techniques, 591
 - oral cancer, chemotherapy consideration, 589
 - oral mucosa
 - age-related changes, 588
 - anatomy/characteristics, 588
 - examination techniques, 588
 - oral prosthetic devices, 587
 - osteonecrosis of the jaws, medications, 590
 - periodontium
 - age-related changes, 593
 - examination techniques, 593
 - prevention/patient considerations, 594
 - prognosis/oral, dental problems, 34
 - prosthetic devices
 - age-related changes, 594
 - examination techniques, 594
 - types of, 594
 - systems assessment, 33
 - teeth, 593
 - age-related changes, 593
 - categories, 593
 - examination techniques, 593–594

Index

- dental care (cont.)
 structure, 593
 vessels, 592
- depression. *See also* antidepressants
 anorexia and, 88
 anxiety with, 276–277
 assessment tools, 35, 40
 in brain diseases, 277
 CAM mind-body therapies, 704, 707
 of caregivers, 4
 CGA assessments, 30, 32, 34–35
 chronic depression, 278–279
 cognitive impairment and, 34
 in dementia patients, 138, 281
 diabetes with, 2
 driving and, 692
 elder mistreatment and, 52
 exercise benefits for, 81, 84
 existential vacuum and, 6
 HIV infection and, 350, 351
 IADLs as indicators of, 36
 interdisciplinary assessment of, 29
 ischemic stroke and, 236
 late-onset mania and, 278
 major depression, 277–278
 medication as cause of, 277
 neuropsychiatric disturbance in, 8
 parkinsonism and, 248
 post-stroke depression, 240, 277
 prevention and screening, 50
 psychotherapy for, 282
 screening tools, 50
 severe, and SPMI, 643
 sleep apnea and, 269
 sleep disorders and, 271
 St. John's Wort for, 706, 709
 suicidal ideation in, 138, 277
 symptoms, 50
 treatment
 electroconvulsive therapy, 278
 psychopharmacologic,
 277–278
 USPSTF screening recommenda-
 tions, 34, 50
- dermatochalasis, 565
- dermatologic conditions, 477–502
 age-related changes, 478
 dermatitis, 399
 dermatomyositis, 207
 in HIV infection, 347
 infectious diseases, 497–502
 cellulitis, 479, 495, 497–499
 erysipelas, 497–499
 herpes zoster, 499–500 (*See also*
 herpes zoster)
 intertrigo, 502
 onychomycosis, 501–502
 scabies, 492, 500–501
- inflammatory diseases, 488–497
 atopic dermatitis, 492–493
 autoimmune blistering disorders,
 495–497
 lower extremity stasis-related
 changes, 493–495
 pruritus, 493
 psoriasis, 490–492
 rosacea, 488–490
 seborrheic dermatitis, 490
- non-melanoma cancer, treatments,
 486
- in phimosis, 376
 pruritus, 399
- skin, functions
 aesthetic, 480
 age-related changes, 478, 480
 immunological barrier, 478–479
 photoaging mitigation, 480–481
 physical barrier, 478
 thermoregulation, 479
 ultraviolet light protection, 479
 wound healing, 479–480
- skin, structure, 477–478
- skin lesions, benign, 481–483
 acrochordons, 481–482
 actinic purpura, 483
 cherry angiomas, 480, 482
 epidermal inclusion cysts, 483
 sebaceous hyperplasia, 483
 seborrheic keratosis, 480, 482
 solar lentigines, 480, 482–483
- skin lesions, malignant, 483–488
 actinic keratosis, 485–487
 basal cell carcinoma, 484–485
 melanoma, 487–488
 squamous cell carcinoma,
 485–487
- in ulcerative colitis, 321
- dermatophytic onychomycosis (tinea
 unguium), 501–502
- desipramine, 277, 338
- dexamethasone, 555
- diabetes, type 2
 DART lifestyle intervention, 645
 exercise recommendations, 69, 70,
 84, 424
 insulin/ketosis resistance in, 422
 screening recommendations, 422
- Diabetes Awareness and Rehabilitation
 Training (DART) program, 645
- diabetes mellitus, 421–432
 aspirin for, 169
 as CAD risk equivalent, 157
 cardiovascular risk factors, 429–430
 cognitive function and, 431
 comorbidities, 431–432
 depression with, 2
 epidemiology of, 421–422
 exercise benefits, risks, 81, 82
 eye disease risk factors, 430
 falling risks, 53
- family considerations, 432
 fixed-dose agents for, 64
 foot care in, 430–431
 foot health and, 602–603
 heart disease comorbidity, 127
 hyperglycemia and, 8
 hypertension and, 189
 hypoglycemic agents, 425–429,
 426
 biguanides, 425–427, 426
 DPP-4 inhibitors, 426, 428
 insulin therapy, 428–429
 meglitinides, 426, 427
 self-monitoring, 429
 SGLT2 inhibitors, 426
 sulfonyleureas, 426, 427
 thiazolidinediones, 426, 427
- infections and, 331
- inflammatory factors in, 20
- insulin-dependent, 21
- ischemic stroke and, 235
- management, 422–425
 CHCF/AGS guidelines, 422–423
 collaborative, 422
 components of care, 423
 diet and weight loss, 423
 exercise, 423–424
 glycemic control, 424–425
 smoking, 424
- in Native Americans, 421
- nephropathy screening, 431
- osteoporosis and, 447
- peripheral arterial disease and, 197,
 199
- polypharmacy and, 361
- renal elimination and, 60
- screening, 422
- sensory peripheral neuropathy in,
 122
- skin conditions related to, 477
- strokes and, 238
- UK Prospective Diabetes Study, 424,
 425
- vitamin D and, 91
- diabetic nephrosclerosis, 358
- diabetic neuropathy, 11, 210–211
 ACE inhibitors for, 190
 angiotensin receptor blockers for,
 191
 forms of, 212
- diabetic retinopathy, 49, 430,
 573–574
- Diagnosis-Related Groups
 (DRG), 777
- Diagnostic and Statistical
 Manual of Mental Disorders
 (DSM-5)*
- delirium diagnostic criteria, 148
- dementia diagnostic criteria, 125,
 148

- depression diagnostic screening tools, 50
- major depressive order definition, 50
- substance use disorder criteria, 288
- substance use disorders diagnostic criteria, 285
- diagnostic rating groups (DGRs), 660
- diarrhea, 317–319, 318
- in autonomic neuropathy, 212
- diagnosis, 318
- infectious, 320
- lower GI bleeding and, 320
- as medication side effect, 135, 253, 313
- from memantine, 135
- treatment, 318–319
- diazepam, 59, 218, 281–282
- diet. *See also* nutrition
- Dietary Reference Intakes, 89–90
- IOM caloric recommendations, 90
- macronutrients and, 90, 423
- micronutrients and, 51, 90, 102, 374
- renal disease modification, 60
- vitamin B12 and, 90–91
- vitamin D and, 91
- Dietary Guidelines for Americans* (2010), 89
- dietary reference intakes (DRIs), 89–90
- dietary therapies, 706
- Diffuse Lewy Body Disease, 249
- Digitalis Investigation Group (DIG), digoxin trial, 169
- digiti flexus (hammertoe deformity), 597, 600
- digoxin, 59, 62, 171
- contraindication in bradycardia, 176
- in heart failure, 169
- in supraventricular tachycardias, 176
- dilated cardiomyopathy, 21
- diltiazem, 163, 176, 177
- dipeptidyl peptidase-4 (DPP-4) inhibitors, 426, 428. *See also* alogliptin; linagliptin; saxagliptin; sitagliptin
- diphenhydramine, 150
- diplopia, 122, 204, 206
- direct thrombin inhibitors, 237. *See also* dabigatran
- disease modifying anti-rheumatic drugs (DMARDs), 455–456
- disengagement theory, of retirement, 731–732
- disposable soma theory of aging, 18
- disseminated mycobacterium avium complex, 345
- distal radius fractures, 471–472
- disulfiram, 292
- diuretics, 60
- falling risks, 62
- in heart failure, 168
- potassium-sparing, 162 (*See also* eplerenone; spironolactone)
- thiazide-type, 190
- divalproex sodium, 278
- diverticular disease, 319–320, 320
- bleeding, 319, 319
- complications, 320
- diagnosis, 319–320
- Dixie-Hallpike maneuver, 119
- dizziness, 116–122. *See also* vertigo
- acute vestibular syndrome, 120–122
- differential diagnosis, 121
- treatment, 121–122
- chest pain, dyspnea, nausea with, 116
- chronic vestibular syndrome, 122
- differential diagnosis, 122
- treatment, 122
- classification, 117–118
- descriptors for, 116
- diagnostic challenges, 118
- episodic vestibular syndrome, 118–120
- differential diagnosis, 119–120
- treatment, 120
- fall risk factors, 53, 63, 116
- from memantine, 135
- presyncope overlap, 116
- seizures and, 216
- triggers/symptoms, 117, 118
- DNA damage theory, 19
- dobutamine, 169
- The Doctor and the Soul* (Frankl), 6
- doctor-patient relationship, 6–8
- partnership building, 1, 6, 7–8
- rules/steps in knowing the patient, 7
- therapeutic benefit of respect in, 12
- DOLOPLUS-2 (pain rating scale), 39
- Donelan, K., 750
- donepezil, 134, 176
- Doorway Thoughts: Cross-cultural Health Care for Older Adults* (American Geriatrics Society), 739
- dopamine agonists, 251, 253. *See also* apomorphine, subcutaneous; pramipexole; ropinirole; rotigotine
- Dopamine Transporter SPECT scan (DaT), 248
- dopaminergic agents, 245, 261
- dorzolamide, for glaucoma, 572
- double effect principle, 799, 799, 680
- Down syndrome (DS)
- Alzheimer's disease and, 641
- cognitive decline rates, 641–642
- dementia comorbidity, 641
- family caregiving in, 646
- intellectual disability and, 640
- premature death risks, 641
- doxazosin (Cardura), 373, 393
- doxepin, 63, 222, 268
- doxycycline
- for blepharitis, 566
- for MRSA, 339, 340
- for pneumonia, 302
- for prostatitis, 375
- for UTI, 368
- DPAHC. *See* durable power of attorney for health care
- DPP-4 inhibitors. *See* dipeptidyl peptidase-4 (DPP-4) inhibitors
- DRIS. *See* dietary reference intakes
- Driver Safety Program (AARP), 695
- driving and the older adult, 691–698
- caregiver resources, 140
- cataract surgery and, 569
- cessation recommendation, 697
- characteristics, 691
- dementia and, 139
- drinking and, 291
- epilepsy and, 220
- family members' assessments, 203
- fatality rates/safety factors, 38–39
- functional changes, 691–692
- interventions
- referral to specialists, 695–696
- resources for older drivers, 696
- self-assessment, education programs, 694–695
- legal and ethical issues, 697–698
- medical assessment
- advisory panels' reports, 692–693
- driving history red flags, 693
- targeted history, 693, 694
- targeted physical exam, 693–694
- medical risk factors, 692, 692
- medication risk factors, 692, 692
- occupational therapy for, 617
- prevention, screening, 54
- sleep apnea and, 269
- Driving Decisions Workbook*, 694
- droperidol, 62
- drug abuse (illicit drugs)
- baby boom prevalence rates, 53, 285, 286
- as history component, 33
- of opioids, 286, 293
- drug use, as history component, 33
- drug-induced liver disease, 326
- drug-induced parkinsonism, 250
- drugs (prescription). *See also* adverse drug reactions; specific categories of drugs, individual drugs
- acidic effects, 59
- adherence, 64
- Beers Criteria, 9, 33, 60–61
- inappropriate prescribing, 58

Index

- drugs (prescription) (cont.)
 nontherapeutic use data, 286
 pharmacodynamic changes, 58, 60
 pharmacokinetic changes, 58
 absorption, bioavailability, 58–59
 adverse reactions to, 61
 age-related changes, 58
 distribution, 59
 metabolism, 59–60
 renal elimination, 60
 polypharmacy, 58, 61, 62
 STOPP/START criteria, 61
 strategies for improving use, 65
 underutilization, 63–64
- ductal carcinoma *in situ* (DCIS), 541
- duloxetine
 for anxiety disorders, 276
 for cancer-related pain, 554
 for chronic pain in dyspepsia, 316
 for neuropathic pain, 215, 215
- duodenal ulcers (DUs), 315, 320
- duodenitis, 320
- durable power of attorney for health
 care (DPAHC), 781, 782, 785, 786, 798
- dutasteride, for BPH, 374, 393
- dysdiadochokinesia, 260
- dyslipidemia
 as CAD risk factor, 157
 growth hormone deficiency and, 415
 HIV infection and, 349
 vitamin D and, 91
- dyspepsia
 antidepressants for depression in, 316
 defined/prevalence, 315–316
 presentation, 316
 treatment, 316
- dysphagia, 313–315
 ALS and, 206
 classifications, 313
 diagnosis, 314
 GERD and, 311, 580
 muscle weakness and, 208
 myasthenia gravis and, 206
 odynophagia, 314, 314
 parkinsonism and, 248
 presentation, 314
 stroke and, 240, 623
 treatment, 314–315
- dyspnea
 in aortic stenosis, 172
 dizziness with, 116
 end-of-life care for, 677–679
 heart failure and, 166
 in pericardial tamponade, 175
 pulmonary embolism and, 302
- dystonic gait, 258
- ear, middle and inner
 age-related changes, 578
 common pathologies, 578–579
 cholesteatomas, 578–579
 otitis media, 578
- ear, outer
 age-related changes, 577
 common pathologies, 577–578
 actinic keratosis, 577
 acute otitis externa, 577
 basal cell carcinoma, 577
 herpes zoster oticus, 578
 malignant otitis externa, 578
 squamous cell carcinoma, 577
- early onset Alzheimer's Disease, 133
- Early Treatment of Diabetic Retinopathy (ETDRS) chart, 49
- EASI. *See* elder abuse suspicion index
- ectopic ACTH production, 415, 416
- edoxaban, in ischemic stroke, 237
- Education in Palliative and End-of-Life Care (EPEC), 672
- Eighth Joint National Committee (JNC8), 47
- Einstein Aging Study, 109
- Elahi, D., 8
- elder abuse, 685–690
 Alzheimer's Disease and, 687–688
 assessment for, 37–38
 breadth and depth of, 685–686
 by caregivers, 687
 decision making capacity and, 688–689
 dementia and, 687–688
 detection strategies, 52, 688
 prevalence, 52, 686
 prevention and screening, 52
 reporting, 689–690
 screening tools, 52
 state legislation, 689
 triggers of concern for, 483
 types of, 37–38, 685
 vulnerability to victimization, 686
- elder abuse suspicion index (EASI), 52
- Elder Mistreatment: Abuse, Neglect, and Exploitation in an Aging America* (National Academies), 685
- elderly patient care, basis principles, 1
- electroconvulsive therapy (ECT), 278
- Electronic Health Record (EHR)
 Incentive Program, 761
- electronic health records (EHRs), 3, 10, 764–765
- emotional disorders, 8
- emphysema
 COPD and, 299
 essential tremor and, 246
 muscle weakness and, 207
- empty nest syndrome, 5
- enalapril, 168
- en-bloc turning, gait pattern in PD, 259
- endocarditis, 175
- endocrine disorders, 408–417
 adrenal glands
 adrenal insufficiency, 417
 Cushing's syndrome, 188, 415, 416–417
 nodules, 415
 pheochromocytoma, 117, 188, 415, 416
 primary aldosteronism, 415–416
- ART cautions and, 348
- muscle weakness and, 207
- neuroendocrine theory, 18
- parathyroid/calcium metabolism diseases
 hypercalcemia of malignancy, 410
 hypoparathyroidism, 410
 multiple parathyroid gland hyperplasia, 450
 primary hyperparathyroidism, 408–409
 secondary/tertiary hyperparathyroidism, 409–410
 vitamin D deficiency, 409
- pituitary gland
 ectopic ACTH production, 415, 416
 hypopituitarism, 413–415
- thyroid gland
 cancer, 413
 hyperthyroidism, 176–177, 188, 411–412
 hyperthyroidism, subclinical, 412
 hypothyroidism, 50–51, 211, 410–411
 hypothyroidism, subclinical, 411
 nodules, 412–413
- endocrine pathways, 100
- Endocrine Society, 409, 412
- endocrine therapy, adjuvant in breast cancer treatment, 542
- end-of-life care. *See also* advance care planning; advance directives
 communication strategies, 672–673
 cultural shifts in, 671
 decision making, 172, 241
- dyspnea
 management, 678–679
 pathophysiology, 678
 for imminently dying, 679–681
 nausea and vomiting
 assessment, 677, 677
 management, 677, 678
 mechanisms, 676–677, 677
 need for improvement, 7
 in nursing facilities, 661–662
 pain management, 674–676
 adjuvant analgesics, 676
 assessment, 674

- dosing and titration, 675–676
 nonpharmacologic approaches, 676
 opioid selection, 674–675, 675
 professional education programs, 672
- End-of-Life Nursing Education Consortium (ELNEC), 672
- endometrial cancer, 399, 401, 542
 endometrial polyps, 399–400
 endometriosis, 399–400
- Endovascular and Open Surgical treatment for Limb Salvage, 198–199
- end-stage renal disease (ESRD)
 chronic kidney disease and, 357
 diabetes and, 431
 dialysis treatment for, 361
 exercise benefits for, 84
 sepsis and, 306
 transplantation in, 361
- enoxaparin, 161, 161
- entacapone
 enhancement of levodopa, 253
 for PD, 251, 253
 side effects, 253
- enterovaginal fistula, 399
- entitlement programs, federal and state
 Medicaid, 725–726 (*See also* Medicaid)
 Medicare, 724–725 (*See also* Medicare)
 Social Security program, 659, 724, 728, 774
- environmental assessment, in CGA, 37
- EPESE (Established Populations for Epidemiological Studies of the Elderly) physical performance tests, 36
- epidermal inclusion cysts, 483
 epidermoid cysts, 483
 epididymitis, 377
- epilepsy. *See* seizure disorders
- epiphora, 565
- epiretinal membrane (ERM), 573
- episodic vestibular syndrome (EVS), 118–120
 differential diagnosis, 117, 119–120
 spontaneous episodes, 119
 treatment, 120
- epirolone, 161, 162
- eptifibatide, 161, 161
- erectile dysfunction (ED), 635, 635
- ergotamines, for migraines, 221, 223
- erysipelas, 497–499
- erythema elevatum diutinum, 495
- erythematotelangiectatic rosacea (ETR), 489
- erythrodermic psoriasis, 491
- Esbensen, A. J., 646
- eslicarbazepine, for seizures, 219
- esomeprazole (Nexium), for GERD, 312
- esophageal candidiasis (thrush), 345
- esophageal disorders
 dysphagia, 313, 313–315, 314 (*See also* dysphagia)
 esophageal adenocarcinoma, 312
 gastroesophageal reflux disease, 311–313 (*See also* gastroesophageal reflux disease)
 squamous cell esophageal cancer, 314
- esophageal dysphagia, 313
- esophageal ulcer, 320
- esophageal varices, 320
- esophagitis, pill-induced, 311
- ESRD. *See* end-stage renal disease
- essential thrombocytosis (ET), 532
- essential tremor
 chief patient complaints, 245
 Parkinsonian tremor comparison, 245, 245, 248
 treatment choices, 245–246, 246
- estrogen creams, 399
- estrogen progesterone therapy (EPT), 403
- estrogen replacement therapy
 for atrophic vaginitis, 380
 ineffectiveness in dementia, 135
 in postmenopausal women, 369, 448
 risk factors, 368
- estrogen therapy (ET), 403
- eszopiclone, for insomnia, 268
- etanercept
 for psoriasis, 491–492
 for rheumatoid arthritis, 456
- ethambutol, for tuberculosis, 337
- ethical decision-making, 1, 797–804
 actions and intentions, 799
 actions resulting in death, 799–801
 case studies
 disclosing dementia diagnosis, 801–802
 nutrition and hydration, 803–804
 substituted judgment and medical futility, 802–803
 clinical decision-making interface, 10
 general principles, 797
 autonomy, 2, 7, 14, 661, 688, 785–786, 797
 beneficence, 38, 788, 790, 797
 double effect, 680, 799, 799
 justice, 797
 nonmaleficence, 797
 goals of care and, 798–799
 informed consent and, 138, 665, 781, 786
 intelligent treatment and, 10–11
- patient involvement, 2, 7, 14, 661, 785–786, 790–790, 797–798 (*See also* advance care planning; advance directives)
 Principle of Double Effect, 799, 799
- ethnicity, lifespan disparities, 22
- Ethnogeriatrics Committee of the American Geriatric Society (AGS), 739
- European Pressure Ulcer Advisory Panel (EPUAP), 510, 511, 514–518
- euthanasia, 7, 799–801
- evidence-based knowledge, 10
- evolutionary senescence, 18
- EVS. *See* episodic vestibular syndrome
- exemestane, 542
- exercise
 aerobic, 78–83 (*See also* aerobic exercise)
 aging goals, 69–70
 AHA guidelines, 48
 balance training, 85–87 (*See also* balance training)
 benefits, 70–75, 71–74
 cardiovascular endurance testing, 75
 claudication and, 82
 diabetes management and, 423–424
 frail elders and, 10, 79, 80, 81, 84, 102
 frailty and, 10
 for gait disorders, 261
 goals and objectives, 69–70
 heart rate and, 80
 intolerance, and heart failure, 166
 isometric contraction, 85
 muscular benefits of, 70
 nutrition and, 70
 for osteoporosis prevention, 48
 pre-exercise assessment, 75–78
 prescription of, 78
 rationale for integration, 70
 risks, 82
 STOP! WAIT! GO! screening, 76–77
 strength assessment, 75
 strength training, 83–85 (*See also* progressive resistance training)
- existential psychotherapy, 6
- exploding headache syndrome, 224
- extrapyramidal disorders, 257
- eyelids and lacrimal system, 564–566
 aging-related structural changes, 565
 basal cell carcinoma, 565–566
 blepharitis, 566
 dermatochalasis, 565
 epiphora, 565
 eyelid malpositions, 567
 eyelid neoplasms, 565–566
 lagophthalmos, 565
 nonmalignant tumors, 566

Index

- eyelids and lacrimal system (cont.)
 ocular cicatricial pemphigoid, 565
 punctal stenosis, 565
 sebaceous cell carcinoma, 566
 squamous cell carcinoma, 566
 eyes. *See* vision/visual conditions
- face pain scales, 39
- facial expression muscles
 age-related changes, 590
 anatomy/characteristics, 590
 examination techniques, 590–591
- facial nerve palsy (Bell's palsy), 583
- falls. *See also* gait disorders
 balance training for, 85
 biomechanics of, 110
 CGA assessment, 34
 commonality of, 107
 in Dementia with Lewy Bodies, 249
 driving and, 692
 environmental hazards, 37
 exercise benefits, 69
 exercise benefits for, 84
 exercise-based interventions, 111–112
 home-visit reduction trials, 37
 insomnia and, 265
 prevention and screening, 53
 risk assessment, 30, 36
 risk factors, 107–108
 vitamin D and, 91
- famciclovir
 for herpes zoster, 338, 500, 568
 for Ramsay Hunt syndrome, 578
- familial Alzheimer's Disease, 133
- family and home, bolstering of, 1, 3–5
- family assessment, 283
- Family Caregiver Alliance National Center on Caregiving, 4
- famotidine, 312
- Fanconi syndrome, 348, 349
- fasting, 706
- fat pad atrophy, 602
- febuxostat, for gout, 457
- fecal incontinence (FI), 321–323. *See also* constipation; urinary incontinence
 absorbent pads/continence products, 394–395
 age-related changes and, 383
 characteristics and types, 387
 classification for, 385
 conditions contributing to, 385–386
 continence/defecation mechanisms, 383–385
 defined, 383
 diabetes and, 212
 evaluation
 diagnosis, 322–323, 388–389
 history, 387
 physical examination, 387–388
 fecal impaction and, 387
 ischemic stroke and, 240
 non-age-related risk factors, 383
 prevalence/underreporting of, 321–322, 383
 treatment options
 biofeedback, 393–394
 dietary modifications, 393
 injectable agents, 394
 in long-term care facilities, 395
 other surgical therapies, 394
 pharmacologic, 394
 sacral neuromodulation, 394
 urge, passive, mixed, overflow, 387, 387
 with urinary incontinence, 383
- Feldenkrais method, 705
- female disorders. *See also* breast cancer; gynecological issues; menopause; ovarian cancer; postmenopause
 atrophic vaginitis, 380
 bacterial vaginosis, 399
 fecal incontinence, 383
 genitourinary fistulae, 379–380
 pelvic organ prolapse, 380
 urethral caruncle, 379
 urethral diverticulum, 379
 urinary incontinence, 383, 386
 vaginal cancer, 400
 vesicovaginal fistula, 399
 vulvar cancer, 400
 vulvar intraepithelial neoplasia, 399, 400
 vulvar squamous cell carcinoma, 400
- femoral neck hip fractures, 466, 467–469
- fentanyl
 for cancer-related pain, 554
 as opioid alternative, 675
- Ferrence, B. A., 436
- fesoterodine, for OAB and UI, 390, 391
- festination, gait pattern in PD, 259
- fetal alcohol syndrome, 640
- fibrinolytic therapy, in acute STEMI patients, 163, 163
- fibrosa cystica, 408
- finasteride, for BPH, 374, 393
- 5 Million Lives Campaign (Institute for Healthcare Improvement), 514
- 5HT-3 antagonists, 555. *See also* ondansetron
- 5- α -reductase inhibitors, 374, 393. *See also* dutasteride; finasteride
- flapping gait, 11
- floppy-iris syndrome, 374
- fluid/electrolyte disorders, 360
- fluoroquinolone
 for bacterial conjunctivitis, 567
 for COPD, 300
 for pneumonia, 301, 302, 335
 for urinary tract infection, 368
- 5-fluorouracil cream, for non-melanoma skin cancer, 485, 486
- fluoxetine (Prozac)
 for anxiety disorders, 276
 for chronic pain in dyspepsia, 316
 interaction/side effect cautions, 138, 282
 for major depression, 277
- focal neurological deficits, 121
- focal segmental glomerulosclerosis, 358
- folate, 236
- foot health, 597–604
 care of the feet, 604
 examination, 597
 foot osteoarthritis, 454
- forefoot disorders
 digiti flexus (hammertoe deformity), 597, 600
 fracture of phalanx/stress fracture, 601
 hallux valgus (bunion), 597, 600
 Morton's neuroma, 601, 602
 sesamoiditis, 600–601
- heel disorders
 Achilles tendinitis, 602
 fat pad atrophy, 602
 plantar calcaneal bursitis, 602
 plantar fasciitis, 602
 tarsal tunnel syndrome, 602
- midfoot disorders
 pes planus (flatfoot), 601
 posterior tibial tendon dysfunction, 601–602
- skin and nail conditions, 597–600
 dystrophies, 600
 hyperkeratotic lesions, 598
 onychocryptosis, 599–600
 onychomycosis, 481, 501–502, 599
 paronychia, 600
 pruritus, 598
 subungual hematomas, 600
 tinea pedis, 494, 497–498, 502, 599
 ulceration, 598–599
 venous stasis dermatitis, 598
 xerosis, 597–598
- systemic diseases
 diabetes, 430–431, 602–603
 gout, 603–604
- forefoot disorders
 digiti flexus (hammertoe deformity), 597, 600
 fracture of phalanx/stress fracture, 601
 hallux valgus (bunion), 597, 600

- Morton's neuroma, 601
 sesamoiditis, 600–601
 Fracture Risk Assessment Tool (FRAX), 48, 350
 fragile X syndrome, 640
 FRAIL (Fatigue, Resistance, Aerobic, Illness, Loss of Weight) scale, 98
 frailty (frail elders), 97–103
 aerobic assessment in, 75
 age-related prevalence, 98–99
 anorexia and, 100, 101
 blood pressure and, 47
 cachexia and, 101
 CGA assessment, 28, 103
 characteristics of, 29
 childhood cancer and, 22
 clinical care/applications, 101
 collaborative treatment for, 11
 comorbidities/disability association, 99
 deficit model, 98
 definition, 97
 driving risk factors, 38
 elder mistreatment and, 37–38, 52
 endocrine pathways and, 100
 exercise recommendations, 10, 79, 80, 81, 84, 102
 frailty cycle, 99
 gait impairment and, 98
 gender-related prevalence, 99
 home-based interventions, 4
 hormonal intervention for, 102–103
 IL-6 correlation to, 20
 immune system and, 100
 individualized treatments, 9
 malnutrition and, 100, 101
 musculoskeletal system and, 100
 natural history of, 99–100
 nutritional intervention for, 102
 pathogenesis of, 99
 phenotype model, 97–98, 98
 polypharmacy and, 103
 race/ethnicity-related prevalence, 99
 risk assessment, 29, 101
 sarcopenia and, 99, 100
 screening tools, 98
 signs and symptoms, 101–102
 sleep disorders and, 271
 stages of, 100
 survival data, 99
 Framingham Risk Score, 157, 436
 Frankl, V. E., 14
 The Doctor and the Soul (Frankl), 6
 Man's Search for Meaning, 6
 on using hope as therapeutic tool, 6
 FRAX. *See* Fracture Risk Assessment Tool
 free radicals, 19
 free thyroxine index (FT4I) test, 51
 frontal lesions/frontal gait pattern, 109, 259–260
 frontotemporal dementia (FTD), 128
 FT4I. *See* free thyroxine index
 FTD. *See* frontotemporal dementia
 Fuchs endothelial corneal dystrophy, 567
 functional ability domain (of CGA), 32
 functional capacity, 28, 31
 functional impairment, as CGA component, 30
 functional limitations, 28
 functional status, 28
 CGA assessment of, 35
 interdisciplinary assessment of, 29
 gabapentin, 150
 for cancer-related pain, 554
 for essential tremor, 245–246
 for herpes zoster, 500
 for neuralgia-induced headaches, 226
 for neuropathic pain, 676
 for postherpetic neuralgia, 338
 for seizure treatment, 219
 gait apraxia (frontal gait disorder), 258, 260
 gait disorders, 107–112
 assessment/examination, 32, 36, 109, 257
 balance training for, 87
 biomechanics of, 79, 110
 causes of instability, 53
 classifications, patterns, etiologies, 258–259
 cautious gait, 259, 261
 cerebellar ataxia, 258, 260–261
 cerebellar gait, 260–261
 choreic gait, 259
 dystonic gait, 258
 frontal lesions/frontal gait pattern, 109, 259–260
 gait apraxia, 258, 260
 hemiparetic gait, 258, 261
 normal pressure hydrocephalus, 260
 paraparetic gait, 258
 Parkinson's Disease, 257–259
 psychogenic gait, 259
 sensory ataxia, 258, 261
 Spastic (scissoring) gait, 261
 steppage gait, 258, 261
 sudden gait failure, 257
 vestibular ataxia, 258
 waddling gait, 258, 261
 contributing conditions, 86
 differential diagnosis, 256–257
 evaluation, 257
 exercise benefits, 75, 102
 exercise-based interventions, 111–112
 flapping gait, 11
 foot problems and, 109
 frailty and, 98
 general concepts, 256
 localization by signs, symptoms, 257
 in multiple sclerosis, 204
 musculoskeletal conditions, 109
 neurological conditions, 108–109
 non-neurological, 109
 parkinsonism and, 250
 prevalence/outcomes, 108
 rehabilitation, 622
 slips and trips, 110–111
 speed determination, 36
 Tinetti Balance and Gait evaluation, 53
 treatment, 261
 gait kinematics/kinetics, 110
 gait speed, 110
 galantamine, 134
 gastric cancer, 316–317, 317
 gastric ulcers (GUs), 315, 320
 gastritis, 320
 gastroesophageal reflux disease (GERD), 311–313
 complications, 312
 differential diagnosis, 312
 dysphagia and, 311, 580
 presentation/diagnosis, 311–312
 treatment and prevention, 311, 312, 312–313
 gastrointestinal diseases, 311–328
 anorectal disorders
 colonic ischemia, 323–325, 324
 constipation/fecal incontinence, 321–323
 biliary disease
 cholecystitis, 327
 cholelithiasis, 327
 bleeding, UGI and LGI, 320
 colon disorders
 colon cancer, 49, 321, 321
 diarrhea, 317–319, 318
 diverticular disease, 319–320, 320
 inflammatory bowel disease, 320, 320–321
 esophageal disorders
 dysphagia, 313, 313–315, 314
 gastroesophageal reflux disease, 311–313
 liver disease, 325
 drug-induced, 326
 hepatic ischemia, 326
 hepatocellular carcinoma, 326
 primary biliary cirrhosis, 326
 viral hepatitis, 325–326
 malnutrition and weight loss

Index

- gastrointestinal diseases (cont.)
 diagnosis, 328
 treatment, 329
 pancreatic disease
 acute pancreatitis, 327–328
 cancer, 328
 chronic pancreatitis, 328
 stomach disorders
 dyspepsia, 315–316
 gastric cancer, 316–317, 317
 peptic ulcer disease, 315, 315
 gastrointestinal stromal tumors (GISTs), 316
 Gattefosse, Rene Maurice, 707
 GDS. *See* Geriatric Depression Scale
 generalized anxiety disorder, 276
 genetic basis for aging, 18–19
 genomics, 12
 GERD. *See* gastroesophageal reflux disease
 Geriatric Depression Scale (GDS), 35, 50, 150, 741, 751
 Geriatric Evaluation and Management (GEM) units
 CGA in, 40
 geriatric medicine, 2
 geriatric nurse practitioners, 28
 geriatric occupational therapy, 28
 geriatric oncology principles, 537–539, 538
 geriatric pharmacy, 28
 geriatric physical therapy, 28
 geropsychiatry, 28, 274–283
 evaluation
 history, 33, 274–275
 mental status, 275–276
 HIV infection management, 350–351
 hospital setting, 274
 irreversible cognitive disorders, treatment, 281
 medical clinic setting, 274
 nursing homes/long-term care, 274
 pharmacotherapy issues, 281–282
 psychotherapy
 barriers to treatment, 283
 family assessment, 283
 individual, 282
 marital, 282–283
 specific conditions
 anxiety disorders, 276
 anxiety with depression, 276–277
 mood disorders, 277–279
 personality disorder, 279–280
 psychotic symptoms, 280–281
 suicide, 279
 Gerstmann-Sträussler-Scheinker syndrome, 129
 Get Up and Go test, 36, 53
 GFR. *See* glomerular filtration rate
 giant cell arteritis (GCA), 225, 227, 458, 575
 ginkgo biloba, 135
 glandular tissue, oral, 591–592. *See also* xerostomia
 age-related changes, 591
 examination techniques, 591–592
 glaucoma, 49, 570–572
 angle-closure glaucoma, 571
 driving and, 692
 management, 571–572
 primary open-angle glaucoma, 570–571
 risk factors, 570
 glipizide, 427
 Global Initiative for Chronic Obstructive Lung Disease (GOLD), 298, 299
 glomerular disease, 358
 glomerular filtration rate (GFR), 60
 glomerulosclerosis, 21
 glucocorticoid therapy
 for cancer-related pain, 554
 for multiple sclerosis, 205
 glyburide, 427
 glycoprotein IIb/IIIa inhibitors, 161, 161. *See also* abciximab; eptifibatid; tirofiban
 Golden Rule, 13
 Goldstein, J., 436
 golimumab, for rheumatoid arthritis, 456
 gonorrhoea, 347, 400
 Goodheart, George, 705
 Gorecki, C., 516
 gout
 description, 456
 diagnosis, 603–604
 differential diagnosis, 454
 foot health and, 603–604
 presentation, 456, 603
 secondary arthritis and, 453
 stone disease and, 371
 thiazide diuretics caution, 190
 treatment, 456–457, 603–604
 types of, 603
 GPRO. *See* Group Practice Reporting Option
 Grave's disease, 411–412
 grief/grieving, 279, 282
 grip strength, 75
 Group Practice Reporting Option (GPRO), 762
 growth factors, 20
 growth hormone
 age-related decline, 100
 deficiency diagnosis, 414
 for frailty, 100, 102
 hypopituitarism and, 415
 mice research, 19, 20
 for muscle strength, 84
 pituitary adenomas and, 413
 growth-hormone (GH) deficiency, 414
 Guide to Clinical Preventive Services, 10
 Guillain-Barré Syndrome, 205, 205–206
 gynecological issues, 398–405. *See also* menopause; post-menopause
 age-related vaginal atrophy, 400
 bacterial vaginosis, 399
 bleeding, 399–400
 cancers
 cervical, 400–401
 endometrial cancer, 399, 401
 ovarian, 401–402
 ovarian cancer, 2, 401–402
 uterine cancer, 401
 vaginal, 400
 vulvar, 400
 differential diagnosis, 399
 dyspareunia, 405
 evaluation, 398
 hormone therapy, risks and benefits, 404
 pelvic organ prolapse, 402
 pruritus, 399, 399
 sexuality and sexual dysfunction, 403–405
 sexually transmitted infections, 399, 400
 vaginal discharge, 399
 vulvodynia, 399
 vulvovaginitis, 398–399
H. pylori infection, 315, 316, 317
 H-2 blockers, 227
 H₂RAs for dyspepsia, 316
 hair, aging-related changes, 481
 Haldane, J. B. S., 18
 hallucinations
 antipsychotic medication and, 138
 assessment for, 275
 elopement issues, 667
 in major depression, 277
 management of, in PD, 252
 as medication side effect, 63, 251
 parkinsonism and, 248
 possible psychiatric causes, 280
 types of, 275
 visual, in Dementia with Lewy Bodies, 129, 249
 hallux valgus (bunion), 109, 454, 597, 600
 haloperidol, 150
 for acute agitation, aggression, 137
 adverse effects, 62
 for delirium management, 155, 680
 for nausea and vomiting, 555, 678

- Hamilton Rating Scale for Depression, 50
- hammertoe deformity (digiti flexus), 109, 597, 600
- HAND. *See* HIV-associated neurocognitive disorder
- hand osteoarthritis, 453–454
- Harman, Denham, 19
- Harner, Michael, 708
- HCAP. *See* health-care associated pneumonia
- headaches, 220–229
 - acute, in HIV infection, 347
 - evaluation of, 228–229
 - primary types, 221–224, 224
 - cluster headache, 223
 - cough headaches, 224
 - exploding headache syndrome, 224
 - hypnic, 224
 - migraines, 222–223 (*See also* migraine headaches)
 - tension headache, 221–222
 - treatments, 221, 222
 - uncommon trigeminal autonomic cephalgias, 224
 - secondary types, 224–228, 225–226
 - carbon dioxide retention, 228
 - cerebrovascular disease, 227–228
 - giant cell arteritis, 227
 - intracranial mass, 227
 - medication-related, 227
 - meningitis-related, 228
 - neck disease-related, 228
 - neuralgia-induced, 224–227
 - ocular etiologies, 228
- Health and Retirement Study, 12
- health care system. *See also* Medicaid; Medicare
 - costs, perspectives on, 778–780
 - delivery stems financing,
 - organization
 - hospitals, 777
 - nursing facilities, 778
 - physicians, 777–778
 - description, 769–770
 - financial principles, 772–774
 - inequalities in, 1
 - insurance basics, 770–772
 - international perspective, 770
- Health Information Technology for Clinical and Economic Health (HITECH), 764
- health literacy
 - assessments, 38, 743
 - definition, 742
 - Healthy People 2010 recommendation, 742
 - influential factors, 742
 - NAAL report, 742
- patient outcomes and, 742–743
 - strategies for addressing
 - clinical communication, 743–744
 - improving print materials, 744
 - optimizing modality, 745
 - universal precautions, need for, 745
- Health Literacy Universal Precautions toolkit, 745
- Health Literate Care Model, 745
- health maintenance, 1, 9–10
- health perception, interdisciplinary assessment of, 29
- health-care associated pneumonia (HCAP), 301, 302
- Healthcare Effectiveness Data and Information Set (HEDIS), 759, 763
- healthcare performance improvement, 756–766
 - Donabedian's structure, process, outcome model, 756
- healthcare information technology
 - electronic health records, 764–765
 - patient registries, 764
 - role of, 763–764
- incentive programs
 - EHR Incentive Program, 761
 - GPRO, 762
 - Hospital Quality Alliance, 762
 - Meaningful Use Initiatives (CMS), 760
 - Medicare Hospital VBP program, 760, 763
 - Medicare Value-based Modifier, 762
 - PQRS, 758, 761–762, 765
 - reporting hospital quality data, 762–763
- Institute of Medicine reports, 1, 756–757
- key organizations, resources, 766
- main approaches, methodologies
 - Lean manufacturing, 757
 - PDSA Cycle, 757
 - Six Sigma, 757
- private sector organizations
 - AMA-PCPI, 759–760
 - HEDIS/CAHPS, 759, 763
 - IHL, 758
 - Leapfrog Group, 759
 - NCQA, 758–759
 - NQF, 760
 - quality improvement organizations, 759
- public sector organizations
 - AHRQ, 757–758
 - CMS, 51, 509, 510–511, 664, 758
- Healthcare-Associated Infection Program (AHRQ), 757
- healthcare-associated pneumonia (HCAP), 301, 302
- healthspan interventions, 22–23
- Healthy People 2020 initiative, 509, 742
- hearing
 - delirium and, 152
 - neurological assessment, 203
 - sundowning and, 137
 - systems assessment, 33
- hearing and vision screen domain (of CGA), 32, 33–34
- Hearing Handicap Inventory for the Elderly, 34
- hearing problems
 - as CGA component, 30
 - prevention and screening, 49
- heart disease. *See also* cardiovascular disease
 - AD comorbidity with, 127
 - in centenarians, 21
 - congenital/rheumatic, 10
 - driving safety and, 54
 - exercise benefits for, 81
 - exercise risks, 82
 - global burden of, 157
 - ischemic heart disease (*See* ischemic heart disease)
 - prevention knowledge limitations, 9
- heart failure (HF)
 - albumin concentration and, 59
 - atrial fibrillation and, 176–177
 - clinical features, 166
 - contributing factors, 157
 - device therapy, 170
 - diagnosis, 166–167, 167
 - epidemiology, pathophysiology, 166
 - etiology, prevention, 166
 - LVADs in, 169–170
 - MI and, 159
 - pharmacologic management, 167–169
 - ACE inhibitors, 168
 - angiotensin receptor blockers, 168
 - anticoagulant/anti-inflammatory drugs, 169
 - beta blockers, 168–169
 - digoxin, 169
 - diuretics, 168
 - hydralazine nitrates, 168
 - inotropic agents/intravenous vasodilators, 169
 - mineralocorticoid antagonists, 169
 - precipitants of, 167
 - prognosis, 172
 - rehospitalizations, 172
 - sleep disorders and, 271

Index

- heart failure with preserved ejection fraction (HFpEF), 170, 171, 172
- Heart Protection Study, 440
- heart transplantation, mechanical circulatory support, 169–170
- heartburn. *See* gastroesophageal reflux disease
- heavy metals, exacerbation of tremors, 247
- HEDIS. *See* Healthcare Effectiveness Data and Information Set
- heel disorders
- Achilles tendinitis, 602
 - fat pad atrophy, 602
 - plantar calcaneal bursitis, 602
 - plantar fasciitis, 602
 - tarsal tunnel syndrome, 211, 602
- Heller, K., 642, 646
- Helping Older People Experience Success (HOPES) program, 645
- hematologic malignancies
- the leukemias, 531–532, 532
 - multiple myeloma, 529–531
 - myeloproliferative neoplasms, 532–533
- hematospermia, 367
- hematuria, 366–367
- associated conditions, 367
 - causes, 366
 - CKD and, 357
 - diagnosis, 366, 366–367
- hemiparetic gait, 109, 258, 261
- hemodialysis, 12
- hemorrhagic strokes, 227–228
- fatality risks, 233
 - fibrinolytic therapy and, 163
 - headaches and, 227–228
 - neuroimaging in, 234
 - risk factors, 235
 - seizures in, 216, 218
 - warfarin and, 178
- hemorrhoids, 320
- hemostatic system, effects of aging, 159
- heparin, low-molecular weight (LMWH)
- for pulmonary embolism, 304
 - for VTE prevention, 240
- heparin, unfractionated, 161
- for pulmonary embolism, 304
 - for VTE prevention, 240
- hepatic failure, 218
- hepatic function, polypharmacy and, 9
- hepatic ischemia, 326
- hepatitis B virus (HBV), 347, 350
- hepatitis C virus (HCV), 347, 350
- hepatocellular carcinoma, 326, 350
- herbal medicines, nutraceuticals, 706–707
- hereditary nonpolyposis colorectal cancer (HNPCC), 401–402
- herpes zoster (shingles), 337–338, 499–500
- acute vestibular syndrome and, 121
 - clinical manifestations, diagnosis, 337–338
 - diagnosis/treatment, 212, 500
 - headache with, 224
 - management, 338
 - pharmacologic treatment, 338, 500
 - postherpetic neuralgia complication, 46–47, 211–212, 338
 - presentation, 499–500
 - prevalence/causes, 499
 - sequelae, 500
 - vaccination, 46–47, 212, 226, 338, 500
- herpes zoster ophthalmicus (HZO), 212, 500
- herpes zoster oticus (Ramsay Hunt syndrome), 121, 500, 578
- HHS Measure Inventory, 758
- high intensity interval training (HIIT), 80
- hiking, 78
- Hill-Burton Act (1946), 660
- hip fractures, 466–469
- from adverse drug reactions, 62
 - balance impairment risks, 85
 - balance training benefits, 87
 - delirium and, 150
 - diagnosis, 467
 - dizziness and, 116
 - femoral neck, 466, 467–469
 - intertrochanteric, 466, 469
 - as medication side effect, 135
 - osteoporosis and, 446
 - outcomes, 467
 - presentation, management, 466–467
 - prevention, 448
 - principles, 466
 - rehabilitation, 624–625
 - resistance training benefits, 84
 - subtrochanteric, 466
 - surgical delay study findings, 465
 - treatment goals, 462
- hip osteoarthritis, 454
- Hippocrates, 13
- Hippocratic tradition, 10, 13, 799
- Hispanics
- dementia, prevalence, 125–126
 - glaucoma, incidence, 570
 - lifespan, 22
- histamine-2 receptor antagonists, 62, 312
- Histoplasma capsulatum*, 334
- HITECH (Health Information Technology for Clinical and Economic Health), 764
- HIV dementia scale, 351
- HIV (human immunodeficiency virus)
- infection, 344–353. *See also* anti-retroviral therapy
 - age-related diagnosis data, 632
 - aging process and, 347–348
 - antiretroviral therapy for, 344
 - clinical characteristics
 - dermatologic conditions, 347
 - infections, 345–347
 - malignancies, 347
 - neurologic conditions, 347
 - older vs. younger adults, 349 - depression and, 350, 351
 - epidemiology of, 344
 - fixed-dose agents for, 64
 - lifestyle changes with, 351
 - management considerations, 348–352
 - ART adherence, 351, 352
 - ART-associated adverse events, polypharmacy, 352
 - bone health, fractures, 350
 - cardiovascular disease, 348–349
 - cognitive impairment, 351
 - functional decline, 351
 - HAND, 351
 - liver disease, 349–350
 - peripheral neuropathy, 351
 - psychiatric illness, 350–351
 - renal disease, 349 - Men's AIDS Cohort Study, 348
 - misdiagnosis/delayed diagnosis, 633–634
 - muscle weakness and, 207
 - premature aging in, 22
 - screening and diagnosis, 344–345, 346
 - small fiber polyneuropathy and, 211
 - testing for, 332
 - transmission risk factors, 630, 632
 - treatment, 352–353
- HIV wasting, 84
- HIV-associated dementia (HAD), 350
- HIV-associated nephropathy, 349
- HIV-associated neurocognitive disorder (HAND), 351
- HIV-associated non-AIDS (HANA) conditions, 633–634
- HIV-related toxoplasmosis, 347
- HNPCC. *See* hereditary nonpolyposis colorectal cancer
- Hobbs, H. H., 436
- Hodgkins lymphoma, 540
- Home and Community Based Services (HCBS), 655
- home care, 652
- bolstering of, for patients, 1, 3–5
 - home health care (HHC), 652
 - information for caregivers about, 140

- medical house calls, 652–653
 physician recommendation for, 4
 problem-specific programs, 653
 safety assessment, 37
 home health agency, 32
 homeopathy, 706, 707–708
 HOPES program. *See* Helping Older People Experience Success (HOPES) program
 hormone therapy (HT). *See also* estrogen replacement therapy; testosterone therapy
 causative for headaches, 227
 for frailty, 102–103
 in hypopituitarism, 414–415
 for post-menopausal symptoms, 402–403, 404
 in postmenopausal women, 448
 risks and benefits, 404
 for urinary tract infection, 369
 vaginal bleeding from, 399–400
 hospice care programs
 Alzheimer's care costs, 126
 complementary pain management in, 676
 continuity of care issues, 3
 description, 655–656
 goals of, 2
 for heart failure, 172
 home hospice, 652
 life expectancy considerations, 172
 Medicare Home Hospice, 661
 in nursing facilities, 661–662
 palliative care comparison, 671
 quality of life focus, 553
 specialized teams in, 3
 Hospital Elder Life Program, 150, 151
 Hospital Insurance Trust Fund, 774
 Hospital Quality Alliance (HQA), 762
 Hospital Readmission Reduction Program (Affordable Care Act), 172
 hospital-acquired pneumonia (HAP), 301, 302
 hospital-acquired pressure ulcers (HAPUs), 509, 511
 HPV. *See* human papilloma virus infection
 human lifespan (life expectancy), 1
 centenarians, 21–22
 childhood cancer survivors and, 22
 HIV patients and, 22
 strategies for increasing, 17
 human papilloma virus (HPV) infection, 347, 400
 hydralazine nitrates, for heart failure, 168
 hydrocele, 377–378
 hydrocephalus. *See* hydrocephalus *ex vacuo*; normal pressure hydrocephalus; obstructive hydrocephalus
 hydrocephalus *ex vacuo*, 260
 hydromorphone, 554, 675
 hydroxychloroquine, for rheumatoid arthritis, 455
 hyperactive delirium/hypoactive delirium, 151
 hyperaldosteronism, 188, 415
 hypercalcemia of malignancy, 410
 hypercholesterolemia
 peripheral arterial disease and, 196–197
 risk factors, 198
 treatment algorithm, 436
 hyperglycemia, 8
 hyperhomocysteinemia, 235, 236
 hyperkalemia, 360
 diuretic side effects, 190
 electrolyte abnormalities in, 179
 hyperkeratotic lesions, feet, 598
 hyperlipidemia. *See also* lipid management
 cardiovascular disease and, 429
 as dementia risk factor, 126
 exercise benefits, 424
 hypertension and, 188, 429
 as ischemic stroke risk factor, 235
 pancreatitis and, 328
 retinal vein occlusion and, 574
 statin therapy for, 48, 207, 326
 hyponatremia, 360
 hyperparathyroidism
 bone mineral density and, 409, 450
 osteoporosis and, 447
 primary, 408–409, 450
 secondary and tertiary, 409–410, 450–451
 hypertension, 187–191
 in acute MI, 160
 antihypertensive considerations, 429
 atrial fibrillation and, 176–177
 as CAD risk factor, 157
 calcium channel blockers in, 161
 as CGA component, 30
 classifications of levels, 188, 188
 comorbidities/end organ effects, 189
 diagnosis, 188
 epidemiology of, 187
 exercise benefits for, 81
 fixed-dose agents for, 64
 heart failure and, 166
 hemorrhagic stroke and, 235
 HIV infection and, 349
 hyperaldosteronism and, 188, 415
 ischemic stroke and, 235
 JNC8 treatment guidelines, 47
 pathophysiology of, 187–188
 peripheral arterial disease and, 197, 199
 polypharmacy and, 361
 prevention and screening, 47
 pseudohypertension, 188
 pulmonary embolism and, 302
 refractory hypertension, 188
 renal disease and, 358
 renal disorders and, 188, 358, 360
 renal elimination and, 60
 secondary causes, 188
 sleep apnea and, 269
 systolic, 157, 166, 360
 treatment
 algorithm, 436
 benefits, 189
 considerations, 190
 nonpharmacologic, 189–190
 targets, 189
 treatment, pharmacologic, 190–191
 ACE inhibitors, 190
 angiotensin receptor blockers, 191
 calcium channel blockers, 190
 thiazide-type diuretics, 190
 treatment targets, 47
 vitamin D and, 91
 hypertensive nephrosclerosis, 190
 hyperthyroidism, 411–412
 atrial fibrillation and, 176–177
 hypertension and, 188
 subclinical, 412
 hypertrophic cardiomyopathy, 166, 191
 hypnic headache, 222, 224
 hypochondriasis, 6
 hypoestrogenic atrophic vaginitis, 399
 hypoglycemic agents, 425–429, 426
 biguanides, 425–427, 426
 DPP-4 inhibitors, 426, 428
 falling risks, 62
 insulin therapy, 428–429
 meglitinides, 426, 427
 sulfonylureas, 426, 427
 thiazolidinediones, 426, 427
 hypogonadotropic hypogonadism, 414
 hypokalemia
 atrial fibrillation and, 176–177
 causative for constipation, 322
 digoxin toxicity in, 169
 as diuretic side effect, 190, 361
 ectopic ACTH production and, 415
 electrolyte abnormalities in, 179
 hypomagnesemia, 169
 causative for constipation, 322
 digoxin toxicity in, 169
 as diuretic side effect, 190
 electrolyte abnormalities in, 179
 hyponatremia, 360
 hypopituitarism, 413–415
 clinical manifestations, 413–414

Index

- hypopituitarism (cont.)
 hormonal assessment, 414
 hormonal deficit symptoms, 414
 treatment options, 414–415
- hypopneas, in sleep apnea, 269
- hypoproliferative anemia, 531
- hypotension
 in acute MI, 160
 MI and, 159
 orthostatic hypotension, 119
 in pericardial tamponade, 175
 postural hypotension, 118
- hypothyroidism, 211, 410–411
 prevention and screening, 50–51
 small fiber polyneuropathy and, 211
 subclinical, 411
 treatment, 411
- IADL. *See* instrumental activities of daily living
- ibandronate, for osteoporosis, 449
- IBD. *See* inflammatory bowel disease
- ICU (intensive care unit)
 medical intensivist role in, 3
 specialist teams in, 3
- ID. *See* intellectual disabilities
- IHI. *See* Institute for Healthcare improvement
- Illness, Management and Recovery (IMR) Program, 644
- imipramine, 63, 417
- imiquimod, topical therapy, 485
- immune thrombocytopenic purpura (ITP), 528, 529
- immunization history, 33
- immunologic barrier function of skin, 478–479
- immunosuppressive agents. *See also* cyclosporine; prednisone; tacrolimus
 for acute kidney disease, 359
 exacerbation of tremors, 247
 for multiple sclerosis, 205
 for myasthenia gravis, 207
 for transplant rejection protection, 331
- immunotherapy. *See also* ipilimumab
 for dementia, 136
 for melanoma skin cancer, 488
- implantable cardioverter-defibrillators (ICDs), 170
- implantable devices
 in bradycardia, 176
 for heart failure management, 170
 in tachy-brady syndrome, 176
- IMR program. *See* Illness, Management and Recovery (IMR) Program
- inclusion body myositis, 207
- inclusion body myositis (IBM), 459
- income level, 1
- incontinence. *See* urinary incontinence
- infections, 331–340
 age-related changes and, 331
 age-related vulnerabilities, 332
 approach to patients, 332
 diagnostic delays, 331
 environmental risk factors, 331–332
 history-taking assessment, 332
 in HIV, 345–347
 HIV testing, 332
 major diseases
 bacterial pneumonia, 333–335, 334
 herpes zoster, 337–338
 influenza, 335–336
 methicillin-resistant *S. aureus*, 332, 338–339
 pulmonary tuberculosis, 336–337
 urinary tract infections, 333
 prevention and screening
 influenza vaccine, 46
 pneumococcal vaccine, 46, 335
 risk factors, 331
- Infectious Disease Society of America, 11
- inflammatory bowel disease (IBD), 320, 320–321
 Crohn's disease, 314, 320–321, 379, 588
 ulcerative colitis, 320, 321, 546
- infliximab
 for psoriasis, 491–492
 for rheumatoid arthritis, 456
- influenza, 335–336
 amantadine use for, 251
 clinical manifestations, diagnosis, 335
 frail patients and, 101
 management, 335–336
 muscle weakness and, 207
 vaccine for, 46, 205, 300
- Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE), 34, 52
- informed consent, 138, 665, 781, 786
- ingrown toenail (onychocryptosis), 599–600
- inotropic agents, in heart failure, 169.
 See also dobutamine; milrinone
- insomnia, 264–266, 268
 cardiovascular disease and, 270
 depression and, 50, 62
 diagnosis/assessment tools, 265, 265
 exercise benefits for, 81, 84
 human prion disease and, 129
 interventions, pharmacologic, 266, 268
 benzodiazepines, 266
 nonbenzodiazepines (z-drugs), 266
 sedating antidepressants, 266
 interventions, psychological, 265–266, 267
 behavioral strategies, 266
 Cognitive Behavioral Treatment for Insomnia, 266
 relaxation strategies, 266
 as medication side effect, 135, 250–251, 252
 mirtazapine benefits for, 138
 negative consequences of, 265
 parkinsonism and, 248
 pharmacotherapy, 266, 268
 prevalence of, 264
 sleep apnea and, 269
 3P Model, 265
 treatment, 265–266
- Insomnia Severity Index, 265
- Institute for Healthcare improvement (IHI), 514, 758
- Institute of Medicine (IOM)
 caloric intake recommendations, 90
 Dietary Reference Intakes, 89–90
 health system redesign imperatives, 1, 756–757
 healthcare performance improvement reports, 763–764
 vitamin D/calcium intake report, 91
- institutionalization, functional status as predictor of, 28
- instrumental activities of daily living (IADL), 36. *See also* activities of daily living
 as CGA domain, 32
 disabilities and, 99
 domains, 35
 pain and, 39
 scale used for assessment, 30–31
- insulin resistance
 cachexia and, 89
 as CVD risk factor, 429
 exercise benefits, 69, 70, 73
 growth hormone deficiency and, 415
 olanzapine and, 138
 thiazolidinediones and, 427
 insulin sensitivity, 88
- insulin therapy, 135–136, 428–429
- Integrated Illness, Management and Recovery (I-IMR) Program, 644
- integrative medicine. *See also* complementary and alternative medicine
 approaches to, 710–711
 challenges/promises of, 711
 definition, 702
 principles and practices of, 710
 rationales for integrating CAM therapies, 708–710

- intellectual disabilities (ID). *See also* severe and persistent mental illness
- autism spectrum disorders, 642–643
 - definition, 640
 - dementia and, 641
 - evidence-based interventions, 642
 - family caregiving for, 646
 - polypharmacy prevalence, 642
 - population characteristics, demographic trends
 - age-related changes, 641–642
 - life expectancy, mortality, 640–641
 - prevalence, 640
 - social characteristics, 641
- intensive care units, 3
- INTERHEART Study, 437
- interleukin-6 (IL-6), inflammatory factor, 2, 20, 89, 100, 348
- intermittent claudication, in PAD, 192, 193, 194, 196, 197
- internal medicine, 2
- interstitial lung diseases (ILD), 304
 - diagnosis, 304
 - treatment, 304
- intertrigo, 502
- intertrochanteric hip fractures, 466, 469
- Interventions Testing Program (ITP), 23
- intracerebral hemorrhage (ICH), 241
- intracranial mass, 227
- intracranial stenosis, 239
- intravenous vasodilators, for heart failure, 169
- ipilimumab, for melanoma skin cancer, 488
- ipratropium bronchodilator, for COPD, 63, 299
- IQCODE. *See* Informant Questionnaire for Cognitive Decline in the Elderly
- irbesartan, 171
- iron deficiency anemia, 524–525
- irritable bowel syndrome (IBS), 317
- ischemic bowel disease, 320
- ischemic heart disease (IHD), 82. *See also* myocardial infarction
- clinical presentation, 158–159
 - epidemiology/primary prevention, 157
 - muscle weakness and, 207
- ischemic option neuropathy, 189
- ischemic strokes
 - acute, classification of subtypes, 234
 - blood pressure management, 237–238
 - fatality risks, 233
 - fibrinolytic therapy and, 163
 - hypertension and, 189
 - neuroimaging and, 121
 - recovery variables, 241
 - risk factors, 234, 235, 235
 - treatment of, 239–240
 - warfarin and, 178
- isometric contraction, 85
- isoniazid, for tuberculosis, 337
- isoproterenol, 247
- Japanese people, lifespan, 22
- Jeste, D. V., 643
- joint replacement
 - for knee/hip, osteoarthritis, 455
 - post-surgery gait retraining, 619
 - PRT benefits for, 84
 - skilled nursing facility recovery, 618
- Judeo-Christian traditions, 799
- jugular venous distension, 175
- JUPITER (Justification for the Use of statin in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial, 439
- Kaposi's sarcoma, 346, 347, 600
- Katz Index of Independence in Activities of Daily Living, 35
- Kegel exercises (pelvic floor muscle training, PFMT), 30, 402
- Kemoun, G., 110
- keratoacanthoma, 485
- keratolytic agents, for onychomycosis, 599
- Kerrigan, D. C., 110
- kidneys, effects of aging, 159. *See also* acute kidney injury; renal disorders
- King's Health Questionnaire (for urinary incontinence), 36
- Kingston Standardized Cognitive Assessment-Revised (mini-KSCAr), 52
- Kirkwood, Thomas, 18
- knee osteoarthritis, 454
- Krieger, Dolores, 705
- Kunz, Dora, 705
- labyrinthitis, 121, 257
- lacrimal system. *See* eyelids and lacrimal system
- lagophthalmos, 565
- lamotrigine
 - for neuralgia-induced headaches, 226
 - for seizure treatment, 219
 - tremors exacerbated by, 247
- lansoprazole (Prevacid), for GERD, 312
- large artery atherosclerosis, 234
- latanoprost, for glaucoma, 571–572
- Laumann, E. O., 685
- Lavizzo-Mourey, Risa, 740
- Lawton, J. M., 36
- laxatives
 - fecal incontinence and, 393, 394
 - lubiprostone as alternative, 323
 - for obstipation, 322
 - types of, 555
 - underuse of, 64
- Leapfrog Group, 759
- LEARN model of cross-cultural communication, 741
- Lee, L. W., 110
- leflunomide, for rheumatoid arthritis, 455–456
- left bundle branch block, 159
- left ventricular assist devices (LVADs), 169–170
- left ventricular dysfunction, 189
- left ventricular hypertrophy (LVH), 159, 166, 173
- Legionella pneumophila*, 334
- leiomyomas, 399–400
- lentigo maligna melanoma, 487
- letrozole, 542
- leucopenia, in HIV infection, 347
- leukemia, 531–532, 532
 - acute myelogenous leukemia, 531–532
 - chronic lymphocytic leukemia, 529, 531
 - chronic myeloid leukemia, 531
- leukocytoclastic vasculitis, 495
- leukocytosis, 159
- levetiracetam, for seizures, 218, 219
- levodopa therapy, 129
 - for multiple system atrophy, 250
 - for Parkinson's disease treatment, 245, 248, 252
 - dosage fluctuations, variations, 252–253
 - reduced mortality effect, 255–256
- levothyroxine, 59
- lichen sclerosis, 376, 399, 399
- lidocaine, 163
 - for herpes zoster, 500
 - topical, for neuropathic pain, 214–215, 215
- life expectancy projections, U.S., 720–721
- life-course perspective, of retirement, 731
- lifespan (life expectancy)
 - biomarkers of, 17
 - caloric restriction research, 23
 - centenarians, 18, 21–22
 - disparities in the U.S., 22
 - early theories of, 18
 - gender differences, 22

Index

- lifespan (life expectancy) (cont.)
 growth hormone receptor knockout mice studies, 19
 healthspan interventions, 22–23
 premature aging, 22
 Rubner/Pearl, theories on, 19
 Lifestyle Management Work Group Guideline, 440
 light chain deposition disease (myeloma), 358
 linagliptin, 428
 linezolid, 340
 lipid management, 436–444
 ACA/AHA guidelines, 436, 437–438, 440
 apolipoprotein A/apolipoprotein B ratio, 437
 ASCOT-LLA program, 439
 cardiovascular risk, 436–437
 clinical trials/duration of study, 438
 Heart Protection Study, 440
 JUPITER trial, 439
 lessons from observational data, 437–438
 low-density lipoprotein cholesterol, 436, 438, 439
 pharmacologic treatment
 adherence/underutilization issues, 442–443
 non-statins, 442
 statins, 48, 196, 438–440, 441–442
 (See also specific statins)
 prevention and screening, 47–48
 primary prevention, 438–439
 PROSPER trial, 439
 secondary prevention, with established CVD, 439–440
 therapeutic lifestyle changes, 440–441
 LIPID (Long-term Intervention with Pravastatin in Ischemic Disease) Study, 439
 lipodermatosclerosis, 495
 lipotoxicity, 21
 Lipp, Martin, 12
 lisinopril, 168
 lithium
 for bipolar disorder, 278
 causative for parkinsonism, 250
 for cluster/hypnic headaches, 222, 223
 dosage/tolerability issues, 282
 exacerbation of tremors, 246, 247
 liver disease, 325
 drug-induced, 326
 hepatic ischemia, 326
 hepatocellular carcinoma, 326, 350
 HIV infection and, 349–350
 primary biliary cirrhosis, 326
 viral hepatitis, 325–326
 Living to Be 100 (Seegerberg), 14
 living will, 172, 781–782, 798
 long-acting anti-muscarinic (LAMA), 299
 long-acting beta agonists (LABA), 299
 long-term care programs. *See also*
 nursing facilities
 institutional, historical background, 659–660
 National Consumer Voice for Long-Term Care, 689
 psychiatric problems of patients, 274
 loop diuretics
 calcium supplementation and, 447
 for heart failure, 168
 for hypertension, 190
 loperamide, for diarrhea, 318
 lorazepam, 59
 dosage/tolerability issues, 281–282
 for dyspnea, 556
 for seizures, 218
 lovastatin, 349
 low bone mineral density (BMD), 350
 low-density lipoprotein cholesterol (LDL-C), 436
 lower extremity edema, 166
 lower extremity stasis-related changes, 493–495
 L-thyroxine therapy, 411
 Lubben Social Network Scale, 37
 lubiprostone, 323
 lung cancer, 347, 550–553
 clinical presentation, 551
 epidemiology, 550–551
 management
 non-small cell lung cancer, 552
 small cell lung cancer, 552–553
 risk factors, 551
 screening and prevention, 551
 staging and diagnosis, 550, 551–552
 lungs, effects of aging, 159
 Lust, Benedict, 708
 LVADs. *See* left ventricular assist devices
 lymphomas
 central nervous system, 347
 chronic diarrhea and, 317
 cutaneous T-cell, 494
 Hodgkin's, 540
 MALT, 317, 317
 non-Hodgkin's, 346, 347, 410
 primary malignancies and, 464
 Sjögren's syndrome and, 459
 testicular tumors, 372
 lymphopenia, in HIV infection, 347
 Lynch syndrome (hereditary nonpolyposis colon cancer), 401–402
 MacKenzie, Amy, 740
 macrobiotic diet, 706
 macrocytic anemias
 myelodysplastic syndrome, 527–528
 vitamin B12 deficiency, 526–527
 macrolide, 335
 macromolecular dysfunction, 20–21
 macronutrients, 90, 423
 macular degeneration, 49, 574–575
 mad cow disease, 130
 Maglione, J. E., 643
 magnetic resonance imaging (MRI), 12
 major depressive disorder (MDD), 50
 male disorders. *See also* prostate cancer
 benign prostatic hyperplasia, 373–375
 fecal incontinence
 prevalence, 383
 hematospermia, 367
 penile disorders, 376–377
 balanoposthitis, 376–377
 paraphimosis, 376
 Peyronie's disease, 377
 phimosis, 376
 prostatitis, 367, 375–376
 scrotal disorders, 377–378
 epididymitis, 377
 hydrocele, 377–378
 scrotal edema, 378
 spermatocoele, 378
 testicular torsion, 378
 varicocele, 378
 urinary incontinence
 overflow, 386–387
 prevalence, 383
 malignant otitis externa, 578
 Mallory-Weiss tear, 320
 Malnutrition Screening Tool (MST), 92
 Malnutrition Universal Screening Tool (MUST), 91, 92
 malnutrition/malnutrition syndromes, 37, 59, 88–89
 albumin levels and, 59
 anorexia, 88–89
 cachexia, 89
 diagnosis, 328
 frailty and, 100, 101
 functional decline and, 37
 prevalence of, 88
 sarcopenia, 89
 social causes, 88
 treatment, 329
 MALT. *See* mucosal-associated lymphoid tissue
 mania, late-onset, 278
 manipulative/body-based therapies
 massage, body work, 221, 705
 touch therapies, 705
 Man's Search for Meaning (Frankl), 6
 marital therapy, 282–283
 Massachusetts Male Aging Study, 635

- massage, 221, 705
 mastalgia (benign breast disease), 405
 MAST-G (Michigan Alcohol Screening Test), 290
 mastication muscles
 age-related changes, 590
 anatomy/characteristics, 590
 examination techniques, 590–591
 MAT. *See* multifocal atrial tachycardia
 matrix modeling factors, 20
 Mayo Clinic Study of Aging (MCSA), 131
 McGill Pain Scale, 516
 McGurk, S. R., 645
 McKibbin, C. L., 645
 MDD. *See* major depressive disorder
 MDRD. *See* Modification in Renal Disease (MDRD) equation
 MDS. *See* Minimum Data Set
 Medawar, Peter, 18
 Medicaid
 annual caregiver funding, 4
 EHR Incentive Programs, 761
 eligibility and coverage, 776–777
 home healthcare coverage, 651, 652
 home-based waiver programs, 4
 Minimum Data Set assessment, 40
 origin, 660, 776
 support for non-medical community services, 655
 Medicaid Waiver program, 660
 medical history, 33
 medical intensivist, 3, 610, 662
 Medical (or Physician) Orders for Life Sustaining Treatment (MOLST/POLST) advance directives, 783, 786, 787, 788, 790, 798
 Medicare, 774–776
 “bundle” payment system exploration, 618
 cochlear implantation coverage, 579
 CPT code system, 778
 EHR Incentive Programs, 761
 establishment of, 660, 774
 home healthcare coverage, 651, 652
 Independence at Home program, 653
 items not covered by, 776
 Minimum Data Set assessment, 40
 opting out, by physicians, 778
 Part A (hospital insurance), 617, 618, 660, 661, 662, 774–775
 Part B (medical insurance), 765, 775
 Part C (Medicare Advantage), 769, 771, 775
 Part D (prescription drug plan), 776
 post-acute care expenditures, 618
 pressure ulcer claims data, 510, 511
 prostatitis treatment data, 375
 role in quality improvement strategy, 10
 urology treatment data, 366, 370
 wellness visits support, 51
 wheelchair payment process, 619
 Medicare Detection of Cognitive Impairment, 134
 Medicare Hospice Benefit (MHB), 655–656, 662
 Medicare Hospital VBP program, 760, 763
 Medicare Prescription Drug, Improvement, and Modernization Act (MMA, 2003), 762
 Medicare Quality Improvement Organizations (QIOs), 668
 Medicare Value-based Modifier (VM), 762
 meditation, 676
 Mediterranean diet, 440
 meglitinides, 426, 427. *See also* nateglinide; repaglinide
 meibomian gland dysfunction, 566
 melanoma, 487–488
 contributing factors, 487
 diagnosis, 487–488
 metastatic, prognosis, 488
 subtypes, 487
 treatment, 488
 melatonin receptor agonists, 268. *See also* ramelteon
 memantine, 135, 255
 Ménière's disease, 117, 119, 257
 meningitis
 bacterial, 347
 cryptococcal, 345
 headaches in, 228
 viral, 347
 menopause. *See also* post-menopause
 endometrial cancer and, 401
 urinary tract infections and, 367–368
 Men's AIDS Cohort Study (MACS), 348
 mental illness. *See also* severe and persistent mental illness
 caregiving for people with, 749
 cultural/societal attitudes towards, 283, 739
 intellectual disabilities with, 642
 nursing facilities regulations, 662
 mental status domain (of CGA), 32
 mental status examination, 275–276
 meperidine, 62
 metabolic acidosis
 osteomalacia, 218
 renal disease and, 358
 metabolic bone disorders. *See also* osteoporosis
 hyperparathyroidism, 449, 450 (*See also* hyperparathyroidism)
 osteomalacia, 448, 449, 463
 Paget's disease, 449, 451
 renal osteodystrophy, 449, 451
 metabolic syndrome
 aging risk factor, 17
 caloric restriction benefits, 23
 description, 429
 insulin resistance factor, 70, 429 (*See also* insulin resistance)
 intellectual disabilities and, 641
 statin benefits for, 326
 metformin, 23, 195, 425–427
 methadone
 for cancer-related pain, 554
 for opioid dependence, 293
 methicillin-resistant *S. aureus* (MRSA), 332, 338–339
 clinical presentation, diagnosis, 339
 community-acquired, 338–339
 hospital-acquired, 338
 management, 339, 340
 methimazole, for Grave's disease, 412
 methotrexate
 for atopic dermatitis, 493
 for autoimmune blistering disorders, 497
 for multiple sclerosis, 205
 for psoriasis, 491
 for rheumatoid arthritis, 455
 metoclopramide
 for cancer-related nausea, vomiting, 555
 causative for parkinsonism, 250
 for migraines with nausea, vomiting, 221, 223
 metolazone, with loop diuretics, for HF, 168
 metoprolol, 162
 metronidazole
 for diarrhea, 318
 small fiber polyneuropathy and, 211
 topical, for rosacea, 489
 for vaginal discharge, 399
 mexiletine, 247
 MI. *See* myocardial infarction
 miconazole nitrate, for tinea pedis, 599
 microcytic anemias
 iron deficiency anemia, 524–525
 thalassemia, 525
 micronutrients, 51, 102, 374
 Middle East respiratory syndrome (MERS), 335
 midfoot disorders
 pes planus (flatfoot), 601
 posterior tibial tendon dysfunction, 601–602
 migraine headaches, 222–223

Index

- migraine headaches (cont.)
 in episodic vestibular syndrome, 117, 119
 four phases, 222–223
 NSAIDs for, 223
 preventive medications, 223
 treatments, 222, 223
 vestibular, 119, 120
- migrainous vertigo, 580
- mild cognitive impairment (MCI), 51, 130–131
 dementia and, 641
 subtypes, 131
- Miller Fisher syndrome, 206
- milrinone, 169
- mind-body therapies
 biofeedback/neurofeedback, 704
 hypnosis, 704
 meditation, 704–705
 mindful exercises, 705
- mineralocorticoid antagonists (MRA), 169. *See also* eplerenone; spironolactone
- Mini-Cognitive Assessment Instrument (Mini-Cog), 34, 51, 132
- minimal interference principle, 10
- Mini-Mental State Examination (MMSE), 34, 51
 for delirium assessment, 150
 for dementia assessment, 132
 for HIV infection, 351
- Minimum Data Set (MDS), 40
- Mini-Nutritional Assessment (MNA), 91
- Mini-Nutritional Assessment Short Form (MNA-SF), 37, 91–92, 101
- minocycline, for MRSA, 340
- mirtazapine, for insomnia, 268
- mistreatment of older adults. *See* elder abuse
- mitral regurgitation, 174
- mitral valve disease
 contributing factors, 157
 mitral regurgitation, 174
 mitral stenosis, 173–174
- MMSE. *See* Mini-Mental State Examination
- MNA-SF. *See* Mini-Nutritional Assessment Short Form
- mobile applications, for geriatric assessment, 31
- mobility assessment, 32, 35
- MoCA. *See* Montreal Cognitive Assessment
- modernization theory, of retirement, 731
- Modification in Renal Disease (MDRD) equation, 60
- Modified Boston Naming test, 133
- Mohs micrographic surgery
 for eyelid neoplasms, 566
 for melanoma skin cancer, 488
 for non-melanoma skin cancer, 485, 486
- molluscum contagiosum, 347, 567
- monamine oxidase inhibitors (MAOIs). *See also* rasagiline; selegiline
 for depression, 277
 for PD, symptomatic treatment, 250–251
- monoclonal gammopathy, 211
- monoclonal gammopathy of undetermined origin (MGUS), 530–531
- monoclonal immunoglobulin disease, 214
- mononeuropathy multiplex, 212
- Montreal Cognitive Assessment (MoCA), 34, 51, 132–133, 351, 741
- mood disorders, 277–279
 anorexia and, 88
 bipolar disorder, 278, 643
 depression, 277–279 (*See also* depression)
 mood assessment, 275
- morphine
 age-related clearance impairment, 59
 for cancer-related pain, 554
 for MI-related pain, 160, 161, 163
 selection factors, 675
- Morton's neuroma, 601, 602
- motor neuron disease, 206
- movement disorders, 245–261. *See also* parkinsonism; Parkinson's disease
 gait disorders, 256–261 (*See also* gait disorders)
 parkinsonism/Parkinson's disease, 246–256
 tremors, 245–246
 action/rest tremors, 245
 cerebellar outflow tremor, 246
 drug-induced tremors, 246
 essential tremor, 245–246, 246
 exacerbating medications, toxins, 247
 intention tremor, 246
 Parkinsonian tremor comparison, 245
 rubral tremor, 246
- MRSA. *See* methicillin-resistant *S. aureus*
- MST. *See* Malnutrition Screening Tool
- mucosal-associated lymphoid tissue (MALT lymphoma), 317
- Mueser, K. T., 645
- Mui, S. W., 741
- multifocal atrial tachycardia (MAT), 176
- multiple myeloma, 214, 529–531
 clinical presentation, 529–530
 diagnosis, 530
 hypercalcemia of malignancy and, 410
 prevalence/mortality rate, 529
 progressive severe anemia and, 524
 multiple parathyroid gland hyperplasia, 450
- multiple sclerosis, 204–205, 205
 driving and, 692
 urinary incontinence in, 386
- multiple system atrophy
 discovery, MRI findings, primary pathology, 249
 types/features of, 249–250
- Murray-Garcia, J., 738
- muscarinic receptor antagonists. *See also* darifenacin; solifenacin; tolterodine; trospium
 adverse drug reactions, 62
 for UI and OAB, 370, 391
- Muscaritoli, M., 89
- muscle weakness, 204–209
 evaluation, 208, 208–209
 neurological causes, 204–207
 amyotrophic lateral sclerosis, 205, 206
 cerebrovascular disease, 205
 Guillain-Barré Syndrome, 205, 205–206
 motor neuron disease, 206
 multiple sclerosis, 204–205, 205
 myasthenia gravis, 205, 206, 206–207
 spinal cord pathology, radiculopathies, 205, 207
 upper vs. lower motor neuron patterns, 204
 non-neurological causes, 207, 207–208
 treatment, 209
- musculoskeletal disorders, 462–473
 age-related changes, 100
 assessment, 34, 54, 122
 as CGA component, 30
 effects of aging, 159
 emotional disorders and, 8, 30
 exercise adaptations, 75, 83
 exercise risks, 83, 84
 falling risk factors, 108, 446
 frailty and, 97, 100
 gait impairment and, 108, 109
 myasthenia gravis manifestations, 206
 PAD comorbidity, 199
 peripheral neuropathy and, 424
 prevalence, 453

- progressive resistance training and, 84–85
- Sjögren's syndrome and, 459
- musculoskeletal injuries
- ankle fractures, 470
 - atypical femur fractures, bisphosphonate use, 464–465
 - distal radius fractures, 471–472
 - hip fractures, 466–469
 - diagnosis, 467
 - femoral neck, 466, 467–469
 - intertrochanteric, 466, 469
 - outcomes, 467
 - presentation, management, 466–467
 - principles, 466
 - subtrochanteric, 466
 - injury factors
 - comminution, 463–464
 - intra-articular fractures, 464
 - open fractures, 463
 - polytrauma, 463
 - long bone injuries, 463
 - metastatic disease, 464
 - patient factors
 - bone quality, 462–463
 - pre-injury status, 462
 - soft tissue quality, 463
 - systemic disease, 462
 - pelvic ring fractures, 463
 - periprosthetic fractures, 464
 - preoperative considerations, 465–466
 - proximal humerus fractures, 462, 470–471
 - vertebral compression fractures, 472–473
- music therapy, 676
- MUST. *See* Malnutrition Universal Screening Tool
- mutation accumulation theory, 18
- myasthenia gravis, 205, 206, 206–207
- mycophenolate mofetil
 - for atopic dermatitis, 493
 - for autoimmune blistering disorders, 497
 - for myasthenia gravis, 207
- myelodysplastic syndrome (MDS), 523, 527–528
- myeloid leukemia, 410
- myeloma cast nephropathy, 358
- myelopathy/spinal cord compression, 256
- myeloproliferative neoplasms, 532–533
- myocardial infarction (MI), 157. *See also* acute ST-segment elevation myocardial infarction
 - acute, symptoms, 158–159
 - atrial fibrillation and, 176–177
 - beta blockers for, 191
 - clinical presentation, 159
 - complications of, 164–165
 - confusion in, 8
 - diagnosis, 159–160
 - differential diagnosis, 160
 - HIV infection and, 347
 - hypertension and, 189
 - management, acute, symptoms, 161
 - peripheral arterial disease and, 199
 - pharmacologic management, 160–163
 - angiotensin/aldosterone inhibition, 162
 - antiplatelet therapy, 160, 161
 - antithrombotic therapy, 161–162
 - beta blockers, 162
 - other agents, 163
 - statin therapy, 162–163
 - strokes and, 238- myocarditis, 166
- myxedema, 10

nails, aging-related changes, 481

naltrexone

 - for alcohol dependence, 292
 - for opioid dependence, 293

narcissistic personality disorder, 280

Narcotics Anonymous, 292

narrow-angle glaucoma, 391

nasal cavity and sinus

 - age-related changes, 581
 - common pathologies, 581–582
 - anosmia, 582
 - epistaxis, 582
 - rhinitis, 581
 - sinusitis, 581–582
 - congestion, in cluster headaches, 223

nateglinide, 427

National Adult Protective Services Association (NAPSA), 689

National Adult Reading Test, 133

National Assessment of Adult Literacy (NAAL) report, 742

National Cholesterol Education Program Guidelines, 436

National Committee for Quality Assurance (NCQA), 758–759

National Consumer Voice for Long-Term Care, 689

National Core Indicators Adult Consumer Survey, 641

National Culturally and Linguistically Appropriate Services (CLAS) in Health and Health Care, 737

National Demonstration Project Quality Improvement in Health Care (IHI), 758

National Epidemiologic Survey of Alcohol and Related Conditions (NESARC), 286

National Family Caregiver Support Program (NFCSP), 752

National Hospice and Palliative Care Organization (NHPCO), 656

National Institute on Aging, 23

National Institute on Alcohol Abuse and Alcoholism, 285

National Nursing Home Quality Care Collaborative (NNHQCC), 668

National Osteoporosis Foundation, 409, 446

National Patient-Centered Clinical Research Network, 430

National Pressure Ulcer Advisory Panel (NPUAP), 510, 511, 514–518

National Quality Forum (NQF), 760

National Quality Measures Clearinghouse (NQMC), 758

National Survey on Drug Use and Health (NSDUH), 286

Native Americans

 - community based services for, 655
 - diabetes prevalence, 421
 - life expectancy, 22

Native Hawaiians, 22

Natural Medicines Comprehensive Database, 707

naturopathic medicine, 706, 708

nausea and vomiting

 - in acute angle closure glaucoma, 226
 - CAM mind-body therapies, 704, 707
 - in chemotherapy treatment, 554–555
 - corticosteroids for, 676
 - at end-of-life
 - assessment, 677, 677
 - management, 677, 678
 - mechanisms, 676–677, 677
 - in intracranial mass, 227
 - management in cancer, 554–555, 555
 - in migraines, 221, 223
 - NSAIDs for, 676
 - in secondary headaches, 225

NCEP ATP III panel, 438

NCQA. *See* National Committee for Quality Assurance

nebulolol, 171

nephrolithiasis, 408

nesiritide, 169

neuraminidase inhibitors, 335–336. *See also* oseltamivir; zanamivir

neuroendocrine theory, 18

neurohumoral system, 159

neuroimaging

 - in Alzheimer's disease, 126

Index

- neuroimaging (cont.)
 in chronic vestibular syndrome, 122
 in dementia, 122, 126, 128, 129, 133–134
 for headaches, 229
 in muscle weakness, 208
 in normal pressure hydrocephalus, 260
 in strokes, 234
 neuroleptics, 282
 neurologic problems, 203–229
 evaluation considerations, 203–204
 headaches, 220–229
 evaluation, 228–229
 primary types, 221–224, 224
 secondary types, 224–228
 muscle weakness, 204–209
 evaluation, 208–209
 neurological causes, 204–207
 non-neurological causes, 207–208
 treatment, 209
 seizure disorders, 215–220
 causes, 216
 differential diagnosis, 217, 217
 evaluation/risk factor assessment, 217, 217–218
 management/treatment, 218–220, 219
 pharmacologic treatment, 219–220
 presentation in the elderly, 216–217
 prevalence rates, 215–216
 sensory disorders/neuropathies, 209–215
 alcohol-related neuropathy, 212–213
 demyelinating neuropathies, 212
 diabetic neuropathy, 11, 190, 210–211
 evaluation, 213–214, 214
 monoclonal gammopathy, 213
 post-herpetic neuralgia, 46–47, 211–212
 related terminology, 213
 sensory peripheral neuropathy, 122
 treatment, 214–215, 215
 vitamin B12 deficiency, 213
 neuromuscular disease, 84
 neuropathies. *See* sensory disorders/neuropathies
 neurotrophic ulcers, feet, 598
 New York City Almshouse, 659
 New York State Elder Abuse Prevalence Study, 686
 nicotine replacement therapy (NRT), 54, 292
 nifedipine, for aortic insufficiency, 173
 nitrates, 60, 163
 nitrofurantoin, for urinary tract infection, 368
 nitroglycerin, 161
 nizatidine (Axid), for GERD, 312
 NK1 receptor antagonists, 555
 NK1 receptor antagonists, for cancer-related nausea, vomiting, 555
 NMDA receptor antagonists (N-methyl-D-aspartate receptor antagonists), 135
 nodular basal cell carcinoma, 485
 nodular melanoma, 487
 nonamestic mild cognitive impairment (naMCI), 131
 nonarteritic ischemic optic neuropathy, 575
 nonbenzodiazepines (z-drugs), 266.
See also eszopiclone; zolpidem
 non-dihydropyridine calcium channel blockers, 62
 non-Hodgkin's lymphomas, 347, 410
 nonischemic dilated cardiomyopathy, 166
 nonmaleficence principle (in ethical decision-making), 797
 non-ST-elevation acute coronary syndromes (NSTEACS), 163–164, 164
 nontuberculous mycobacterium (NTM), 304–305
 presentation, diagnosis, 305
 treatment, 305
 normal pressure hydrocephalus (NPH), 130, 250
 gait patterns, 260
 ventriculoperitoneal shunting for, 261
 normocytic anemias, 328
 anemia of chronic kidney disease, 526
 anemia of inflammation, 525–526
 North American Symptomatic Carotid Endarterectomy Trial (NASCET), 239
 nortriptyline, 54
 for major depression, 277
 for migraines/tension type headaches, 222
 for postherpetic neuralgia, 338
 nose valves, for sleep apnea, 270
 nosocomial infections, 332, 338, 368.
See also urinary tract infection
 NQF. *See* National Quality Forum
 NSAIDs nonsteroidal anti-inflammatory drugs (NSAIDs), 135
 acute kidney injury and, 359
 for acute pericarditis, 175
 acute tubular necrosis and, 359
 avoidance in HF patients, 169
 for benign breast disease, 405
 for cancer-related pain, 554
 causative for headaches, 227
 GERD and, 311
 for gout, 456
 interaction cautions, 282
 for migraines, tension headaches, 221, 223
 for osteoarthritis, 454
 peptic ulcers and, 315
 risk factors, 311
 for tension type headaches, 221
 NSTEACS. *See* non-ST-elevation acute coronary syndromes
 NTM. *See* nontuberculous mycobacterium
 nuclear medicine, 12
 numeric rating scales, 39
 nurse practitioner (NP), 2
 as activists/sounding boards, for patients, 3
 geriatric, 28
 health maintenance emphasis, 9–10
 in nursing facilities, 663
 nursing facilities, 3
 AMDA's improvement focus, 668–669
 infection risk factors, 331
 legal regulation/quality of care
 civil litigation, 665
 criminal prosecutions, 664
 discrimination issues, 667
 drug prescription, management, 667
 elopement, 667
 improvement opportunities, 667–668
 informed consent, 665
 overview, 663–664
 restraints, 665–667
 long-stay residents, 662
 mental ill patients, regulations, 662
 psychiatric problems of patients, 274
 short-stay residents/patients
 post-acute care, 660–661
 respite care, 661
 terminal care/hospice care, 661–662
 structure of medical practice
 full-time, facility-based physician, 663
 nurse practitioner/physician assistant, 663
 physician/continuity of care model, 662–663
 post-acute/LTC practitioner, unassigned admissions, 663
 nutrition
 anorexia and, 88–89
 BMI and, 92
 cachexia and, 89

- calcium, 91
 caloric recommendations, 90
 CGA assessment, 28, 32, 34, 37
 dementia and, 136
 diabetes management and, 423
 dietary therapies, 706
 exercise and, 70
 frailty intervention, 102
 grip strength and, 75
 interprofessional collaboration, 11
 lipid management recommendations, 440
 lipotoxicity and, 21
 macronutrients, 90, 423
 malnutrition/malnutrition syndromes, 37, 59, 88–89
 micronutrients, 51, 90, 102, 374
 MNA assessment, 91
 MNA-SF assessment, 37, 91–92
 MST assessment, 92
 MUST assessment, 91, 92
 oral considerations, 88
 for pressure ulcers, 509, 515, 516
 protein-energy undernutrition, 88
 PRT and, 84
 requirements, 89–90
 sarcopenia and, 89
 supplements and, 92–93
 vitamin B12, 90–91, 131, 213, 236
 vitamin D, 91
 weight loss and, 92
 nystagmus, 120
- OAB. *See* overactive bladder (OAB)
- obesity
 central, and osteoporosis, 447
 exercise benefits for, 81, 84
 HIV infection and, 349
 insulin-resistance and, 69
 intellectual disabilities and, 641
 ischemic stroke and, 235
 peripheral arterial disease and, 199
 pulmonary embolism and, 302
 sleep apnea and, 267
 strokes and, 238
- obsessive thinking, 275
- obsessive-compulsive personality disorder, 279–280
- obstructive hydrocephalus, 260
- obstructive sleep apnea (OSA)
 carbon dioxide retention in, 228
 description, 267
 hypertension in younger patients and, 188
 multiple system atrophy and, 250
 parkinsonism and, 248
- obstructive uropathy, 358
- occult cancer, 8
- occupational therapy, 28, 261
- ocular cicatricial pemphigoid, 565, 567
- ocular conditions. *See* vision/visual conditions
- ocular rosacea, 489
- odynophagia, 314, 314
- olanzapine, 62, 137, 645
- Older Americans Act (1965), 655
- Older Americans Act Programs (for caregivers), 752
- olfactory hallucinations, 275
- olivopontocerebellar atrophy (OPCA), 249
- Olmstead Decision (Supreme Court, 1999), 660
- omeprazole (Prilosec), 312
- onabotulinumtoxinA (Botox), 481
- oncologist, 2
- oncology centers, 3
- Oncotalk program, 672
- ondansetron, for cancer-related nausea, vomiting, 555
- onychocryptosis (ingrown toenail), 599–600
- onychomycosis, toenails, 481, 501–502, 599
- opioid analgesics. *See also* fentanyl; hydromorphone; morphine; oxycodone
 in acute headaches, 221, 223
 in cancer-related pain, 554
 dosing and titration, 675–676
 in end-of-life care, 674–675, 675
 falling risks, 62, 63
 in herpes zoster, 500
 in neuropathic pain, 215, 215
 nonmedical use of, 286
 in osteoarthritis, 454
 rebound headaches from, 227
 risk factors for delirium, 150
- optic nerve disorders, 575
 atrophy, 570
 giant cell arteritis, 225, 227, 458, 575
 nonarteritic ischemic optic neuropathy, 575
 temporal arteritis, 458, 575
- optic neuritis, 228
- optimization with compensation theory, of retirement, 732
- oral and dental health domain (of CGA), 32, 34
- oral appliances, for sleep apnea, 270
- oral candidiasis (thrush), 345, 582–583
- oral cavity. *See also* dental care
 age-related changes, 582
 cancer/chemotherapy consideration, 589
 common pathologies, 582–583
 bacterial parotitis, 583
 candidiasis (thrush), 345, 582–583
 erythroplakia, 583
- leukoplakia, 583
 parotid gland enlargement, 583
 lesions, characteristics, 582
- oral mucosa
 age-related changes, 588
 anatomy/characteristics, 588
 examination techniques, 588
- oral prosthetic devices, 587
- oropharyngeal dysphagia, 313–315
- oral factor Xa agents, 237. *See also* apixaban; betrixaban; edoxaban; rivaroxaban
- oral hairy leukoplakia, 347
- organ transplants, 12
- organizational cultural competence, 736–738, 737
- organ/tissue transplants, 12, 331
- oropharyngeal dysphagia, 313
- orphenadrine, 63
- orthopnea, heart failure and, 166
- orthostasis
 antipsychotics and, 62
 falling risks, 53
 levodopa and, 250
 pheochromocytoma and, 416
- orthostatic hypotension, 191
 alpha receptor antagonist caution, 191
 BPPV differential diagnosis, 119
 dehydration and, 190
 diabetic neuropathy and, 212
 hypertension treatment and, 189, 360
 levodopa and, 252
 in parkinsonism, 248
 pheochromocytoma and, 416
 tricyclic antidepressants and, 62
- oseltamivir, for influenza, 335–336
- OST. *See* Osteoporosis Self-Assessment Screening Tool
- osteitis, 408
- osteoarthritis, 453–455
 clinical presentation, 453
 driving and, 692
 foot, 454
 hand, 453–454
 knee, 454
 spine and hip, 454
 treatment, 454–455
- osteomalacia, 218
- osteopenia, 159, 447, 449, 455, 462–463
- osteoporosis
 antiepileptic therapy and, 218, 219
 ART treatment and, 350
 Cushing's syndrome and, 416, 447
 diagnostic technologies, 447
 exercise benefits, 72, 78, 81, 84
 fracture risks, 360
 HIV infection and, 350
 malnutrition and, 328

Index

- osteoporosis (cont.)
 medical conditions associated with, 447
 overt hyperthyroidism and, 411
 PPI use and, 311, 312
 prevalence, 446
 prevention, 48
 primary hyperparathyroidism and, 408
 screening, 48, 446–447
 treatments, 14
 bone health nutrition, 447–448
 monitoring, 449
 nonpharmacologic, 449
 pharmacologic, 448, 449
 prophylactic, 463
 vitamin D deficiency and, 91
- Osteoporosis Self-Assessment Screening Tool (OST), 48
- otitis media, 121
- otolaryngology, 577–583
 age-related changes
 in balance, 580
 in middle and inner ear, 578
 in nasal cavity and sinus, 581
 in oral cavity, 582
 in outer ear, 577
 in throat/swallowing, 580
 in the voice, 581
- auditory
 age-related hearing loss, 579
 sudden sensorineural hearing loss, 579
 tinnitus, 579–580
- common pathologies
 in balance, 580
 in middle and inner ear, 578–579
 in nasal cavity and sinus, 581–582
 in oral cavity, 582, 582–583
 in outer ear, 577–578
 in the throat, swallowing, 580–581
 in the voice, 581
- facial nerve palsy, 583
 head and neck cancer, 583
- Outcome and Assessment Information Set (OASIS), 514
- ovarian cancer, 2, 401–402
- overactive bladder (OAB)
 anticholinergic agents for, 391
 behavioral treatment for, 389–391
 defined, 385
 medications for, 370
 muscarinic receptor antagonists for, 391
 PTNS treatment, 391–392
- overflow fecal incontinence, 387, 387
- overflow urinary incontinence (neurogenic bladder), 333, 386–387, 393
- oxazepam, 59, 281–282
- oxcarbazepine, for seizures, 219
- oxidative stress, 19
- oxybutynin, or for urinary incontinence, 391
- oxycodone
 with acetaminophen, 553
 for cancer-related pain, 554
 types of preparations, 675
- oxygen, high flow, for acute cluster headache, 221, 223
- P2Y₁₂ receptor antagonists, 160, 161.
See also prasugrel; ticagrelor
- PACE programs. *See* Programs for All Inclusive Care of the Elderly
- Pain Assessment Checklist for Seniors with Limited Ability to Communicate (PACSLAC), 39
- Pain Assessment in Advanced Dementia (PAINEAD), 39
- pain management
 CAM mind-body therapies, 704, 707
 for chronic pancreatitis, 328
 end-of-life care, 674–676
 adjuvant analgesics, 676
 assessment, 674
 dosing and titration, 675–676
 nonpharmacologic approaches, 676
 opioid selection, 674–675, 675
 for phantom limbs, 626
 for postherpetic neuralgia, 338
 for pressure ulcers, 516
- palliative care. *See also* end-of-life care; hospice care
 in cancer patients, 552, 553–556
 definition, 553, 671
 in delirium, 152–154
 goal of, 2
 growth of hospital-based programs, 671
 in heart failure, 172
 professional education programs, 672
 specialist vs. generalist care, 671–672
 transitioning to, 662
 in wound care, 516–517
- Palmer, D. D., 708
- pancreatic disease
 acute pancreatitis, 327–328
 cancer, 328
 chronic pancreatitis, 328
- panic disorder, 117, 119, 276, 351
- pantoprazole (Protonix), 312
- Pap smear tests, 49
- PAP (positive airway pressure) therapy, for sleep apnea, 269, 270. *See also* CPAP (continuous positive airway pressure) therapy
- papulopustular rosacea (PPR), 489
- paraneoplastic cerebellar degeneration (PCD), 260
- paranoid delusions, 275
- paraparetic gait, 258
- paraphimosis, 376
- parathyroid/calcium metabolism diseases
 hypercalcemia of malignancy, 410
 hypothyroidism, 211, 410
 multiple parathyroid gland hyperplasia, 450
 muscle weakness and, 207
 primary hyperparathyroidism, 408–409
 secondary/tertiary hyperparathyroidism, 409–410
 vitamin D deficiency, 409
- Paré, Ambrose, 509
- parkinsonism, 246–256
 atypical/secondary vs. idiopathic, 248
 causes, 246
 clinical features of, 247–248
 differential diagnosis, 248–250
 DLB and, 129
 drug-induced, 250
 gait pattern in, 257–259
 neuropsychiatric manifestations, 248
 secondary forms, 250
 secondary/nonmotor features, 248
 therapeutic strategies, 254–255
 tremors in, 247
- Parkinson's disease (PD), 246–256
 aggregation of proteins in, 21
 bradykinesia in, 247
 diagnosis/diagnostic challenges, 248
 differential diagnosis, 248–250
 discovery, MRI findings, primary pathology, 249
 dizziness in, 116
 driving and, 692
 falling risks, 53, 108–109
 gait pattern in, 257–259
 hallmarks of, 247
 musculoskeletal injuries and, 462
 prevalence of, 247
 rehabilitation, 624
 treatment, 250–256
 advanced disease, 252–253
 clinical algorithm, 253–255
 deep brain stimulation, 245, 255, 624
 natural history, 255–256
 nonmotor symptoms, 254–255
 surgical therapy, 255
 symptomatic, 250–252, 251, 252
 urinary incontinence in, 386
- Parkinson's Disease Dementia (PDD), 129

- Parkinson's Plus syndromes, 249
 paroxetine (Paxil), 138, 316
 paroxysmal nocturnal dyspnea, 166
 paroxysmal unilateral headache, 226
 Partnership for Patients (AHRQ), 758
 passive fecal incontinence, 387, 387
 patent foramen ovale (PFO), 238
 Patient Education Materials
 Assessment Tool (PEMAT), 744
 Patient Health Questionnaire-2 (PHQ-2), 50
 Patient Health Questionnaire-9 (PHQ-9), 35, 40, 50
 Patient Protection and Affordable Care Act (2010), 32
 Patient Safety Measure Tools & Resources (AHRQ), 758
 Patient Self-Determination Act (PSDA, 1990), 782–783
 Patient-Centered Medical Home, 2
 Patient-Centered Outcomes Research Institute, 430
 PDE5 inhibitors, for erectile dysfunction, 635
 PE. *See* pulmonary embolism
 Peabody, F. W., 5
 Pearl, Raymond, 19
 pegloticase, for gout, 457
 pelvic floor muscle training (PFMT, Kegel exercises), 30, 392, 402
 pelvic organ prolapse, 402
 Pelvic Organ Prolapse Quantitation (POPQ) system, 402
 pelvic ring fractures, 463
 pemphigoid, 496, 498
 pemphigus, 496, 498
 penile disorders, 376–377
 balanoposthitis, 376–377
 paraphimosis, 376
 Peyronie's disease, 377
 phimosis, 376
 peptic ulcer disease, 315, 315
 diagnosis/treatment, 315
 gastric bleeding and, 240
 MI and, 160
 presentation, 315
 percutaneous coronary intervention (PCI)
 in acute MI, 161, 161
 in acute STEMI, 163
 percutaneous pericardiocentesis, 175
 percutaneous tibial nerve stimulation treatment (PTNS), 391–392
 performance improvement. *See* healthcare performance improvement
 pericardial diseases
 pericardial constriction, 175–176
 pericardial effusion and tamponade, 175
 pericarditis, 175
 perindopril, 171
 periodic lateralizing epileptiform discharged (PLEDS), 217
 periodic limb movement of sleep (PLMS), 248
 periorificial dermatitis, 490
 peripheral arterial disease (PAD), 192–199
 aspirin for, 169
 as CAD equivalent, 440
 clinical presentation, 194
 comorbidities, 199
 complications, 199
 differential diagnosis, 196
 hypertension and, 189
 intermittent claudication in, 192, 193, 194, 196, 197
 limb salvage recommendations, 198–199
 management, 196
 antiplatelet/antithrombotic drugs, 197
 diabetes, 197
 exercise rehabilitation, 197–198
 hypercholesterolemia, 196–197
 hypertension, 197
 smoking cessation, 196
 vasodilators, 197
 screening, diagnosis, intervention, 194–196, 195
 peripheral neuropathy
 as ART therapy side effect, 351
 in HIV infection, 347, 351
 peripheral vascular disease
 PRT benefits for, 84
 vitamin D and, 91
 peroxisome proliferator-activated receptor-gamma (PPAR- γ) agonists, 427. *See also* pioglitazone; rosiglitazone
 persecution delusions, 275
 persistent vegetative state (PVS), 781, 790
 personality disorders, 279–280
 Personality Outlook Profile Scale, 14
 personalized medicine, 12
 pes planus (flatfoot), 601
 Peyronie's disease, 377
 Pfeiffer, Jules, 6
 PFMT. *See* pelvic floor muscle training
 Pharmacy Health Literacy Center (AHRQ), 758
 phenobarbital, 245–246
 phenothiazines, 247
 phenotype model of frailty, 97–98, 98
 phenytoin, 59, 218, 226
 phenytoin/fosphenytoin, 219
 pheochromocytoma, 117, 188, 415, 416
 Philadelphia Almshouse, 659
 phimosis, 376
 PHN. *See* postherpetic neuralgia
 phobias, 276
 phosphodiesterase inhibitors, 393. *See also* sildenafil; tadalafil; vardenafil
 photoaging mitigation role of skin, 480–481
 photodynamic therapy
 for non-melanoma skin cancer, 486
 for onychomycosis, 599
 PHPT. *See* primary hyperparathyroidism
 phymatous rosacea (PhR), 489
 Physical Activity Guidelines Advisory Committee Report (2008), 69
 physical barrier function of skin, 478
 physical health domain (of CGA), 32
 physical performance assessment, 36
 physical therapy
 for gait disorders, 261
 geriatric, 28
 in pain management, 676
 physician assistant (PA), 663
 Physician Quality Reporting System (PQRS, CMS), 758, 761–762, 765
 physician-assisted suicide (euthanasia), 7
 physician-assisted suicide (PAS), 7, 799–801
 physicians. *See also* doctor-patient relationship
 as activists/sounding boards, for patients, 3
 attitude problems, U.S., 3
 communication skills, 1, 5–6
 compassionate care, 1, 12–13
 culturally sensitive care, 5
 health maintenance emphasis, 9–10
 as integrator of biopsychosocial-spiritual model, 1–3
 intelligent treatment, ethical decision-making, 10–11
 interprofessional collaboration, 11
 recommendations to caregivers, 4
 specificity in nursing home recommendations, 3
Physician's Guide to Assessing and Counseling Older Drivers (AMA/NHTSA), 692, 693, 694
 Pilates, 261, 705
 pill-induced esophagitis, 311
 pimecrolimus, 491
 PIMs. *See* potentially inappropriate medications
 pioglitazone, 427
 Pittsburg Sleep Quality Index, 265
 pituitary gland disorders
 adenomas, 413

Index

- pituitary gland disorders (cont.)
 ectopic ACTH production, 415, 416
 hypopituitarism, 413–415
 plantar calcaneal bursitis, 602
 plantar fasciitis, 602
 plant-based whole-food diet, 706
 plasma-cell dyscrasia, 530–531. *See also*
 monoclonal gammopathy of
 undetermined origin
 pneumococcal pneumonia vaccine, 46,
 335
 pneumococcal vaccine, 46
 pneumocystis pneumonia, 345
 pneumonia, 301–302
 in acute MI, 160
 atrial fibrillation and, 176–177
 bacterial pneumonia, 333–335, 334
 causes of, 334
 classifications, 301, 302
 confusion in, 8
 diagnosis, 301
 pneumococcal pneumonia vaccine,
 46, 335
 pneumocystis pneumonia, 345
 treatments, 301–302, 302
 polycythemia vera (PV), 532
 polyethylene glycol-based laxatives,
 555
 polymyalgia rheumatica, 227
 polymyalgia rheumatica (PMR), 458
 polymyositis, 207
 polypharmacy, 9, 103
 Positive Attitude Towards Life domain
 (Personality Outlook Profile
 Scale), 14
 positron emission tomography (PET),
 12
 posterior fossa tumors, 119
 posterior vitreous detachment (PVD),
 572–573
 postherpetic neuralgia (PHN), 46–47,
 211–212, 224, 338, 500
 postmenopause
 atrophic changes, vulvovaginal area,
 398
 benign breast disease and, 405
 BMD testing, 48
 endometrial cancer in, 401
 hormone therapy, risks and benefits,
 404
 iron requirements, 90
 osteoporosis and, 448
 sexuality and sexual dysfunction,
 403–405
 symptoms, 402–403
 thyroid function testing, 50–51
 verrucous carcinoma in, 400
 postpolypectomy, 320
 postural hypotension, 118
 potassium-sparing diuretics, 162
 potentially inappropriate medications
 (PIMs), 9, 33
 PQRS. *See* Physician Quality Reporting
 System
 pramipexole, for PD, 251
 prasugrel, 160
 pravastatin, 439
 PRCA. *See* pure red cell aplasia
 prednisone
 for polymyalgia rheumatica, 458
 tremors exacerbated by, 246, 247
 pregabalin
 for cancer-related pain, 554
 for herpes zoster, 500
 for neuropathic pain, 676
 for seizure treatment, 219
 premature aging syndrome, 22
 pressure ulcer cellulitis, 497–498, 499
 Pressure Ulcer Scale for Healing
 (PUSH 3.0), 513
 pressure ulcers, 509–518
 avoidability/unavoidability of, 509
 causes of, 478, 480, 509–510
 definitions, 511
 economic impact of, 509, 513
 epidemiology of, 511–513
 historical background, 509
 hospital-acquired (HAPUs), 509,
 511
 morbidity/mortality, 510, 511
 pathophysiology of, 513–514
 prevention interventions, 514–515
 home health agency assessments,
 514
 nutritional, 509, 515
 pressure redistribution, repositioning,
 514–515
 screening tools, 514
 topical, 515
 quality of life (PU-QOL), 513
 racial differences in incidence, 511
 rates, in long-term care facilities,
 510–511
 skin anatomy and, 509
 stages and categories, 512
 treatment, 515–518
 electrical stimulation, 516
 electromagnetic therapy, 516
 interdisciplinary approach,
 517–518
 nutritional, 516
 pain management, 516
 palliative wound care, 516–517
 pressure redistribution, repositioning,
 515
 surgical interventions, 516
 wound management, 515–516
 presyncope, 116
 prevention, maintenance, wellness
 revolution (U.S.), 9–10
 preventive medicine, 1, 9–10
 primary aldosteronism (PA), 415–416
 primary biliary cirrhosis, 326
 primary care infrastructure (U.S.), 2
 primary care providers, role of, 2
 primary hyperparathyroidism (PHPT),
 408–409, 450
 primary lateral sclerosis, 206
 primary myelofibrosis (PMF), 532–533
 primary open-angle glaucoma
 (POAG), 570–571
 primary progressive aphasia, 128
 primidone, 245–246, 246
 probenecid, 457
 procainamide, 247
 prochlorperazine, 250, 555
 progenitor cells, 21
 programmed aging, 18–19
 Programs for All Inclusive Care of the
 Elderly (PACE), 4, 656, 776
 progressive fluent aphasia (semantic
 dementia), 128
 progressive glomerulonephritis, 359
 progressive mixed aphasia (logopedic
 aphasia), 128
 progressive multifocal leukoencephalo-
 pathy, 347, 351
 progressive nonfluent aphasia (non-
 fluent/agrammatic aphasia), 128
 progressive resistance training
 (strength training)
 balance training combination, 86
 benefits, 84
 blood pressure and, 85
 circulatory stress during, 85
 equipment, 83
 for frail elders, 84
 intensity, 83
 nutrition and, 84
 recommendation for, 83
 risks, 84–85
 velocity, 83–84
 volume, 83
 progressive supranuclear palsy (PSP),
 129, 248–249, 249
 propranolol, 59, 162, 245–246
 prospective payment system (PPS), 660
 Prospective Study of Pravastatin in the
 Elderly (PROSPER), 439
 prostaglandin analogs, for glaucoma,
 571–572
 prostate cancer, 543–546
 advanced/recurrent
 castrate resistant (CRPC), 546,
 547
 hormone sensitive disease, 546
 age-related changes in, 17
 clinical presentation, diagnosis, 544
 epidemiology, 543
 management

- active surveillance, 545
brachytherapy, 546
localized disease, 545, 545
radiation therapy, 545–546
radical prostatectomy, 545
watchful waiting, 545
- prevention and screening, 49
prognosis, 544–545, 545
risk factors, 543
screening and prevention, 543–544
staging, 544
- prostatitis, 367, 375–376
prosthetic joints, 331, 464
protease inhibitors, 348
protein-energy undernutrition, 88
proteinomics, 12
proton pump inhibitors (PPIs), 311
 complications, 313
 for dyspepsia, 316
 for GERD, 312
provider cultural competence, 738
proximal humerus fractures, 462, 470–471
- PRT. *See* progressive resistance training
- pruritus, 399, 399, 493
 causes, 493
 differential diagnosis, 494
 groupings/types, 493
 treatments, 493, 496
- pseudohypertension, 188
psoriasis, 490–492
 differential diagnosis, 399, 490
 in HIV infection, 347
 treatment, 491–492
 triggers, 491
- psoriatic arthritis (PsA), 491
PSP. *See* progressive supranuclear palsy
- psychiatry. *See* geropsychiatry
psychogenic gait, 259
psychological function, maintaining, 1
psychosis/psychotic symptoms, 280–281
 in dementia, 280, 281
 driving and, 692
 management of, in PD, 252
- psychotherapy
 barriers to treatment, 283
 family assessment, 283
 individual, 282
 marital, 282–283
- psychotropic medications
 adverse reactions to, 62
 gait disorder evaluation and, 261
 prescribing caution, 281, 643
 tremor exacerbation by, 246
 use in nursing facilities, 665
- PTNS. *See* percutaneous tibial nerve stimulation treatment
- ptosis
 in cluster headaches, 223, 228
 in dermatochalasis, 565
 eyelid ptosis, 206
 myasthenia gravis and, 206
 in uncommon TACs, 224
- pulmonary embolism (PE), 302–304
 confusion in, 8
 diagnosis, 302–303, 303
 hospitalization risks, 467
 morbidity/mortality, regional
 anesthesia, 466
 mortality rate, 302
 regional anesthesia and, 466
 risk factors for, 302
 signs and symptoms, 302
 special considerations, 304
 strokes and, 240
 treatment, 303–304
- pulmonary fibrosis
 cancer risk factors, 551
 idiopathic, 304
 muscle weakness and, 207
 rheumatoid arthritis and, 455
- pulmonary issues, 298–306. *See also* chronic obstructive pulmonary disease
 aging-related physiologic changes, 298
 interstitial lung diseases, 304
 lung cancer, 347
 nontuberculous mycobacterium, 304–305
 pneumonia, 301–302, 302
 pulmonary fibrosis, 207
 sleep-related breathing disorders, 305–306
- pulmonary tuberculosis, 336–337
 clinical manifestations/diagnosis, 336–337
 fixed-dose agents for, 64
 HIV infection and, 347
 management, 337
 nursing home outbreaks, 332
- pulsus paradoxus, 175
punctal stenosis, 565
pure red cell aplasia (PRCA), 531
purigo nodularis, 347
pustular psoriasis, 347
pyomyositis, 345
pyrazinamide, 337
- qigong, 705
- Quality and Resource Use Reports (QRURs), 762
- Quality Assurance and Performance (QAPI) Program, 668
- quality improvement organizations (QIOs), 759
- Quality Measure Tools & Resources (AHRQ), 758
- quality of life (QoL)
 ACE inhibitors and, 168
 atopic dermatitis and, 492
 cachexia and, 89
 caloric restriction and, 23
 cardiac rehabilitation and, 165
 cataract surgery and, 569
 CRT and, 170
 driving and, 691
 exercise benefits, 69, 88, 102, 198
 falls and, 53, 63
 functional capacity and, 28
 heart failure and, 167, 177
 HIV treatment and, 344
 hormone sensitive disease and, 546
 hospice care and, 655, 656
 informed consent and, 665
 insomnia and, 265
 life expectancy and, 720
 muscle weakness and, 209
 myelodysplastic syndrome and, 528
 nocturia and, 373
 nutrition and, 423
 obstructive sleep apnea and, 305
 PAD and, 192, 198
 palliative care and, 671
 palliative wound care and, 517
 pelvic organ prolapse and, 402
 post-stroke depression and, 240
 pressure ulcers (PU-QoL), 513, 515
 pruritus and, 493
 psychological, social, cognitive components, 28
 rehabilitation medicine and, 613
 research on improving, 17
 sarcopenia and, 89, 100
 screening procedures and, 46
 seizure disorders and, 215
 sensory loss and, 209
 sexuality and, 403, 630
 ulcers and, 598
 urinary/fecal incontinence and, 383
 xerostomia and, 592
- quetiapine, 62, 137, 645
quinupristin-dalfopristin, for MRSA, 339, 340
- rabeprazole (AcipHex), 312
radiation proctitis, 320
radiofrequency ablation, in supraventricular tachycardias, 176
raloxifene, for osteoporosis, 449
ramelteon, for insomnia, 268
ramipril, 168
Ramsay Hunt syndrome (herpes zoster oticus), 121, 500
ranitidine (Zantac), 312
rapamycin, 23

Index

- Rapid Estimate of Adult Literacy in Medicine, 38, 743
- rasagiline, for PD, 250–251
- “rate of living” hypothesis. *See* somatic inevitability
- raw food diets, 706
- REACH Study (of caregiving interventions), 751
- reflex presyncope, 119
- reflexology, 705
- refractory hypertension, 188
- “Registries for Evaluating Patient Outcomes: A User’s Guide” (AHRQ), 764
- rehabilitation, 613–626
 - activities of daily living and, 35
 - assistive devices, 618–621
 - cardiac, 82, 83, 161, 165, 167, 462
 - driver rehabilitation programs, 39, 54
 - exercise component, 75, 87, 197–198
 - functional aging models, 613–614
 - functional assessment
 - Barthel Index, 615
 - current functional status, 615–616
 - elder’s personal goals, 616
 - FIM[®] Instrument, 615, 615
 - living environment, equipment, 616
 - physical examination, 616
 - premorbid functional status, 615
 - social and caregiver support, 616
 - hip fracture, 624–625
 - Impairment, Activity, Participation model, 614, 614
 - low vision, 575
 - lower extremity amputation, 625–626
 - malnutrition and, 101
 - nutrition component, 88
 - Parkinson’s disease, 624
 - peripheral artery disease, 196, 198
 - pulmonary, 300, 304
 - settings
 - comparing/selecting, 618
 - home health/outpatient, 618
 - inpatient facilities (IRFs), 617
 - multidisciplinary vs. interdisciplinary, 616–617
 - skilled nursing facilities (SNFs), 618
 - specific physician recommendations, 11
 - stroke, 239, 240, 241, 368, 621–624
 - team members, 616, 617
 - voice disorders, 581
- Rehabilitation Act (1973), 667
- Reiki massage, 676, 705
- REM sleep behavior disorder (RBD), 129
- multiple system atrophy and, 250
- parkinsonism and, 248
- symptoms, 271
- remitting seronegative symmetric synovitis with pitting edema (RS3PE), 458–459
- renal disorders, 357–362. *See also* acute kidney injury
 - acute kidney injury, 358–360
 - albumin concentration and, 59
 - cachexia and, 89
 - chronic kidney disease, 358
 - end-stage renal disease, 84, 306, 357, 361
 - etiology of, 358, 358
 - fluid/electrolyte disorders, 360–361
 - hyperkalemia, 360
 - hyponatremia, 360
 - GFR and, 60
 - glomerular filtration rate, 60
 - HIV infection and, 349
 - hypertension and, 188, 358, 360
 - MDRD and, 60
 - polypharmacy prevalence in, 361–362
 - renal artery stenosis, 188
 - renal elimination and, 60
 - Veterans Aging Cohort Study findings, 349
- repaglinide, 427
- reperfusion therapy
 - in acute MI, 161
 - in acute STEMI, 163, 163
 - in non-ST-elevation acute coronary syndromes, 163–164, 164
- reserpine, 250, 277
- Resource-Based Relative Value System (RBRVS), 777–778
- respect, therapeutic benefits, in doctor-patient relationship, 12
- Respectful Treatment: A Practical Handbook of Patient Care* (Lipp), 12
- respiratory system. *See* pulmonary issues
- restless legs syndrome (RLS), 248, 271
- retinal artery occlusion, 189
- retinal detachment, 569
- retinal vascular disorders, 573–574
 - diabetic retinopathy, 49, 430, 573–574
 - retinal artery occlusion, 574
 - retinal vein occlusion, 574
- retinoids, topical, 481
- retirement, 730–733
 - Continuing Care Retirement Communities, 653
 - definition, 730
 - downsizing of housing after, 722
 - evaluation of adjusting to, 274
 - health and, 733
 - Health and Retirement Study, 12
 - impact on marriages, 282
 - reduced restrictions on age, 12, 722
 - sexuality and, 631
 - Social Security benefits, 724
 - social status and, 732–733
 - substance use disorder and, 287, 288
 - theoretical approaches, perspectives
 - activity theory, 731
 - continuity theory, 732
 - disengagement theory, 731–732
 - life-course perspective, 731
 - optimization with compensation, 732
 - role theory, 732
 - unexpected/forced, 287
 - varied constructs of, 730–731
- revascularization therapy, 198–199
- reversible dementia, 130
- rhegmatogenous retinal detachment, 573
- rheumatic heart disease, 10, 173
- rheumatoid arthritis, 59, 455–456
- rheumatological diseases, 453–459
 - basic calcium pyrophosphate hydroxyapatite deposition disease, 457
 - calcium pyrophosphate deposition disease, 457
 - crystal-induced arthritis, 456–457
 - giant cell arteritis, 458
 - inclusion body myositis, 459
 - osteoarthritis, 453–455
 - polymyalgia rheumatica, 458
 - remitting seronegative symmetric synovitis with pitting edema, 458–459
 - rheumatoid arthritis, 59, 455–456
 - Sjögren’s syndrome, 211, 459
- rhinorrhea, in cluster headaches, 223
- rhytides (wrinkles), 480
- rifampin, 337, 340
- right ventricular (RV) infarction, in acute interior STEMI, 164
- riluzole, for ALS, 206
- rimantadine, for influenza, 335–336
- risedronate, for osteoporosis, 448, 449
- risperidone, 62, 137, 155, 645
- rivaroxaban
 - in ischemic stroke, 237
 - prescribing cautions, 61, 174
 - for pulmonary embolism, 304
 - warfarin comparison, 179
- rivastigmine, 134
- Roadside Review* program (AAA), 695
- Rockwood Frailty Index, 98
- role theory, of retirement, 732
- Rolf, Ida, 705

- Rolfing (structural integration), 705
ropinirole, for PD, 251
rosacea, 488–490
 acne rosacea, 566
 erythematotelangiectatic rosacea, 489
 ocular rosacea, 489
 papulopustular rosacea, 489
 phymatous rosacea, 489
rosiglitazone, 427
rosuvastatin, 439
rotigotine, for PD, 251
Rubner, Max, 19
running, 78
- safety assessment, 37
salmeterol, for COPD, 299
sarcopenia, 89, 159
 chronic inflammation in, 19
 frailty and, 99, 100
saxagliptin, 428
scabies, 492, 500–501
Scandinavian Simvastatin Survival Study, 438, 439
schizoaffective disorder, 643
schizophrenia, 280
 age-related cognitive decline, 644
 DART lifestyle intervention, 645
 elopement issues, 667
 hallucinations in, 280
 life expectancy data, 643
 lifestyle changes, 644
 onset of, 280
 SPMI and, 643
scleritis, 228
Screen for Caregiver Burden, 37
scrotal disorders, 377–378
 epididymitis, 377
 hydrocele, 377–378
 scrotal edema, 378
 spermatocele, 378
 testicular torsion, 378
 varicocele, 378
scrotal edema, 378
sebaceous cell carcinoma, 566, 567
sebaceous cyst, 483
sebaceous hyperplasia, 483
seborrheic blepharitis, 566
seborrheic dermatitis, 347, 490
seborrheic keratoses, 480, 482
secondary hyperparathyroidism, 409–410, 450–451
sedating antidepressants, 266, 268. *See also* doxepin; mirtazapine; trazodone
sedatives/hypnotics, adverse drug reaction, 62
Seegal, D., 10
seizure disorders, 215–220
 alcohol-induced seizures, 275
 causes, 216
 differential diagnosis, 217, 217
 elderly vs. young patient comparison, 216
 evaluation/risk factor assessment, 217, 217–218
 management/treatment, 218–220, 219
 presentation in the elderly, 216–217
 prevalence rates, 215–216
selective noradrenergic/serotonergic uptake inhibitors (SNRIs), 276. *See also* duloxetine; venlafaxine
selective serotonin reuptake inhibitors (SSRIs), 62–63, 138, 276. *See also* citalopram; fluoxetine; sertraline
selegiline, for PD, 250–251
SelfCARE questionnaire, 35
Seltzer, M. M., 646
senescence-associated secretory phenotype (SASP), 20, 23. *See also* cytokines; growth factors; matrix modeling factors
senolytic therapy, 23
sensitive thyrotropin (sensitive-TSH) test, 51
sensory ataxia, 258, 261
sensory disorders/neuropathies, 209–215
 alcohol-related neuropathy, 212–213
 causes of sensory loss, 209–210
 demyelinating neuropathies, 212
 diabetic neuropathy, 11, 190, 210–211
 evaluation, 213–214, 214
 monoclonal gammopathy, 213
 normal sensory pathways, 209
 pathology of sensory loss, 209
 patterns due to central nervous system pathology, 210
 patterns due to peripheral nervous system pathology, 211
 post-herpetic neuralgia, 46–47, 211–212
 related terminology, 213
 sensory peripheral neuropathy, 122
 treatment, 214–215, 215
 vitamin B12 deficiency, 213
sensory long axon peripheral neuropathy, 212
sensory neuropathy, 256
sensory peripheral neuropathy, 122
sentinel lymph node biopsy (SLND), 542
sepsis
 in acute MI, 160
 comorbid conditions, 306
 ICU/hospitalization data, 306
 impact on blood-brain barrier, 149
 orthostatic hypotension from, 119
 sleep disorders and, 270
serotonin 5-HT 1b/1d receptor agonists. *See* triptans
serotonin-norepinephrine reuptake inhibitors (SNRIs), 215, 215, 554. *See also* duloxetine; venlafaxine
sertraline
 for anxiety disorders, 276
 for major depression, 277
 for postherpetic neuralgia, 338
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7), 188
severe acute respiratory syndrome (SARS), 335
severe and persistent mental illness (SPMI). *See also* bipolar disorder; Down syndrome; intellectual disabilities; schizoaffective disorder; schizophrenia
 definition, 643
 evidence based treatments, 644–645
 Cognitive Behavior Social Skills Training, 645
 HOPES program, 645
 I-IMR Program, 644
 IMR Program, 644
 SHAPE health promotion program, 645
 ST+HM intervention, 644
family caregiving for, 646
population characteristics, demographic trends
 age-related changes, 644
 life expectancy, mortality, 643
 prevalence, 643
 social characteristics, 644
severe psoriasis, 347
sexuality, 630–638
 disorders
 barriers to treatment, 631, 631
 gender specific, 635, 635
 dysfunction assessment, 398, 403–405
 encounter enhancements
 coital positions, 638
 lubricants, 637–638
 sex toys, 637
 HIV infection and, 352
 sexual activity survey data, 630–631
 sexual response cycles, 631–632, 633, 634
 sexually transmitted diseases (STDs), 380, 399
 sexually transmitted infections
 HIV infection, 633–634 (*See also* HIV infection)

Index

- sexuality (cont.)
 misconceptions, 632
- SGLT2 inhibitors. *See* sodium-glucose cotransporter-2 (SGLT2) inhibitors
- shamanism, 708
- SHAPE health promotion program, 645
- shingles. *See* herpes zoster
- Short Alcohol Related Problems Survey, 291
- Short Portable Mental Status Questionnaire (SPMSQ), 52
- Shulman, E., 738
- Shy-Drager Syndrome (SDS), 249
- Sibbald, R. G., 513
- sick sinus syndrome, 176
- sickle cell disease (SCD), 235
- sildenafil citrate, 171, 393, 635
- simvastatin, 349, 439
- single-domain mild cognitive impairment (sdMCI), 131
- sitagliptin, 428
- sitaxsentan, 171
- Sjögren's syndrome
 clinical presentation, 459
 musculoskeletal disorders and, 459
 small fiber polyneuropathy and, 211
 treatment, 459
 xerostomia and, 313, 459, 591–592, 592
- skeletal muscle relaxants, 63
- skills training and health management (ST+HM) intervention, 644
- skin, functions
 aesthetic, 480
 age-related changes, 478, 480
 immunological barrier, 478–479
 photoaging mitigation, 480–481
 physical barrier, 478
 structure, 477–478
 thermoregulation, 479
 ultraviolet light protection, 479
 wound healing, 479–480
- skin, structure, 477–478
- skin diseases, infectious, 497–502
 cellulitis, 479, 495, 497–499
 erysipelas, 497–499
 herpes zoster, 499–500 (*See also* herpes zoster)
 intertrigo, 502
 onychomycosis, 501–502
 scabies, 492, 500–501
- skin diseases, inflammatory, 488–497
 atopic dermatitis, 492–493
 autoimmune blistering disorders, 495–497
 lower extremity stasis-related changes, 493–495
 pruritus, 493
- psoriasis, 490–492
 rosacea, 488–490
- seborrheic dermatitis, 490
- skin lesions, benign, 481–483
 acrochordons, 481–482
 actinic purpura, 483
 cherry angiomas, 480, 482
 epidermal inclusion cysts, 483
 sebaceous hyperplasia, 483
 seborrheic keratosis, 480, 482
 solar lentiginos, 480, 482–483
- skin lesions, malignant, 483–488
 actinic keratosis, 485–487
 basal cell carcinoma, 484–485
 melanoma, 487–488
 squamous cell carcinoma, 484, 485–487
- sleep apnea, 266–270. *See also* obstructive sleep apnea
 associated medical conditions, 269
 carbon dioxide retention headaches in, 228
 central sleep apnea, 266–267, 305
 diagnosis, 269
 ischemic stroke and, 235
 prevalence rates, 267–269
 STOP-BANG screening tool, 269
 strokes and, 239
 treatment, 269–270
- sleep diary, 265
- sleep disorders, 264–272. *See also* insomnia; REM sleep behavior disorder; restless legs syndrome; sleep apnea
 advanced phase disorder, 271
 age-related changes, 264
 delirium and, 154
 dementia and, 267, 271–272
 hospital-related, 270
 nursing home-related, 271
 as parkinsonism manifestation, 248
- sleep-related breathing disorders, 305–306. *See also* obstructive sleep apnea; sleep apnea
 diagnosis, 305
 treatment, 305–306
- slips (slipping), biomechanics of, 110–111
- SLUMS. *See* St. Louis University Mental Status Exam
- small fiber neuropathy, 212
- SMAST-G (Short Michigan Alcoholism Screening Test-Geriatric Version), 53, 290
- smoking cessation
 AHA guidelines, 196
 in benign breast disease, 405
 in COPD, 300
 erectile dysfunction and, 635
 medications, 292–293
- nicotine replacement therapy, 54, 292
- in osteoporosis prevention, 48, 449
- in peripheral artery disease, 196
- in post-MI convalescence, 165
- strategies, 54, 196, 292–293
- Snellgrove Maze test, 54
- SNRIs. *See* selective noradrenergic/serotonergic uptake inhibitors
- social activity, interdisciplinary assessment, 29
- social assessment, 37–38
- social history, as CGA component, 33
- Social Security Act (1935), 659
- Social Security Act (1935), Title XIX, 776
- Social Security Disability Income (SSDI), 774
- Social Security program, 659, 724, 728, 774
- social support
 as CGA domain, 32
 protective effects of, 2
- Society for Hospital Medicine, 11
- Society for Post-Acute and Long-Term Care Medicine (AMDA), 668–669
- Society of General Internal Medicine, 11
- Society of Sarcopenia, Cachexia and Wasting Disorders (SCWD), 89
- sodium-glucose cotransporter-2 (SGLT2) inhibitors, 426
- solanezumab, 136
- solar lentiginos, 480, 482–483
- solar lentiginos (actinic lentigo), 480, 482–483
- solifenacin, for OAB, 391
- somatic inevitability (“wear and tear” theory), 19
- somatization, 6
- Sorensen, A., 642
- Spastic (scissoring) gait, 261
- specialized care units, 3
- speech assessment, 275
- spermatocoele, 378
- spinal cord pathology, radiculopathies, 205, 207
- spinal muscular atrophies, 206
- spine osteoarthritis, 454
- spinocerebellar ataxias (SCA), 260
- spiritual healing practices, 708
- spirituality and religiosity, 38
- spironolactone, 162, 171
- SPMI. *See* severe and persistent mental illness
- squamous cell bladder cancer, 369
- squamous cell carcinoma, 400, 484, 485–487, 566, 577
- squamous cell carcinoma in situ (SCCis), 485

- squamous cell esophageal cancer, 314
 squamous cell hyperplasia, 399
 SSRIs. *See* selective serotonin reuptake inhibitors
 St. John's Wort, for depression, 706
 St. Louis University Mental Status Exam (SLUMS), 34
 stair climbing, 78, 85
 staphylococcal blepharitis, 566
 START (Screening Tool to Alert Doctors to the Right Treatment) criteria, 61
 stasis dermatitis, 493–495
 statin therapy, 135. *See also* lovastatin; pravastatin; rosuvastatin; simvastatin
 ACC/AHA guidelines, 437–438
 for acute MI, 161, 162–163
 adverse effects/safety factors, 207, 438, 441
 age-related duration, 47
 for cardiovascular disease, 429–430
 coronary artery disease study, 64
 diabetes treatment and, 429
 for lipid management, 48, 196, 438–440, 441–442
 liver disease and, 326
 pravastatin, 439
 for stroke/TIA, 238, 239
 status epilepticus, convulsive/nonconvulsive, 216
 Stead, Eugene, Jr., 13
 steppage gait, 258, 261
 stercoral ulcers, 320
 stereotactic thalamotomy, for ET treatment, 246
 Stevens-Johnson syndrome, 218, 565
 ST+HM intervention. *See* skills training and health management (ST+HM) intervention
 stomach disorders
 dyspepsia, 315–316 (*See also* dyspepsia)
 GERD, 311–313 (*See also* gastroesophageal reflux disease)
 peptic ulcer disease, 315, 315 (*See also* peptic ulcer disease)
 stone disease, urinary, 370–371
 stool softeners, 555
 STOPP (Screening Tool of Older People's Potentially Inappropriate Prescriptions) criteria, 33, 61
 strength training. *See* progressive resistance training
Streptococcus pneumoniae, 334
 stress urinary incontinence, 386
 behavioral treatment, 392
 pharmacological treatment, 392
 surgical management, 392–393
 striatonigral degeneration (SND), 249
 Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL), 440
 stroke units, 3
 strokes, 233–241. *See also* hemorrhagic strokes; ischemic strokes; transient ischemic attack
 anorexia and, 88
 anticoagulation therapy
 dabigatran, 237
 oral factor Xa agents, 237
 selection, 237
 timing of, 236
 warfarin, 237
 antiplatelet therapy, 237
 aortic arch atheroma and, 239
 atrial fibrillation and, 236
 blood pressure management, 237–238
 CAM mind-body therapies, 704, 707
 caregiving for patients, 241
 carotid disease and, 237, 238–239
 CHADS2/CHA2DS2-VASc scores, 236
 cognitive impairment in, 623–624
 complications, long-term
 depression, 240, 277
 urinary incontinence, 241
 cryptogenic stroke, 236
 depression, post-stroke, 240, 277
 diabetes and, 238
 diagnosis, 234
 driving and, 692
 dysphagia and, 240, 623
 end-of-life decision making, 241
 epidemiology of, 233
 epileptic seizures and, 216
 evaluation in AVS, 118
 exercise benefits for, 81
 falling and, 53, 108
 fever and, 240
 intracranial stenosis and, 239
 lipid lowering, 238
 MI/cardiomyopathy in, 238
 obesity and, 238
 patent foramen ovale and, 238
 peripheral arterial disease and, 199
 post-stroke gastrointestinal complications, 240
 prevention strategies, 235–236
 pulmonary embolism and, 302
 rehabilitation, 239, 240, 241, 368, 621–624
 risk factors, modifiable, non-modifiable, 234–235
 sleep apnea and, 239, 269
 statin therapy, 238, 239
 statin therapy impact on, 162
 systolic BP and, 429
 valvular heart disease and, 238
 venous thromboembolism and, 240
 vitamin B6, vitamin B12, and, 236
 structural integration (Rolfing), 705
 Strydom, A., 641
 Stuck, A. E., 28–29
 Study of Osteoporotic Fractures, 98
 subarachnoid hemorrhage, 241
 subclinical hypothyroidism (SH), 51
 subdural hematomas, 228
 Subjective Global Assessment, of nutrition, 37
 substance use disorders (substance abuse). *See also* alcohol misuse/abuse; drug abuse (illicit drugs); tobacco use
 baby boom rates, 53, 285
 brief interventions, 291
 CAM mind-body therapies, 704, 707
 definitions, 285
 diagnosis of, 287–289
 DSM, *Fifth Edition*, criteria, 288
 follow-up/continued support for, 291–292
 as history component, 33
 HIV infection and, 349, 351
 potential indicators of, 289, 290
 prevention and screening, 53–54
 psychosocial/behavioral treatments, 292
 risk factors, 287
 screening and assessment, 289–291
 subtrochanteric hip fractures, 466
 sudden gait failure, 257
 suicide/suicidal ideation, 279
 assessment for, 14, 274, 275
 in depressed patients, 138, 277
 in stroke patients, 240
 Suitability Assessment of Materials (SAM), 744
 sulfacetamide-sulfur formulations, 489
 sulfasalazine, 455
 sumatriptan, 223
 sundowning, 137, 271
 superficial basal cell carcinoma, 485
 superficial spreading melanoma, 487
 supportive therapeutic models (STM), for substance use disorders, 292
 supraventricular tachycardias (SVTs), 176–179. *See also* multifocal atrial tachycardia
 surgical care, 607–611
 emergency surgery, trauma, 610
 history, 33
 post-operative, communication challenges, 610–611
 post-operative, complications management
 cardiac care, 609
 delirium, 609

Index

- surgical care (cont.)
 hypothermia, 609
 pain control, 609
 polypharmacy, 609–610
 pulmonary care, 609
 pre-operative
 medications assessment, 608
 physician-patient communication, 608–609
 risk assessment, 607–608
 Surveys on Patient Safety Culture (AHRQ), 758
 swimming, 78
 syncope, 116
 in aortic stenosis, 172
 in Dementia with Lewy bodies, 249
 as medication side effect, 135
 syphilis, 347, 400
 HIV risk factor, 347
 systemic lupus erythematosus (SLE), 490
 systemic parenteral anticoagulants, 161
 systolic hypertension, 157, 166, 360
- tachycardia
 MI and, 159
 in pericardial tamponade, 175
 pulmonary embolism and, 302
 tachypnea, 302
 tacrolimus, 247, 491
 TACs. *See* trigeminal autonomic cephalalgias
 tactile hallucinations, 275
 tadalafil, for BPH, 393
 tai chi, 86, 261, 705
 tamsulosin (Flomax), 373, 393
 tardive dyskinesia, 282
 tarsal tunnel syndrome (TTS), 602
 telangiectasias, 320
 temazepam, 59, 268
 temporal arteritis, 458, 575
 temporomandibular joint (TMJ)
 age-related changes, 589
 examination techniques, 590
 range of motion, 589
 tinnitus and, 580
 tenofovir, 348, 349
 tension headaches, 221–222
 tension type headache, 221–222
 terazosin (Hytrin), 373, 393
 terbinafine hydrochloride, 599
 teriparatide, for osteoporosis, 449
 tertiary hyperparathyroidism, 409–410, 450–451
 Tervalon, M., 738
 Test of Functional Health Literacy in Adults, 38, 743
 testicular cancer, 347, 372
 testicular torsion, 378
 testosterone therapy
 for frailty, 102
 risk factors for men, 448
 tetrabenazine, 250
 tetracycline
 for blistering disorders, 497
 causative for headaches, 227
 for papulopustular rosacea, 489
 for pruritus, 494
 thalassemia, 525
 theophylline, 59, 246
 therapeutic massage, 676, 705
 therapeutic touch, 705
 thermoregulation role of skin, 479
 thiazide type diuretics, 190
 thiazolidinediones, 426, 427. *See also* troglitazone
 thiothixene, 62
 Thompson, P. D., 438
 thoracic aortic aneurysms, 189
 3P Model of insomnia, 265
 throat/swallowing. *See also* dysphagia
 age-related changes, 580
 common pathologies, 580–581
 thrombocytopenia
 in HIV infection, 347
 immune thrombocytopenic purpura, 528, 529
 Thrombolysis in Myocardial Infarction (TIMI) group, 164
 thyroid gland disorders
 in acute MI, 160
 cancer, 413
 heart failure and, 166
 hyperthyroidism, 176–177, 188, 411–412
 hyperthyroidism, subclinical, 412
 hypothyroidism, 50–51, 211, 410–411
 hypothyroidism, subclinical, 411
 muscle weakness and, 207
 nodules, 412–413
 screening tests, 50–51
 thyroid nodules, 412–413
 thyrotoxicosis, 411, 447
 TIA. *See* transient ischemic attack
 tiagabine, for for seizures, 219
 ticagrelor, 160
 tigecycline, for MRSA, 339, 340
 Time and Change test, 34
 Timed Up and Go Test, 53
 TIMI Risk Score, 164
 timolol, 162
 tinea corporis, 490, 492
 tinea pedis (Athlete's foot), 494, 497–498, 502, 599
 tinea unguium (dermatophytic onychomycosis), 501–502
 Tinetti Performance-Oriented Assessment of Gait, 53, 109
 tiotropium, for COPD, 299
 tirofiban, 161, 161
 tissue-level changes in aging
 cellular senescence, 20
 chronic “sterile” inflammation, 19–20
 macromolecular dysfunction, 20–21
 progenitor cell function decline, 21
 Title VI, Civil Rights Act (1964), 737
 Title XIX, Social Security Act (1935), 776
 tizanidine, for spasticity, 622
 “To Err is Human: Building a Safer Health System” report (IOM), 756–757
 tobacco use/dependence
 cessation methods, 54, 196, 292–293
 (*See also* smoking cessation)
 COPD and, 299
 diabetes and, 424
 as history component, 33
 HIV infection and, 349
 ischemic stroke and, 235
 peripheral arterial disease and, 196
 prevalence rates, 286
 risk factors, 157, 286
 tofacitinib, 455–456
 tolcapone, with levodopa, for PD, 253
 tolterodine, for OAB, 391
 topiramate
 for essential tremor, 245–246
 for migraines/cluster headaches, 222, 223
 for seizure treatment, 220
 total thyroxine (TT4) test, 51
 toxoplasmosis encephalitis, 345
 Traditional Chinese Medicine (TCM), 706, 707
 Traditional Oriental Medicine, 707
 Trails A and B tests, 54
 tramadol
 for cancer-related pain, 554
 for neuropathic pain, 215, 215
 transcatheter aortic valve replacement (TAVI), 172–173
 transient ischemic attack (TIA), 118, 120
 blood pressure management, 237–238
 clinical management, 235
 defined, 233, 234
 delirium and, 150
 diabetes and, 238
 diagnosis, 234
 driving and, 692
 migraine similarity to, 223
 modifiable risk factors, 234, 235
 peripheral arterial disease and, 199
 risk stratification for, 234, 234
 statin therapy, 238, 239
 trastuzumab, 542

- travoprost, for glaucoma, 571–572
- trazodone
for depression, 277
for insomnia, 268, 271–272
- treatment. *See also* under specific diseases and disorders
avoidance recommendation, 2
benefit vs. risk determination, 9
as CGA plan component, 28
ethical decision-making in, 10–11
physician attitude/success of, 7
potential harm from, 46–54
preliminary steps, 8, 13
- tremors, 245–246
action/rest tremors, 245
cerebellar outflow tremor, 246
drug-induced tremors, 246
essential tremor, 245–246, 246
exacerbating medications, toxins, 247
intention tremor, 246
in parkinsonism, 247
reemergent tremor, 247
rubral tremor, 246
- Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification, 233, 234
- tricuspid/pulmonic valve disease, 174
- tricyclic antidepressants (TCAs). *See also* amitriptyline; doxepin; nortriptyline
adverse drug reactions, 62, 62
for cancer-related pain, 554
for chronic pain in dyspepsia, 316
for depression in dementia, 138
exacerbation of tremors, 247
for herpes zoster, 500
interaction cautions, 282
for migraines/tension type headaches, 222, 222
for neuralgia-induced headaches, 226
for neuropathic pain, 214–215, 215, 676
- trigeminal autonomic cephalalgias (TACs), 223
- trigeminal neuralgia (TN)
headaches induced by, 224
in multiple sclerosis, 204
symptoms, 591
- trihexyphenidyl
for parkinsonian tremor, 245
for PD, symptomatic treatment, 251
- trimethoprim-sulfamethoxazole
exacerbation of tremors, 247
for MRSA, 340
for urinary tract infection, 368
- Triple Aim (IHI), 1, 10, 758
- trips (tripping), biomechanics of, 110–111
- triptans (serotonin 5-HT 1b/1d receptor agonists)
for migraines, tension headaches, 221, 223
- troglitazone, 427
- tropium, for OAB, 391
- trunk mononeuropathy, 212
- TT4. *See* total thyroxine (TT4) test
- tumor necrosis factor-alpha (TNF α), 100
- tumor necrosis factor-alpha (TNF α) inhibitors, 491–492. *See also* adalimumab; etanercept; infliximab
2008 *Physical Activity Guidelines for Americans* (U.S. HSS), 90
- ulceration of the feet, 598–599
- ulcerative colitis (UC), 320, 321, 546
- ultraviolet radiation (UVR)
impact on skin, 477
skin as protective barrier from, 479
sunscreen blockers, 480–481
- uncommon trigeminal autonomic cephalgias (TACs), 224
- United Kingdom Prospective Diabetes Study (UKPDS), 424, 425
- urgency fecal incontinence, 387, 387
- Urinary Distress Inventory, 36
- urinary incontinence (UI). *See also* fecal incontinence; overactive bladder
absorbent pads/continence products, 394–395
age-related changes and, 383
CGA assessment, 30, 36–37
characteristics and types, 386
classification, 385
conditions contributing to, 385–386
continence/micturition mechanisms, 383–385
defined, 383
evaluation
diagnosis, 387–388, 389
history, 387
physical examination, 387–388
overflow incontinence, 333, 386–387, 393
pelvic floor muscle training for, 392
pharmacological treatment, 391
prevalence, 383
PTNS treatment, 391–392
sleep disorders and, 271
stress urgency incontinence, 386
behavioral treatment, 392
pharmacological treatment, 392
surgical management, 392–393
- treatment options
ambulatory care, 389
behavioral treatment, 389–391
dietary management, 389
in long-term care facilities, 395
urgency incontinence, 385–386, 389
behavioral treatment, 389–391
dietary management, 389
pharmacological therapy, 391
- urinary issues
female disorders
atrophic vaginitis, 380
genitourinary fistulae, 379–380
pelvic organ prolapse, 380
urethral caruncle, 379
urethral diverticulum, 379
hematuria, 357, 366–367
indwelling catheterization, 333, 368–369
male disorders
benign prostatic hyperplasia, 373–375
hematospermia, 367
penile disorders, 376–377
prostatitis, 375–376
scrotal disorders, 377–378
- malignancies
bladder cancer, 371–372
kidney cancer, 372
prostate cancer, 371
testis cancer, 372
urethral cancer, 372
- in multiple sclerosis, 204
- overactive bladder, 369, 370
- sexual health, 380
- stone disease, 370–371
- urethral strictures, 378–379
- urinary tract infection (UTI), 333, 367–369
asymptomatic bacteriuria, 368
bladder emptying disorders and, 331, 333, 368
Candida and, 333
clinical manifestations, diagnosis, 333
cognitive dysfunction in, 63
confusion in, 8
differential diagnosis, 368
gram-positive/gram-negative organisms in, 368
hematuria and, 367
indwelling catheterization and, 333, 368–369
management, 333, 368, 369
risk factors for, 241
symptomatic bacteriuria, 368
symptoms, 368
urological issues, 357, 366–380
U.S. Department of Health and Human Services (HHS), 90
U.S. Preventative Services Task Force (USPSTF)
bone mineral testing recommendations, 446

Index

- U.S. Preventative Services (cont.)
 cancer screening recommendations, 46, 49
 conservative approach of, 46
 depression screening recommendations, 34, 50
 elder mistreatment screening efforts, 52
 hearing loss recommendations, 49
 Medicare coverage recommendations, 776
- uterine cancer, 401
- UTI. *See* urinary tract infection
- uvulopalatopharyngoplasty, for sleep apnea, 270
- vaccinations
 Bacillus-Calmette-Guérin vaccination, 337
 for influenza, 46
 for pneumococcal pneumonia, 46, 335
 for rheumatoid arthritis, 456
 for shingles, 46–47, 212, 226, 338
- vacuum pumps, for erectile dysfunction, 635
- VaD/VCI. *See* vascular dementia/vascular cognitive impairment
- vaginal cancer, 400
- valacyclovir
 for facial nerve palsy, 583
 for herpes zoster, 338, 500
 for postherpetic neuralgia, 212
- valium, for spasticity, 622
- valproate, for migraines/cluster headaches, 222
- valproic acid
 exacerbation of tremors, 247
 for seizure treatment, 220
 side effects, 218
- valvular heart disease, 166
 aortic insufficiency, 173
 aortic stenosis, 172–173
 endocarditis, 175
 mitral regurgitation, 174
 mitral stenosis, 173–174
 strokes and, 238
 tricuspid/pulmonic valve disease, 174
- Van Citters, A. D., 645
- vancomycin, for MRSA, 339, 340
- vardenafil, for BPH, 393
- varenicline, for tobacco dependence, 292–293
- varicella zoster virus, 46, 345
- varicocele, 378
- VAS. *See* Visual Analog Scale
- vascular dementia/vascular cognitive impairment (VaD/VCI), 127–128, 189
- vascular parkinsonism, 250
- vasodilators, for PAD, 197
- VDS. *See* verbal descriptor scales
- vegetarian diet, 706
- venlafaxine
 for anxiety disorders, 276
 for cancer-related pain, 554
 for chronic pain in dyspepsia, 316
 for neuropathic pain, 215, 215
- venous stasis ulcers, feet, 599
- venous thromboembolism (VTE), 542
 pulmonary embolism and, 302
 strokes and, 240
- ventilator-associated pneumonia (VAP), 301, 302
- ventricular arrhythmias, 179
- verapamil, 59, 163
 for atrial fibrillation, 177
 for cluster/hypnic headaches, 223
 contraindication in bradycardia, 176
- verbal descriptor scales, 39
- verrucous carcinoma, 400
- vertebral compression fractures, 472–473
- vertigo
 benign paroxysmal positional, 116, 118, 119
 differential diagnosis, 121
 syncope/presyncope overlap, 116
- vesicovaginal fistula, 399
- vestibular disorders, 257. *See also* labyrinthitis; Menière's disease
- vestibular neuritis, 121
- Veterans Affairs Cooperative Study, 500
- Veterans Affairs Diabetes Trial (VADT), 424
- Veterans Aging Cohort Study (VACS), 349
- Veterans Health Administration (VHA), 656
- VHA. *See* Veterans Health Administration
- viral conjunctivitis, 567
- viral hepatitis, 325–326
- viral meningitis, 347
- vision/visual conditions
 acute vestibular syndrome and, 120
 age-related macular degeneration, 49, 574–575
 cataracts/cataract surgery, 49, 568–570, 569
 as CGA component, 30
 choroidal disorders, 574–575
 conjunctiva/conjunctivitis, 566–567
 cornea, 567–568
 acanthamoeba infection, 568
 Fuchs endothelial corneal dystrophy, 567
- fungal keratitis, 568
 infectious keratitis, 568
- cystoid macular edema, 569
- delirium and, 149, 152
- diabetes risk factors, 49, 423, 430
- diabetic neuropathy and, 212
- eyelids and lacrimal system, 564–566
 aging-related structural changes, 565
- basal cell carcinoma, 565–566
- blepharitis, 566
- dermatochalasis, 565
- epiphora, 565
- eyelid neoplasms, 565–566
- lagophthalmos, 565
- nasolacrimal duct obstruction, 565
- nonmalignant tumors, 566
- ocular cicatricial pemphigoid, 565
- punctal stenosis, 565
- sebaceous cell carcinoma, 566
- squamous cell carcinoma, 566
- falling risks, 53, 108–108, 111
- giant cell arteritis and, 225, 227, 458
- glaucoma, 570–572
 acute angle-closure glaucoma, 571
 management, 571–572
 primary open-angle glaucoma, 570–571
 risk factors, 570
- headaches and, 228
- hypertension and, 189
- iris ischemia, 571
- low vision, 575
- medication side effects, 370
- muscle weakness and, 208
- neurological assessment, 203
- ocular rosacea and, 489
- optic nerve atrophy, 570
- optic nerve disorders, 575
 giant cell arteritis, 225, 227, 458, 575
- nonarteritic ischemic optic neuropathy, 575
- temporal arteritis, 458, 575
- postherpetic neuralgia and, 212
- presbyopia, 568, 569
- retinal detachment, 569
- retinal vascular disorders, 573–574
 diabetic retinopathy, 49, 430, 573–574
 retinal artery occlusion, 574
 retinal vein occlusion, 574
- screening, 49, 54
- sundowning and, 137
- systems assessment, 33
- vitreous and retina, 572, 572–573
- epiretinal membrane, 573

- posterior vitreous detachment, 572–573
- rhegmatogenous retinal detachment, 573
- Visual Analog Scale (VAS), 39, 674
- vitamin A, 90
- vitamin B6, 236
- vitamin B12, 90–91, 131, 213, 236, 463
- vitamin B12 deficiency
- description, treatment, 526–527
 - sensory peripheral neuropathy in, 122
 - small fiber polyneuropathy and, 211
- vitamin C, 90
- vitamin D, 91
- deficiency
 - and PHPT, 409
 - prevalence, complications, 409
 - in secondary hyperparathyroidism, 409
 - dementia and, 126, 135
 - for frailty, 102
 - for osteoporosis, 48, 218
 - renal osteodystrophy and, 451
- vitamin E, 90, 135
- vitamin K antagonists, 178, 237. *See also* warfarin
- vitreous and retina, 572, 572–573
- epiretinal membrane, 573
 - posterior vitreous detachment, 572–573
 - rhegmatogenous retinal detachment, 573
- voice
- age-related changes, 581
 - common pathologies, 581
- vorapaxar (antiplatelet), 160
- vulvar cancer, 400
- vulvar intraepithelial neoplasia (VIN), 399, 400
- vulvar squamous cell carcinoma, 400
- vulvovaginitis, 398–399
- waddling gait, 258, 261
- walking. *See also* gait disorders
- as exercise, 78, 85
 - gait changes and, 110
 - prevalence of difficulties, 108
- warfarin, 59
- for acute MI, 162, 163
 - for atrial fibrillation, 174
 - bleeding risks, 199, 319, 467
 - drug-drug interactions, 282, 362
 - for ischemic strokes, 178
 - pharmacokinetics of, 60
 - popularity of, 304
 - for pulmonary embolism, 304
 - reversal factor, 237
 - surgery preparation and, 608
- wastebasket diagnoses, 8
- “wear and tear” theory. *See* somatic inevitability
- weight loss
- depression and, 50
 - diabetes management and, 423
 - frailty and, 100
 - mirtazapine benefits for, 138
 - nutrition and, 92
- wellness revolution, in the U.S., 9–10
- white matter lesions, 127
- Wiglesworth, A., 687
- Williams, George, 18
- Wilson, D. B., 745
- Women’s Health Initiative study, 403, 446
- Woodruff, Margaret, 509
- Word Fluency-Animal Naming screening tool, 52
- Word List Memory test, 133
- World Health Organization (WHO)
- BMI guidelines, 92
 - CAGE questionnaire, 33
 - wound healing role of skin, 479–480
- xanthines (in coffee and tea), 247
- xerostomia, 88, 313, 459, 591–592, 592
- Yalom, I. D., 6, 14
- yoga, 86, 261, 705
- zaleplon, for insomnia, 268
- zanamivir, for influenza, 335–336
- Zarit Burden Interview (for caregiver burden), 37, 751
- Zenker’s diverticulum, 580
- Zigman, W. B., 641
- zoledronic acid, for osteoporosis, 448, 449
- zolpidem, 62, 268
- zonisamide, 220
- Zung Depression Scale, 50